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Introduction 
The heart is an aerobic organ, relying almost exclusively on the aerobic oxidation of substrates to 
generate adenosinetriphosphate, which is required for maintaining contractile function. As 
oxygen extraction from arterial blood is relatively constant in the human heart (~70%), changes 
in myocardial oxygen demand, in response to varying cardiac workload, are predominantly 
facilitated by changes in myocardial blood flow (MBF).1 Impairment of MBF, therefore, plays a 
pivotal role in the pathophysiology of the heart and its assessment is of importance in diagnosing 
cardiac disease and evaluating therapeutic interventions, both in clinical and research settings. 
Radiolabelled microspheres have made it possible to measure absolute values of MBF and they 
are commonly used in experimental animal studies. The invasive nature of this method, however, 
prohibits its use in clinical practice.2 
Positron emission tomography (PET) allows for noninvasive regional quantification of different 
biochemical pathways. PET is a tomographic imaging technique that is based on the detection of 
annihilation photons following the administration of a compound of biological interest, labeled 
with a positron emitting radionuclide. Positron emitters have a very short half life, so they have 
to be produced on site by means of a particle accelerator, usually a cyclotron. They are 
characterized by an excess of protons, resulting in an unstable nucleus. In order to regain 
stability, a positron is emitted which subsequently combines with an electron to form 
positronium. This is highly unstable, annihilating within 10-9 seconds. As a result of this 
annihilation, simultaneously two photons are emitted in opposite direction, each with an energy 
of 511 keV. Detectors of a PET scanner are able to detect these photons. When two opposing 
detectors in a PET scanner record 511 keV photons within a very short time interval (~10-8 
seconds), it is assumed that this coincidence event is the result of an annihilation that has taken 
place along the line connecting these two detectors (line of response). Following the registration 
of these events, counts from all lines of response (sinograms) are reconstructed to provide maps 
of the radioactivity distribution during the scan. By performing rapid scans following 
administration of the labeled compound the time course of radioactivity can be determined. 
Using tracer kinetic models, these measurements of radioactivity (in time and place) can be 
translated into quantitative estimates of physiologically relevant processes.3-5 
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H215O as a tracer of myocardial blood flow 
Oxygen-15-labelled water (H215O) is a (virtually) freely diffusible, metabolically inert positron 
emitting tracer with a short physical half life of 123 seconds. Reported methods for quantification 
of myocardial perfusion are all based on the principle of inert gas exchange originally developed 
by Kety6. The behavior of labelled water can be described by a single tissue compartment model, 
which contains two parameters: MBF and the tissue/blood partition coefficient of water. The 
latter is the ratio of the water content in myocardium (0.78 g water/g tissue) to that in blood (0.86 
g water/ml blood for a hematocrit of 0.45). This parameter can be fixed (0.78 / 0.86 = 0.91 ml/g). 
For the model to be valid the following assumptions have to be met: 1) water is freely diffusible 
between blood and tissue, and 2) the partition coefficient is indeed constant. The first assumption 
is dependent on the product of the capillary permeability and surface area (PS-product). For any 
diffusible tracer the permeability across the membrane can be a limiting factor, especially with 
increasing MBF. For H215O, however, this does not pose a problem in the (patho)physiological 
flow range7. The second assumption is debatable, especially for necrotic and other pathological 
states of the myocardium. To date this issue still needs further clarification. 
Nearly two decades ago, the first validation studies were performed for quantification of MBF 
using H215O and PET. Bergmann et al.7 demonstrated that regional distribution of H215O 
correlated well with values obtained using labelled microspheres, the accepted gold standard. 
Coronary artery stenoses could be detected accurately by measuring relative regional MBF in 
dogs during pharmacologically induced vasodilation.8 These results were successfully 
reproduced in patients with angiographically documented coronary artery disease.9 As already 
stated, for absolute quantification of MBF a single compartment model can be used, requiring an 
arterial input function and accurate measurement of the myocardial radiotracer concentration. 
The latter issue remained difficult because of partial volume (the underestimation of true 
radiotracer concentration in regions smaller than twice the full width at half maximum of the 
resolution of the tomograph) and corresponding spillover effects (contamination of activity in 
one region with that from an adjacent one), resulting from the limited spatial resolution, which 
are enhanced by cardiac and respiratory motion.10 Although solutions have been proposed to 
correct for these effects (e.g. assessment of cardiac dimensions for partial volume and 
spillover11;12 and electrocardiographic gating for cardiac motion corrections12;13), they are 
cumbersome and may themselves induce errors in estimating absolute myocardial blood flow.  
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Iida and coworkers14 were the first to correct for partial volume and cardiac motion by including 
the perfusable tissue fraction as an additional parameter in the standard single compartment 
model. This perfusable tissue fraction represents the amount of tissue that is capable of 
exchanging H215O rapidly within a given region of interest (PTF, in g/ml). Bergmann et al.15 
introduced a model that not only corrected for partial volume and cardiac motion but also for 
spillover. This model adds a third fitting parameter for spillover of arterial blood (Va). 
Consequently three parameters are estimated from the dynamic H215O emission images: MBF, 
PTF and Va. A good correlation was found between MBF measured with H215O and that with 
labelled microspheres in closed chest dogs. MBF in humans was 0.90±0.20 ml/g/min, which 
increased to 3.55±1.15 ml/g/min during pharmacologically induced vasodilation.15 
For acquisition of arterial time activity curves (needed to quantify MBF), a region of interest in 
either the left atrium or the left ventricle chamber can be used (image derived input 
function).15;16hese input curves correlated closely with those measured invasively by arterial 
cannulation.15;16 
Clinical studies of perfusion with PET 
After the validation of H215O as a myocardial perfusion tracer, PET studies in a large cohort of 
healthy human volunteers have demonstrated that MBF at rest ranges from approximately 0.6 to 
2.0 ml/g/min (average 0.98 ± 0.23 ml/g/min).17 Resting MBF is higher in female subjects and 
increases with age. The latter is predominantly related to an increase in myocardial oxygen 
demand caused by an increase in systolic blood pressure. Under conditions of (near) maximal 
vasodilation, MBF ranges from approximately 1.9 to 6.0 ml/g/min (average 3.77 ± 0.85 
ml/g/min) and a decline in hyperemic MBF can be observed after the age of about 60 years.17 
In patients with coronary artery stenoses due to atherosclerosis, baseline MBF remains relatively 
constant and comparable with that in normal subjects up to a stenosis diameter of about 80%, as 
the microvascular bed has the capacity to adjust vascular tone, resulting in vasodilation.18 In 
contrast, during hyperemia when the autoregulatory mechanism of the microvascular vessels is 
exhausted, MBF is already attenuated in myocardium subtended by a coronary artery with a 
stenosis diameter of 40% and higher.18;19 Revascularisation procedures, such as percutaneous 
transluminal angioplasty and coronary artery bypass surgery, can subsequently restore perfusion 
in these patients and alleviate anginal symptoms.20;21 
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Perfusion abnormalities, however, are not limited to patients with coronary artery disease. 
Primary cardiomyopathies such as hypertrophic22, idiopathic dilated23, and noncompaction 
cardiomyopathy24 are all characterized by an impairment in hyperemic perfusion, despite 
angiographically normal coronary arteries, which is indicative of microvascular dysfunction. It 
has been postulated that ischemia may therefore also occur in these patients which likely 
contributes to cardiac dysfunction25. Furthermore, recent studies have demonstrated that the 
extent of hyperemic perfusion impairment is an independent predictor for future adverse cardiac 
events in idiopathic dilated cardiomyopathy and hypertrophic cardiomyopathy22;23. Interventions 
that can restore perfusion abnormalities are therefore of therapeutic interest not only in patients 
with coronary artery disease, but also in patients with primary cardiomyopathies. 
Principles and validation of PTF, ATF and PTI 
Having introduced the perfusable tissue fraction (PTF) to circumvent the problem of partial 
volume effect during perfusion studies with H215O, Iida et al.26 compared this parameter with the 
anatomical tissue fraction (ATF). The ATF represents the mass of extravascular tissue in a region 
of interest and was first developed by Rhodes et al.27 for lung tissue. This technique calculates 
extravascular tissue density (g/ml) by subtracting a blood pool image from a transmission image. 
The transmission image, routinely acquired for attenuation correction purposes, comprises both 
vascular and extravascular tissue. A blood volume image derived from a C15O scan represents the 
vascular space only. Subtraction of the blood volume image from the transmission image, 
normalized to the density of blood (1.06 g/ml), provides a quantitative image of extravascular 
tissue density. Figure 1 shows typical transmission, blood volume and extravascular density 
images from a healthy volunteer. In theory, PTF and ATF should provide similar results for 
normal myocardium because both underestimate true radioactivity in the myocardium to the 
same degree, provided that spatial resolution of emission and transmission images are identical. 
The ratio of PTF and ATF, the so called perfusable tissue index (PTI), should therefore equal 
unity in normal myocardium, assuming all extravascular tissue (i.e. myocardium) is able to 
exchange water rapidly. 
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Figure 1. Example of transmission (A), blood pool (B) and extravascular density (C) images in 
a transaxial view from a healthy volunteer.  
 
Figure 2 provides a schematic representation of ATF, PTF and PTI. As the single tissue 
compartment model cannot distinguish myocardium from venous blood26, however, PTF is 
approximately ten percent higher than ATF, as venous blood volume within the myocardium 
amounts to approximately 0.10 ml per gram of net myocardium.28 PTI for normal myocardium 
should therefore be close to 1.1. PTI not only is independent of partial volume effects (and 
cardiac motion), but also of the size of the region of interest (ROI). A larger ROI will contain 
more extramyocardial components and result in an equal decrease in both PTF and ATF. PTI will 
therefore remain unaffected by changes in ROI definition. In a study by Iida et al.26 mean ATF’s 
for nine healthy volunteers were 0.62±0.05, 0.64±0.04 and 0.62±0.05 g/ml for septal, anterior 
and lateral regions, respectively. Mean PTF’s were 0.86±0.08, 0.72±0.09 and 0.71±0.05 g/ml for 
the same regions. Calculated from these results, PTI was 1.40±0.19, 1.14±0.13 and 1.14±0.10, 
respectively (Table 1). These values confirmed the expected values for the anterior and lateral 
regions. PTF and consequently PTI for septal regions, however, were significantly higher due to 
spillover of activity from the right ventricle chamber (vide infra). Four patients with previous 
myocardial infarction showed comparable results for ATF (0.64±0.25 g/ml), but consistently 
reduced values for PTF (0.44±0.16 g/ml) in the infarcted segments. Therefore PTI was also 
reduced in the infarcted segments (0.71±0.26) (Table 2). The disparity between ATF and PTF 
was thought to be the result of the inability of scar tissue to exchange water rapidly, leading to a 
reduction in PTF.  
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Figure 2. Schematic diagram of a region of interest (ROI) containing both H215O perfusable 
and non perfusable tissue. Panel A: volume of the ROI. Panel B: Anatomical tissue fraction 
(ATF). Panel C: Perfusable tissue fraction (PTF) which excludes the non-perfusable tissue 
from the ROI. Perfusable tissue index (PTI) equals the ratio of PTF and ATF. PTI represents 
the fraction of anatomical tissue that is perfusable by water. Reproduced with permission from 
Yamamoto et al.36 
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Table 1. Mean values for ATF, PTF and PTI in healthy volunteers 
Authors No. Adm.  ATF    
g/ml 
   PTF  
g/ml 
   PTI   
 
   Septal 
 
Ant Lat All Septal Ant Lat All Septal Ant Lat All 
Iida et al.26 9 C15O2 0.62 0.64 0.62 0.63 0.86 0.72 0.71 0.76 1.40 
 
1.14 1.14 1.22 
 
Yamamoto 
et al.36 
 
8 
 
C15O2 
 
0.63 
 
0.68 
 
0.66 
 
0.66 
 
0.77 
 
0.70 
 
0.67 
 
0.71 
 
1.23 
 
1.03 
 
1.02 
 
1.08 
 
Gerber et 
al.33 
 
6 
 
H215O 
 
0.55 
 
0.63 
 
0.64 
 
0.61 
 
0.58 
 
0.58 
 
0.60 
 
0.58 
 
1.05 
 
0.94 
 
0.95 
 
0.99 
No., number of subjects ; Adm., administration protocol; Ant, Anterior; Lat, Lateral 
 
Table 2. Mean values for ATF, PTF and PTI for dysfunctional myocardium 
Author No. Subjects ATF  
g/ml 
 PTF   g/ml  PTI  
   Dysf. Remote Dysf. Remote Dysf. Remote 
Iida et al.26 
 
4 Humans* 0.64±0.25 0.69±0.02 0.44±0.16 0.79±0.03 0.71±0.26 1.15±0.07 
Yamamoto 
et al. 36 
26 Humans* 0.74±0.07 0.72±0.06 0.51±0.15 0.72±0.07 0.69±0.19 1.00±0.07 
Iida et al.29 
 
12 Dogs* 0.48±0.05 0.48±0.09 0.31±0.13 0.49±0.10 0.62±0.24 1.02±0.11 
Itoh et al.38 
 
15 Humans 0.68±0.10 0.64±0.08 0.45±0.08 0.47±0.06 0.66±0.09 0.74±0.04 
* Documented myocardial infarction in dysfunctional myocardium 
No., number; ATF, Anatomical tissue fraction; PTF, Perfusable tissue fraction; PTI, Perfusable tissue index; 
Dysf., Dysfunctional 
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ATF is preserved in scar tissue because it only represents extravascular tissue density, 
independent of its structure. PTI, and to a lesser extent PTF, are thus able to identify infarcted 
myocardium (Figure 2). This has recently been confirmed histochemically in an experimental 
canine study.29 Both PTF and PTI were decreased significantly in infarcted segments. ATF did 
not differ between normal and infarcted segments. ATF, however, can be reduced in infarcted 
segments due to reduced wall thickness, even after adjustment of the ROI size. This effect is 
caused by the partial volume effect.26;29 An overview of the studies with sufficient ATF, PTF and 
PTI data in healthy volunteers and in patients or dogs with dysfunctional myocardium is given in 
Tables 1 and 2. The values for PTI vary considerably for the studies in Table 1, mainly due to 
differences in PTF (for septum and non-septum regions). More studies in healthy volunteers are 
needed. Table 2 demonstrates a consistent reduction of PTI in dysfunctional myocardium.  
Practical issues 
Administration protocol 
The overestimation of PTF in the septum mentioned above can be explained by the fact that in 
that particular study C15O2 was used.17 C15O2 converts to H215O in the lung by the enzyme 
carbonic anhydrase. Using this mode of administration, the concentration in the right ventricular 
chamber is the same as that in venous blood, which cannot be distinguished from tissue.7;26 
Spillover from the right ventricular chamber will therefore cause an overestimation in PTF. This 
problem can be solved by intravenous administration of H215O, either by slow infusion or by 
bolus injection. Using this mode of administration, the right ventricular chamber will be at 
arterial concentration and can thus be separated from tissue. Studies comparing different 
administration protocols (C15O2 inhalation, H215O slow infusion and H215O bolus injection) have 
demonstrated that bolus injection of H215O provides the most accurate results for PTF and 
MBF.30;31 In particular, there is no overestimation of PTF in the septum. A further improvement 
in accuracy of PTF in the septum has been achieved by correcting for both left and right ventricle 
spillover separately (note that the time course of radioactivity in both ventricles will be different 
after an intravenous injection; the bolus first passes through the right ventricle).30 Although the 
bolus injection technique yields the best results, the fast transit of activity through the cardiac 
chambers result in high count densities that can lead to dead-time losses. This effect, especially 
for PET scanners with relative low count rate performance, can result in unreliable image derived 
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input curves. The mode of administration of H215O must be optimized according to the technical 
capabilities op the PET scanner. 
Interpretation of MBF values 
 It needs to be emphasized that implementation of the perfusable tissue fraction within the H215O 
model results in myocardial blood flow values that represent blood flow in perfusable tissue 
only.14 In normal myocardium this will represent actual flow. In contrast, after myocardial 
infarction, scar tissue is not able to exchange water rapidly and will therefore not be included in 
the MBF calculation. This results in higher MBF values compared with other flow tracers. This 
effect has been demonstrated in a direct comparison between H215O and labeled microspheres in 
infarcted dog hearts.32 Comparison between 13N-labeled ammonia (13NH3) and H215O in human 
infarcted myocardium showed similar results (13NH3 estimates transmural myocardial blood in 
infarcted myocardium, making it comparable to the microsphere technique).33 MBF in perfusable 
tissue (MBFp) can be converted to MBF per units of mass of total tissue (MBFt) by multiplying 
MBFp with PTI (Figure 2). MBFt represents transmural blood flow and allows comparisons to be 
made with other techniques such as 13NH3 and labelled microspheres. The correlation between 
13NH3 and MBFt in human dysfunctional myocardium, however, was less than perfect in a study 
by Gerber et al.33 (r=0.51, p<0.05). More studies are needed to account for these differences.   
Flow heterogeneity 
Although the hypothesis that PTI in infarcted myocardium is reduced due to the inability of scar 
tissue to exchange water rapidly is an attractive one, the truth might be more complex. In regions 
of acute and old myocardial infarction, often a state of low instead of zero flow exists. Diffusion 
of H215O in necrotic tissue of old myocardial infarction in dogs does occur.34 Theoretically, a 
region with low flow should have normal PTI. Furthermore, a typical region of interest placed on 
dysfunctional myocardium will most likely contain a mixture of intact myocytes and necrotic 
tissue with varying degrees of perfusion. Using computer simulations, Herrero et 
al.34demonstrated that a heterogeneous flow pattern (4 different flows with a minimum of 0.10 
ml/min/g) can cause an underestimation of PTI. PTI was consistently lower for heterogeneously 
perfused regions and decreased further in regions with very low absolute flow. To evaluate the 
clinical importance of these findings, heterogeneity of extreme low (25 % tissue with blood flow 
of 0.01 ml/min/g) and normal (75% tissue with blood flow of 1.0 ml/min/g) flow was simulated 
showing little influence on the expected PTI (0.76). This probably reflects more realistic 
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differences of flow between scar tissue and well perfused myocardium. Nevertheless, the 
simulations by Herrero et al.34 indicate that flow heterogeneity might result in a bias in PTI. To 
what extent this affects PTI as a marker of viability needs to be determined in future studies. 
Recently, Schäfers et al.35 demonstrated a decrease in PTF and PTI after administration of 
dipyridamole in an ischemic porcine model, whilst MBF increased moderately. Vasodilation can 
induce steal effects and a pressure drop behind a coronary stenosis. This could cause flow to 
become inhomogeneous. In addition, a pressure drop results in the shut down of the 
microvascular bed through vasoconstriction, thereby actually reducing the perfused vascular bed. 
Both explanations could be responsible for the reduction in PTF and PTI.  
ATF spillover artifacts 
ATF is defined by the extravascular myocardial tissue density when regions of interest are placed 
on the myocardium. The heart is, however, surrounded by other anatomical structures, potentially 
leading to spillover artifacts. Especially the anterior myocardial wall is prone to spillover effects 
from the adjacent chest wall. Overestimation of ATF might occur with a corresponding 
underestimation of PTI as PTF is unaffected. Iida et al.29 found a significant ATF difference 
between open and closed chest dogs, confirming this spillover effect. The clinical relevance 
probably is limited, because values of ATF for anterior myocardium in healthy volunteers are 
comparable with those of other regions (Table 1). The effects of ATF spillover might be more 
pronounced in patients with dilated cardiomyopathies as these hearts have larger contact areas to 
adjacent structures such as the chest wall. More studies in these patient groups are needed.      
Blood pool imaging 
Although blood pool images for calculating ATF are best acquired using C15O, 18FDG has been 
used. By considering only the early images after tracer injection (45 seconds), 18FDG 
predominantly reflects the blood pool before significant extraction into the myocardium has 
occurred. Gerber et al.33 compared these two different methods of calculating ATF in healthy 
volunteers and demonstrated a reasonable correlation (r=0.77, p<0.01). Whether this method 
holds true for patients with ischemic heart disease and increased anaerobic glycolysis, remains to 
be investigated.  
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PTI as a marker of viable myocardium 
PTI reflects the fraction of extravascular tissue being perfused by water. A decrease in PTI 
indicates a relative decrease in perfused tissue. Assuming the non-perfused fraction to be scar 
tissue, the reduction of PTI is a measure of the amount of damaged myocardium. Under certain 
circumstances, dysfunctional myocardium has the capability of regaining function after 
revascularization. This myocardium is in a state of hibernation and is said to be viable.1 
Dysfunctional myocardium with a normal or near normal PTI would be expected to be viable 
because the amount of scar tissue is limited. In contrast, dysfunctional myocardium with reduced 
PTI is less likely to be viable, because more scar tissue is present. This hypothesis of PTI being a 
marker of viability was first tested more than a decade ago. To date, four studies on the relation 
between PTI and myocardial viability have been published (table 3).  
 
Table 3. Comparison of studies predicting viability based on PTI  
Author Cut off 
value 
Compared to No. 
Seg. 
Sens. Spec. PPV NPV 
 
Yamamoto et 
al.36 
 
PTI > 0.7 
PTI > 0.7 
 
H215O - 18FDG  
Recovery of 
function 
 
15 
12 
 
56 (5/9) 
100 (7/7) 
 
100 (6/6) 
100 (5/5) 
 
100 (5/5) 
100 (7/7) 
 
 
0.60 (6/10) 
100 (5/5) 
De Silva et al.37 PTI > 0.7 Recovery of 
function 
33 100 (26/26) 100 (7/7) 100 (26/26) 100 (7/7) 
Gerber et al.33 PTI > 0.9* Recovery of 
function 
30 75 (12/16) 86 (12/14) 86 (12/14) 75 (12/16) 
Itoh et al.38 PTI > 0.7 Recovery of 
function 
15 71 (5/7) 100 (8/8) 100 (5/5) 80 (8/10) 
Combined PTI Recovery of 
function 
90 89 (50/56)      94 (32/34) 96 (50/52) 84 (32/38) 
* 18FDG used for blood pool image and calculation of ATF 
 
No. Seg., Number of segments; Sens., Sensitivity; Spec., Specificity; PPV, positive predictive value; NVP, 
negative predictive value. 
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Yamamoto et al.36 estimated viability in fifteen patients with old myocardial infarction (OMI) 
determining a metabolism-flow match or mismatch using 18FDG and H215O. Nine patients had a 
mismatch pattern and were thus called viable, six patients were considered to be non viable. 
Mean PTI in the viable group was 0.75±0.14 and significantly higher than the mean PTI of 
0.53±0.12 in the non-viable group (p<0.01). The differences in PTI were solely due to 
differences in PTF (0.54±0.07 vs. 0.36±0.06 g/ml, p<0.01) as ATF was similar in both groups 
(0.72±0.08 vs. 0.70±0.07 g/ml, p=NS). Furthermore, PTI was determined in eleven patients (12 
dysfunctional segments) who suffered from acute myocardial infarction (AMI) with patency of 
the infarct related artery, either spontaneously or after successful thrombolysis. An 
echocardiogram was performed on the same day as the PET study (1-4 days after admission to 
the hospital) and repeated at 4 months follow-up to assess improvement of cardiac function. 
Seven of twelve dysfunctional segments showed improved systolic wall thickening at follow-up. 
PTI in the recovery segments was significantly higher than in the non-recovery segments 
(0.88±0.10 vs. 0.53±0.11, p=0.017). In both patient groups (OMI and AMI) PTI in remote 
myocardial control regions with normal function was equal to that in healthy volunteers. PTI in 
recovery segments of both patient groups was reduced slightly compared with control regions, 
although no statistical difference was reached. This indicates that although some myocardium 
was compromised, enough survived to regain function. In the AMI patient group, recovery 
occurred only in segments with a PTI of at least 0.7. This suggests that at least 70% of the 
myocardium needs to be able to exchange water rapidly in order to improve contractile function. 
De Silva et al.37 from the same group determined PTI in twelve patients with previous 
myocardial infarction shortly before revascularization by CABG or PTCA. Of the 33 
dysfunctional segments 26 improved after revascularization. Another 26 segments had no wall 
motion abnormalities prior to the procedure. These segments without dysfunction were used as 
control regions. MBFp in the control segments (0.97±0.22 ml/min/g) was significantly higher 
(p<0.001) than in both recovery (0.73±0.18 ml/min/g) and non-recovery (0.45±0.11 ml/min/g) 
segments. Although MBFp showed significant differences between the three groups, there was 
great overlap. The values of PTI in recovery segments were reduced slightly compared with 
control segments (0.99±0.15 vs. 1.10±0.15, p=0.013). All recovery segments had a PTI > 0.7. In 
the non-recovery segments PTI was significantly lower than in both control and recovery 
segments (0.62±0.06, p<0.02) and always < 0.7. Therefore, PTI could discriminate accurately 
between viable and non-viable tissue using a cut off value of 0.7, confirming the data of 
Yamamoto et al.36 
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Gerber and coworkers33 further tested PTI as marker of viability in 30 patients with dysfunctional 
anterior myocardium scheduled for revascularization. PTI was significantly higher in viable 
(1.07±0.07) than in non-viable tissue (0.78±0.05, p<0.01). A cut off value of 0.9 yielded the best 
diagnostic accuracy with a sensitivity of 75% and a specificity of 86%. Recently, Itoh et al.38 
found reduced PTI in eight non-recovery segments after revascularization (0.59±0.04) compared 
with seven recovery segments (0.73±0.06, p<0.0001). A cut off value of 0.7 gave the best 
diagnostic accuracy. The cut off value in the study by Gerber et al.33 is higher than that in the 
other studies. This can be explained by the method of determining ATF in this study. The blood 
pool images were derived from the early phase images after injection of 18FDG, resulting in 
lower ATF values than found in the three other studies. 18FDG has a larger volume of distribution 
than C15O, especially in patients with ischemic myocardium. The lower ATF in turn also causes 
PTI to be higher, explaining the discrepancy in cut off value for PTI. In table 3 a total of 90 
segments from these 4 studies have been pooled, comparing PTI in relation to recovery of 
function. Overall sensitivity and specificity are 89 and 94%, respectively, and compare favorably 
to other techniques for assessment of viability.39 It should be noted that although these results are 
promising, they are based on studies from a limited number of centers in a small number of 
patients. Furthermore, direct comparison with other techniques of detecting viable myocardium is 
scarce.36;37 One reason for the lack of more extensive data on PTI is that presently only a few 
centers worldwide are capable of measuring MBF using H215O and C15O. 
Suggestions have been made to use only PTF as a marker of viability.40 The rationale for using 
PTF rather than PTI is the fact that ATF has been shown to be relatively constant for viable, non-
viable and control regions since ATF only represents extravascular tissue, independent of its 
composition. PTF determines the fluctuations in PTI in pathological conditions and can therefore 
also be used for detecting viable myocardium. Furthermore this approach obviates the need for 
blood pool imaging. Although using PTF instead of PTI is convenient, PTF values depend on 
ROI size14, making this approach more operator dependent. In addition, ATF has been shown to 
decrease in a relatively thin myocardial wall after infarction.14;29 Taking ATF out of the equation 
could lead to erroneous conclusions. On the other hand, determination of PTI not only requires 
the ability to produce H215O and C15O with an on-site cyclotron, but also full cooperation of the 
patient. PTI can only be calculated after obtaining a transmission scan, a dynamic H215O 
emission scan, and a static C15O scan. Motion artifacts can therefore be an important source of 
error. For determination of the best strategy, either PTI or PTF, more investigations are required 
23
                     
 23 
comparing both techniques directly as well as comparing them with other techniques. A 
multicenter pilot trial in Japan recently showed promising results concerning the variability of 
PTF in healthy volunteers, provided ROI definition was standardized.41     
Outline of the thesis 
The aim of this thesis was to further investigate the mechanisms that cause impairment of 
myocardial perfusion in patients with dilated (both ischemic and idiopathic) and hypertrophic 
cardiomyopathy. The relation between perfusion and contractile function was investigated and 
effects of therapy on myocardial perfusion were assessed. Furthermore, the value of PTI as a 
noninvasive marker of fibrosis was extended to patients with idiopathic dilated and hypertrophic 
cardiomyopathy. 
In chapter 2.1 the effects of cardiac resynchronization therapy (CRT) on regional and hyperemic 
perfusion in patients with congestive heart failure and electrical dyssynchrony are evaluated. A 
review of the currently available literature on the metabolic effects of CRT and on techniques to 
assess dyssynchrony is given in chapter 2.2. 
Chapter 3.1 compares values of PTI found in healthy controls versus those measured in patients 
with idiopathic dilated cardiomyopathy with the view of evaluating the potential of PTI as a 
marker of fibrosis in this patient group, as this could be of important prognostic relevance.  
Having demonstrated a reduction in PTI, chapter 3.2 describes the results from a study that 
evaluates the interrelations between interstitial fibrosis, perfusion, and contractile function in 
patients with idiopathic dilated cardiomyopathy. Furthermore, potential mechanisms of left 
ventricular dysfunction are discussed. 
In chapter 4.1 noninvasive assessment of fibrosis using PTI is tested in patients with 
hypertrophic cardiomyopathy and compared with the pattern of delayed contrast enhanced 
magnetic resonance imaging (DCE-MRI), an alternative marker of myocardial fibrosis. Patients 
with previous myocardial infarction served as a control group. This study provides more insight 
into the histological basis of both PTI and DCE-MRI in patients with hypertrophic 
cardiomyopathy. Subsequently, chapter 4.2 presents data from a subgroup of patients studied in 
the previous chapter, in order to explore the mechanisms of regional heterogeneity in resting 
perfusion in patients with hypertrophic cardiomyopathy. 
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Chapter 5 further validates the use of PTI as a marker of fibrosis in patients with ischemic 
cardiomyopathy by direct comparison with DCE-MRI. In this chapter an optimal PTI cutoff 
value to detect myocardial viability is also defined, taking DCE-MRI as a reference. 
Finally, in chapter 6, a summary of the thesis is given and the results are discussed. 
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Effects of Cardiac Resynchronization Therapy on
Myocardial Perfusion Reserve
Paul Knaapen, MD; Linda (C.)M.C. van Campen, MD; Carel C. de Cock, MD, PhD;
Marco J.W. Götte, MD, PhD; Cees A. Visser, MD, PhD;
Adriaan A. Lammertsma, PhD; Frans C. Visser, MD, PhD
Background—Cardiac resynchronization therapy (CRT) is a relatively new treatment strategy for patients with heart
failure and mechanical asynchrony. Reported effects of CRT on regional myocardial blood flow (MBF) are conflicting,
and effects on hyperemic MBF are scarce. The aim of the present study was to assess serial changes of MBF and MBF
reserve in patients receiving a biventricular pacemaker.
Methods and Results—Fourteen patients with heart failure (NYHA class III or IV; left ventricular ejection fraction35%), QRS
width120 ms, and sinus rhythm were studied (mean age, 5810 years; 8 men). MBF and hyperemic MBF were measured
at baseline, 3 months after biventricular pacing (CRT on), and after cessation of pacing (CRT off) with PET and H2
15O. CRT
had no significant effect on resting MBF (baseline versus CRT on versus CRT off: 0.820.25 versus 0.690.24 versus
0.740.24 mL · min1 · mL1; PNS). Hyperemic MBF increased during CRT (1.911.03 versus 2.661.66
versus 1.921.06 mL · min1 · mL1; P0.01 by MANOVA), as did MBF reserve (2.251.00 versus 3.762.38
versus 2.490.94 mL · min1 · mL1; P0.023). CRT (reversibly) resulted in a more homogeneous distribution
of regional resting MBF as demonstrated by the septal-to-lateral ratio. The decrease in the ratio of left ventricular
end-diastolic volume to left ventricular mass, as a reflection of wall stress, was related to the increase in hyperemic
MBF (r0.53, P0.05). Left ventricular ejection fraction increased from 257% to 379% (P0.01).
Conclusions—Resting MBF is unaltered by CRT despite an increase in left ventricular function. However, the distribution
pattern of resting MBF becomes more homogeneous. Hyperemic MBF and consequently MBF reserve are enhanced by CRT.
(Circulation. 2004;110:646-651.)
Key Words: blood flow  heart failure  pacing  tomography, emission-computed
In recent years, cardiac resynchronization therapy (CRT)has emerged as a new treatment strategy for a subgroup of
patients with heart failure and an asynchronous contraction
pattern.1,2 It has been demonstrated that CRT improves
hemodynamic function,3,4 heart failure symptoms, exercise
capacity, and quality of life (QOL) and that it reduces
morbidity and mortality.5 A number of studies have shown
that function improves without an increase in oxygen con-
sumption, indicating increased efficiency.6–9 Furthermore,
oxygen consumption seems to be distributed more homoge-
neously during CRT.7 These findings support the hypothesis
that CRT rebalances the loading condition of the heart.1,2
Changes in oxygen consumption are expected to be accom-
panied by similar changes in myocardial blood flow (MBF).
Nevertheless, conflicting results have been reported with
regard to the effects of CRT on regional MBF.6,8,10–13 These
studies, however, are difficult to compare because MBF was
evaluated with different imaging modalities and at varying
follow-up periods. In addition, in none of these studies were
serial measurements performed before, during, and after
cessation of pacing therapy. Furthermore, data on the effects
of CRT on MBF reserve are scarce,9 despite its important role
in the pathophysiology of the failing heart. Therefore, the
present study was performed to serially assess the effects of
CRT on regional MBF and MBF reserve with PET and H215O.
Methods
Patients
Sixteen consecutive patients with heart failure (NYHA class III or IV
despite optimized medical therapy), left ventricular ejection fraction
(LVEF) 35%, intraventricular conduction delay (QRS width 120
ms), LV end-diastolic diameter 55 mm, and sinus rhythm were
enrolled in the study. The cause of heart failure was idiopathic
dilated cardiomyopathy in 9 patients and ischemic heart failure in 7.
Angiography revealed severe coronary artery disease not eligible for
further revascularization procedures in 4 of these patients. The
remaining 3 patients had suffered from large myocardial infarctions
leading to heart failure. No significant coronary artery stenoses were
present after percutaneous interventions in the latter patients. At the
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time of enrollment, all patients were in a clinically stable condition
on standard heart failure medication, including ACE inhibitors
(n14), angiotensin receptor antagonist (n2), -blockers (n13),
diuretics (n14), and digoxin (n3). The doses of this background
medication were stable for 3 months. Medication was kept con-
stant during the study. Serial resting MBF and hyperemic MBF
measurements were performed 1 month before and 3 months after
biventricular pacemaker implantation. The postimplantation mea-
surements were performed both during biventricular pacing (CRT
on) and shortly after reprogramming the pulse generator to AAI
mode with a lower rate of 40 bpm (CRT off). Effectively, the latter
pacing mode results in a normal sinus rhythm comparable to
baseline. The order of the postimplantation studies was randomized.
In 8 patients, this sequence was “on-off”; in the remaining 6, it was
“off-on.” Two patients died during the follow-up period because of
sudden death and progressive pump failure, resulting in 14 com-
pleted protocols. QOL was assessed with the Minnesota Living With
Heart Failure questionnaire14 before and after 3 months of CRT.
Scores range from 0 to 105; higher scores reflect a worse QOL. All
subjects gave written informed consent, and the Medical Ethics
Committee of the VU University Medical Center approved the
protocol.
Biventricular Pacemaker Implantation
Three transvenous pacing leads were inserted, 1 in the atrial
appendage and 1 in the right ventricular apex. In addition, a coronary
sinus lead was positioned in the posterolateral (n12) or anterolat-
eral (n4) position. The pacing leads were connected to a biven-
tricular pacemaker (either Insync II, Medtronic, or Triplos LV,
Biotronik). The pacemaker was programmed in DDD mode. A
predischarge AV optimization was performed in all patients.15
Positron Emission Tomography
All scans were performed in 2D mode with an ECAT EXACT HR
(Siemens CTI). Subjects were constantly monitored with single-lead
ECG, and blood pressure was measured every 3 minutes. After a
transmission scan, 1100 MBq of H2
15O dissolved in 5 mL saline was
injected intravenously via a pump in 2 seconds, followed by a 40-mL
saline flush at a rate of 4 mL/s (bolus injection). A dynamic scan was
acquired, consisting of 40 frames with variable frame length for a
total time of 10 minutes (125, 1210, 620, and 1030 seconds).
After the rest study, a hyperemic study was performed by infusing
adenosine at a rate of 140 g · kg1 · min1. Subsequently, blood
pool imaging was performed. During a 2-minute period, the patient
inhaled 2000 MBq of C15O, and a single frame was acquired for a
duration of 6 minutes, starting 1 minute after the end of inhalation to
allow for equilibration in the blood pool.
The postimplantation study was identical to the baseline study
except that resting MBF and hyperemic MBF measurements were
performed both during CRT on and CRT off.
Emission data were corrected for physical decay of 15O and for
dead time, scatter, randoms, and photon attenuation. Reconstruction
of the H2
15O emission sinograms was performed with filtered back
projection with a Hanning filter at 0.5 of the Nyquist frequency,
resulting in a transaxial spatial resolution of 	7 mm full width at
half-maximum.
Anatomic tissue images were generated by subtracting the blood
pool image from the transmission image16 and resliced into short-
axis images according to the anatomic axis of the heart. The same
reslicing parameters were automatically applied to the dynamic
H2
15O images. Thirteen regions of interest (ROIs) (6 basal, 6 distal,
1 apical) were defined as described previously.17 Additional ROIs
were defined on the anatomic tissue images in left and right
ventricular chambers for image-derived input functions. The set of
ROIs was projected onto the dynamic H2
15O images to generate
time-activity curves. With the standard single-compartment model,
MBF (mL · min1 · mL1 of perfusable tissue) was determined from
these time-activity curves. Corrections were made for left and right
ventricular spillover effects by use of the method described by
Hermansen et al.18 Global MBF was calculated by grouping all
ROIs. In addition, septal and lateral MBFs were determined by
grouping of the corresponding septal and lateral ROIs. MBF reserve
was calculated as the ratio of hyperemic MBF to resting MBF.
Because resting MBF is related to the rate-pressure product (RPP;
RPPsystolic blood pressureheart rate), corrected resting MBF
(MBF/RPP10.000) was also determined. Myocardial vascular
resistance was calculated by dividing mean arterial pressure by
MBF.
Echocardiography
All patients underwent complete 2D and Doppler echocardiography
at baseline and after 3 months of follow-up to determine LV and
valve function. Standard parasternal and apical views were recorded
on VHS videotape for subsequent offline analysis. LV end-diastolic
volume (LVEDV), LV end-systolic volume, LVEF, LV mass, LV
ejection time, and LV filling time were determined according to the
recommendations of the American Society of Echocardiography.19
The ratio of LVEDV to LV mass (LVM) was calculated as a
reflection of global end-diastolic LV wall tension, as described by
Gaasch.20
Diastolic Perfusion Time Calculation
The R-R interval was measured at rest and during hyperemia on the
ECGs obtained during the PET scans. Diastolic perfusion time
{DPT; DPT (s/min)[(R-R intervalLV ejection time)heart
rate]}21,22 was calculated during baseline and CRT on for both rest
and hyperemia.
Statistical Analysis
Data were expressed as meanSD. For comparison of 2 data sets, a
paired Student’s t test was performed. Intragroup comparisons of
hemodynamic and PET data were tested for significance with a
general linear model for repeated measures (MANOVA). Linear
regression was used to test the relationship between variables. A
value of P0.05 was considered significant. All analyses were
Results
Biventricular pacemaker implantation was uncomplicated in
all 14 patients. Patient characteristics are summarized in
Table 1.
Hemodynamic Data
Table 2 lists the hemodynamic results. CRT did not have an
effect on heart rate or blood pressure. Infusion of adenosine
consistently caused an increase in heart rate and a decrease in
systolic blood pressure, resulting in a higher RPP.
TABLE 1. Patient Characteristics
Age, y 5810
Sex, M/F 8/6
Cause, ischemic/nonischemic 6/8
NYHA class, III/IV 12/2
QOL score 38
Conduction, LBBB/RBBB 12/2
QRS duration, ms 17328
LVEF, % 257
LVEDV, mL 27384
LVESV, mL 20772
LBBB indicates left bundle-branch block; RBBB, right bundle-branch block;
and LVESV, left ventricular end-systolic volume. n14.
Knaapen et al Effects of CRT on Perfusion Reserve
performed with SPSS 9 (SPSS Inc).
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Myocardial Blood Flow
There were no significant differences in resting global MBF
between the 3 measurements (Table 3 and Figure 1), although
there was a trend toward a reduction in MBF during CRT on
compared with baseline (0.690.24 versus 0.820.25 mL ·
min1 · mL1; P0.092). Corrections for RPP did not alter
the results (baseline versus CRT on versus CRT off,
1.120.39 versus 0.950.32 versus 0.980.30 mL · min1 ·
mL1; PNS). Microvascular resistance did not change
significantly during the different pacing modes.
Hyperemic MBF
Hyperemic global MBF before implantation was blunted in
the study population (mean, 1.911.03 mL · min1 · mL1).23
During CRT, hyperemic MBF increased to 2.661.66 mL ·
min1 · mL1 (P0.013 versus baseline). After cessation of
CRT, hyperemic MBF returned to baseline values
(1.921.06 mL · min1 · mL1; P0.018 versus CRT). As a
result of the increased hyperemic MBF, MBF reserve was
also increased during CRT. Changes in hyperemic MBF were
independent of the protocol (on-off or off-on; see Methods).
Nonischemic dilated cardiomyopathy patients had a more
pronounced response to CRT (baseline versus CRT on versus
CRT off, 2.350.98 versus 3.491.43 versus 2.460.99 mL
· min1 · mL1; P0.021) compared with ischemic dilated
cardiomyopathy patients (1.320.96 versus 1.551.31 ver-
sus 1.190.66 mL · min1 · mL1; PNS), although both
showed an increase in hyperemic MBF during CRT. Mean
QOL score and NYHA class decreased by 19% and 0.86,
respectively (both P0.01). However, nonischemic patients
tended to benefit more from CRT (QOL score and NYHA
class decrease, 23% and 1.0, respectively) than ischemic
patients (decrease, 15% and 0.67, respectively).
MBF Distribution Pattern
At baseline, resting MBF distribution was inhomogeneous
with a septal-to-lateral ratio (SLR) of 0.770.27. CRT
resulted in a more homogeneous resting MBF pattern, with an
SLR of 0.970.34 (P0.049 versus baseline). SLR returned
to baseline after cessation of CRT (0.770.26, P0.023
versus CRT; Figure 3). There were no significant changes in
SLR for hyperemic MBF during CRT (Table 3).
Echocardiography
At baseline, mean LVEDV, LV end-systolic volume, and
LVEF were 27384 mL, 20772 mL, and 257%, respec-
tively. After 3 months of CRT, LV end-systolic volume
decreased to 16469 mL (P0.01). Although not significant,
LVEDV decreased to 25688 mL (P0.08). LVEF in-
creased to 379% (P0.01). Filling time increased from
TABLE 3. PET Data
Baseline CRT On CRT Off P (MANOVA)
Average
MBF 0.820.25 0.690.24 0.740.24 NS
MBF stress 1.911.03 2.661.66* 1.921.06 0.01
Flow reserve 2.251.00 3.762.38* 2.490.94 0.02
Septal
MBF 0.700.27 0.710.22 0.640.21 NS
MBF stress 1.820.90 2.821.56* 1.831.00 0.01
Flow reserve 3.042.42 4.332.95 2.951.10 NS
Lateral
MBF 0.930.29 0.770.24 0.900.34 NS
MBF stress 2.031.14 2.501.60 2.001.15 NS
Flow reserve 2.050.74 3.161.58* 2.250.80 0.01
Septal/lateral
Rest 0.770.27 0.970.34* 0.770.26 0.04
Stress 0.980.34 1.240.30 1.030.49 NS
Average
MVR rest 11139 13040 12637 NS
MVR stress 5730 4835 5631 NS
MBF indicates myocardial blood flow (mL  min1  mL1); MVR, microvas-
cular resistance (mm HgmL1  min1  mL1). n14.
*P0.05 vs baseline and CRT off.
TABLE 2. Hemodynamic Data (n14)
Baseline CRT On CRT Off
Measure Rest Adenosine Rest Adenosine Rest Adenosine
Heart rate, bpm 6512 7911* 659 8016* 658 7815*
Systolic BP, mm Hg 11720 11220 11217 10717 11417 10621*
Diastolic BP, mm Hg 7013 7010 678 6911 7111 6711
MAP, mm Hg 8514 8411 8310 8111 8512 8013*
RPP, bpm/mm Hg 76321911 89312246* 74421381 88242295* 75761267 83541922*
BP indicates blood pressure; MAP, mean arterial pressure.
*P0.05 vs rest.
Figure 1. Serial changes in resting MBF before implantation of
biventricular pacemaker, 3 months after CRT, and immediately
after cessation of CRT. There are no signiﬁcant changes
between measurements.
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367101 to 401107 ms (P0.01). At baseline, DPT
decreased from 39.39.6 s/min during rest to 34.013.4
s/min (P0.01) during adenosine infusion because of a
higher heart rate. CRT did not alter DPT (rest versus stress,
40.39.0 versus 34.912.9 s/min) compared with baseline.
Interrelation Among Measured Parameters
There was a significant relation between the decrease in wall
stress, expressed as the LVEDV/LVM ratio, and increase in
hyperemic MBF during CRT compared with baseline (Figure
4), whereas there was no correlation between changes in
hyperemic DPT time and hyperemic MBF (Figure 5).
Discussion
Resynchronization therapy is a relatively new treatment for
patients with heart failure and mechanical LV dyssynchrony,
usually identified by the presence of intraventricular conduc-
tion delay such as left bundle-branch block.1,2 Left bundle-
branch block reduces myocardial perfusion in the septum
because of impaired systolic thickening and augmented in-
tramyocardial pressure in the septum.24 The present findings
also demonstrate an inhomogeneous perfusion pattern, with a
reduced SLR of resting MBF. In line with data from Nowak
et al10 using SPECT, CRT was found to have a homogenizing
effect on perfusion. Similar effects on perfusion were ob-
served by the same group using PET.13 Although not signif-
icant, septal perfusion increased and lateral perfusion de-
creased. Ukkonen et al7 also demonstrated a more even
distribution of oxygen consumption during CRT. After 3
months of pacing, changes in regional perfusion were com-
pletely reversible after cessation of CRT. These results
suggest that CRT rebalances the loading conditions of the
heart. Furthermore, improvement in LV function was not
accompanied by an increase in global MBF. Because MBF is
closely coupled to oxygen consumption, this suggests im-
proved efficiency, confirming the pioneering work of Nelson
and coworkers.6
The main finding of the present study was the effect of
CRT on hyperemic MBF and MBF reserve. Both parameters
increased during CRT compared with baseline and decreased
after cessation of CRT to values similar to those found at
baseline. We explored the role of changes in wall stress and
DPT in relation to the observed changes in hyperemic
perfusion.
First, congestive heart failure is accompanied by increased
LV filling pressures and wall stress. Myocardial perfusion
may be affected by these increased pressures through ex-
travascular compression of the coronary vascular bed.22,25
Under baseline conditions, however, myocardial perfusion is
autoregulated at the microvascular level in response to
varying demand.26 Therefore, changes in LV filling pressures
and wall stress do not affect resting myocardial perfusion
because the microvascular bed has the capability of compen-
Figure 2. Serial changes in MBF before implantation of biven-
tricular pacemaker, 3 months after CRT, and immediately after
cessation of CRT. *During CRT, hyperemic MBF is signiﬁcantly
higher compared with baseline MBF (P0.013) and MBF after
cessation of CRT (P0.018).
Figure 3. Serial changes in SLR of resting MBF before implan-
tation of biventricular pacemaker, 3 months after CRT, and
immediately after cessation of CRT. *During CRT, SLR is signiﬁ-
cantly higher compared with baseline SLR (P0.049) and SLR
after cessation of CRT (P0.023).
Figure 4. Relationship between changes induced by CRT in hy-
peremic MBF and LVEDV/LVM ratio (r0.53, P0.05).
Figure 5. Relationship between changes induced by CRT in
MBF and DPT time during hyperemia (r0.17, PNS).
Knaapen et al Effects of CRT on Perfusion Reserve
36
37
sating for these changes by vasodilatation.27 During pharma-
cologically induced maximum vasodilatation, however, this
autoregulatory mechanism is exhausted, and augmentation of
filling pressures and wall stress might lead to a reduction in
hyperemic myocardial perfusion.28 CRT results in a reduction
in LV filling pressures and wall stress.1,2 The reduction in
LVEDV/LVM ratio, as a reflection of end-diastolic wall
stress, was directly related to the increase in hyperemic MBF
during CRT in the present study, supporting the hypothesis of
a relation between the 2 parameters.
Second, myocardial perfusion is a predominantly diastolic
process. Dyssynchrony of the heart reduces diastole by
prolonging the overall tension development time during the
cardiac cycle29 and shortening of LV filling time.30 The latter
phenomenon is even more pronounced in patients with
dilated cardiomyopathy.30 In the presence of autoregulation
of vascular tone, myocardial perfusion is unaffected by
changes in DPT. A reduction in DPT, however, could cause
a reduction in hyperemic MBF when autoregulation is abol-
ished.22 Resynchronization of the heart by means of biven-
tricular pacing increases diastolic filling time,3,31 which may
prolong DPT. CRT could therefore in theory be responsible
for the enhanced hyperemic perfusion observed in the
present study. DPT, however, was unaltered in the present
study because ejection time is hardly affected by CRT,32
even though filling time was increased. Furthermore, there
was no correlation between the change in hyperemic DPT
and hyperemic MBF in our study population. Our data
suggest that, in contrast to wall stress, DPT does not play
an important role in the changes observed in hyperemic
perfusion during CRT.
Independent of the mechanism for the increase in hyper-
emic MBF and MBF reserve, the observation is important
from a pathophysiological point of view. Impairment of MBF
reserve in congestive heart failure, independent of its cause, is
believed to cause repetitive stunning (intermittent periods of
ischemia), leading to chronic reversible LV dysfunction,
which in turn is associated with an adverse prognosis.33,34
Restoration of flow reserve by revascularization therapy can
induce recovery of function and improve prognosis.33 Al-
though the benefit of biventricular pacing is related to
mechanical resynchronization of the interventricular septum
and lateral free wall, the present study suggests that enhance-
ment of MBF reserve might also play a role in the recovery
of function associated with CRT.
Follow-up PET studies were performed after 3 months of
CRT. In general, reverse remodeling occurs over this period
of time.3,4 The reversed remodeling process could have
contributed to the effects of CRT on myocardial perfusion.
The immediate return to baseline values after cessation of
pacing, however, suggests that the effect of remodeling is
limited. Furthermore, once reverse remodeling has occurred,
some of the benefits of CRT are lost gradually over time after
suspension of pacing.3 This is in contrast to the acute changes
in regional MBF and hyperemic MBF observed in the present
study.
Because the present study population was relatively small,
the value of subgroup analyses is very limited. There was,
however, a tendency toward greater augmentation of hyper-
emic MBF by CRT in nonischemic than in ischemic patients.
Flow-limiting stenoses and the presence of scar tissue may be
responsible for these differences.
Recently, Sundell et al9 did not observe a significant
change in hyperemic MBF after cessation of CRT in 10
nonischemic heart failure patients after an average period of
8 months of pacing, although a slight decrease occurred. A
possible explanation for the discrepancy between that study
and the present one could be a difference in patient popula-
tion. Hyperemic perfusion after cessation of CRT was sub-
stantially lower compared with nonischemic patients in our
study (1.60.9 versus 2.51.0 mL · min1 · mL1), indicat-
ing a more advanced stage of dilated cardiomyopathy.28,34
Interestingly, in the present study, enhancement of hyperemic
perfusion was observed predominantly in patients with rela-
tively preserved baseline hyperemic perfusion (Figure 2),
which may be responsible for the discrepancy compared with
the results from Sundell et al.9 This issue, in addition to
underlying mechanisms responsible for the perfusion changes
during CRT, needs to be addressed in future studies.
Conclusions
CRT does not alter resting MBF despite an increase in LV
function, suggesting increased efficiency. The heterogeneous
regional distribution of resting MBF, however, is normalized
by CRT. Furthermore, hyperemic MBF and consequently
MBF reserve are enhanced by CRT.
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In recent years cardiac resynchronization therapy has emerged as a promising new 
treatment strategy in a subgroup of patients with congestive heart failure and an 
asynchronous contraction pattern. By simultaneously pacing both right ventricular apex and 
lateral side of the left ventricle, ventricular synchrony can be partially restored and beneficial 
effects on cardiac performance can be observed. This review discusses the principles of 
ventricular dyssynchrony, and the acute and chronic effects of cardiac resynchronization 
therapy on systolic function, cardiac metabolism, and clinical parameters. Furthermore, the 
issue of identifying patients who do not respond to this therapy is addressed.
In Western civilized countries congestive heart
failure is an increasing public health problem,
affecting about 1% of adults in the USA. The
lifetime risk is now estimated at nearly 20% [1].
Despite advances in medical therapy and revas-
cularization procedures, which have reduced
morbidity and mortality substantially, prognosis
remains poor [2]. Life expectancy for patients
with end-stage heart failure is particularly poor,
with a 1-year survival rate below 50% [3].
In the chronically failing heart structural
changes occur from a subcellular molecular level
to the organ level contractile dysfunction, collec-
tively referred to as remodeling [4]. It is mani-
fested clinically by changes in cardiac size, shape,
and function. The process of remodeling is,
among other, affected by hemodynamic load and
neurohumoral activation factors [4]. In up to a
third of patients the disease process is compli-
cated by intraventricular conduction delay, usu-
ally in the form of left bundle branch block
(LBBB) [5]. The presence of LBBB in patients
with congestive heart failure is associated with an
unfavorable outcome; it may induce an asyn-
chronous contraction pattern, thereby reducing
the efficiency of contraction in the already failing
heart and consequently worsen cardiac failure [5].
In recent years, biventricular (BiV) or left
ventricular (LV) pacing have emerged as new
treatment strategies for this subgroup of patients
with heart failure and ventricular dyssynchrony
[6,7]. Simultaneously pacing the interventricular
septum (RV-apex) and lateral left ventricular
free wall can restore ventricular synchrony and,
therefore, is also known as cardiac resynchroni-
zation therapy (CRT). Studies have demon-
strated that CRT improves hemodynamic
function, heart failure symptoms, exercise
capacity and quality of life, and that it reduces
morbidity and possibly mortality [8–11]. Beside to
effects on acute hemodynamics and oxidative
metabolism [12–15] it has been demonstrated that
CRT induces more chronic structural alterations
that reverse the chamber remodeling process
[9,11,16]. The exact underlying mechanisms respon-
sible for these acute and chronic changes, however,
are not entirely clear.
Positron emission tomography (PET) allows
for noninvasive regional quantification of
different biochemical pathways, while
echocardiography and cardiovascular magnetic
resonance imaging (CMR) have the capability of
assessing mechanical cardiac function. A number
of studies have recently been published that have
assessed the effects of CRT on perfusion, oxida-
tive metabolism, substrate utilization, and the
mechanical activation sequence of the heart.
This review discusses the results from these stud-
ies and the insight they have provided with
respect to the mechanisms involved in
myocardial dyssynchrony and CRT.
Pathophysiology of dyssynchrony
Normal electrical conduction of the heart
modulates the timing of atrial and ventricular
contraction, resulting in an atrial systole followed
by an appropriately timed and coordinated ven-
tricular systole to optimize blood transfer. Disease
of any part of the conduction system can lead to
suboptimal cardiac performance.
Atrioventricular (AV) nodal disease will result
in a delayed ventricular contraction relative to
onset of atrial systole. As a consequence, atrial
systole will occur during the passive filling
period of the left ventricular chamber, rendering
its role as a booster pump ineffective [17].
Optimal AV delay is important to mitral valve
competence, as too much delay leaves the mitral
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leaflets open in mid-plane position when
ventricular systole starts. The latter condition
promotes mitral regurgitation [18].
Infranodal conduction delay changes the
activation sequence of the left ventricle
markedly. In the normal human heart, the onset
and magnitude of contraction in the lateral free
wall is slightly earlier and greater than in the
interventricular septum [19,20]. In LBBB or sin-
gle-site right ventricular (RV) pacing, however,
the septum is activated early and shortening
occurs when left ventricular pressure is relatively
low, typically inducing reciprocal stretch of the
lateral free wall and thus minimally contributing
to ejection of blood [21,22]. The lateral wall is
activated late in the cardiac cycle and contracts
against the high load which has been developed
by the early activated myocardium. Again, work
is wasted by stretching of the septum that has
already started to relax, resulting in paradoxical
septal motion (Figure 1) [21,22]. Consequently,
systolic performance reduces, end-systolic wall
stress increases, and myocardial efficiency
declines, as much of the myocardial work is lost
in shifting of blood within the heart itself
instead of contributing to ejection [21,23]. These
effects are even more pronounced in dilated
failing hearts [24].
Due to the altered loading conditions in
dyssynchrony, regional mechanical work is
distributed inhomogeneously [21,25]. During RV-
apex pacing, septal mechanical work is reduced
by approximately 50%, whereas it is 50%
increased in the lateral free wall (Figure 1) [21]. In
response to the regional decline in metabolic
demand, oxygen consumption, glucose uptake
and myocardial blood flow are reduced in the
interventricular septum [21,25–28].
Cardiac resynchronization therapy
In an attempt to counteract the detrimental
effects of an asynchronous activation sequence
of the failing heart, experiments were conducted
to resynchronize this sequence by
simultaneously stimulating the septum and the
LV-free wall.
Acute hemodynamic effects
Acute beneficial hemodynamic effects were
observed within a few heart beats after initiating
BiV pacing in patients with heart failure and
LBBB [12,13,29]. BiV pacing (or LV pacing only)
immediately increases systolic pressure, maximal
rate in pressure rise (dP/dtmax) and stroke vol-
ume, whereas left ventricular filling pressures are
reduced (Figure 2). The improvement in hemody-
namics in turn induces acute diminution of
sympathetic nerve activity, suggesting favorable
effects on the neurohumoral pathway [30].
Reverse remodeling
Several large studies including hundreds of
patients have shown that CRT causes a gradual
decline in end-diastolic and end-systolic ven-
tricular volumes with an associated increase in
ejection fraction [9,11]. Figure 3 visualizes reverse
remodeling using 3D echocardiography in a
patient before and 6 months after CRT. Fur-
thermore, Yu and coworkers demonstrated that
after pacing therapy for 3 months, immediate
cessation did not result in an acute change in
left ventricular volumes, but in a gradual return
to baseline values within the ensuing month [16].
These studies clearly demonstrate that CRT
reverses the chamber remodeling process that is
associated with progressive heart failure.
Effects on metabolism & perfusion
After the initial observations of improved cardiac
function during CRT, concerns arose that this
may be at the expense of increased use of oxygen,
in concordance with positive inotropic agents.
Previous experience with these agents in heart
Figure 1. Simplified fibre–stress–fibre–length relations 
showing the simultaneous development of muscle force and 
deformation during a normal and abnormal (left bundle 
branch block) activation sequence of the heart. 
In the early stimulated region (septum), there is initial shortening at low stress 
levels, as this motion is principally converted to prestretch of the still inactive 
lateral wall. Stress then develops, but the septal region is pushed on by the later 
activated lateral wall and stretches towards the right ventricle. The net loop area 
of the early activated muscle (septum) is small, indicative of reduced external 
work (EW). The later activated lateral wall initiates stress development from a 
higher prestretch, and the work loop is enlarged compared with normal 
activated myocardium. PE: Potential energy. Reprinted with permission [21].
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failure patients has shown that the beneficial
effects on hemodynamics and quality of life are at
the expense of long-term prognosis [31].
Nelson and colleagues were the first to
determine the acute effects of BiV pacing on
global myocardial oxygen consumption
(MVO2) by measuring the arterial-coronary
sinus oxygen content difference and myocardial
blood flow in ten patients with idiopathic
dilated cardiomyopathy and LBBB [12]. Despite
an increase in dP/dtmax and arterial pulse pres-
sure, MVO2 slightly decreased. Interestingly,
similar changes in dP/dtmax induced by dob-
utamine were accompanied by a significant
increase in MVO2 (Figure 4). In recent years, four
studies have been published investigating the
chronic effects of CRT on LV MVO2 using PET
[15,32–34]. Despite an acute decrease in cardiac
performance after suspension of several months
of CRT, MVO2 remained unaltered. These
studies indicate that CRT, in contrast to positive
inotropic agents, immediately increases myocar-
dial efficiency (work-to-oxygen-consumption
ratio) and this effect is maintained over time.
Furthermore, myocardial metabolic reserve, i.e.,
the ability to increase MVO2 in response to
stress, tends to be increased during long-term
CRT [33,34]. Although data are very limited,
effects of CRT on oxidative metabolism and
metabolic reserve seem to be similar for the left
and right ventricle [32,35].
As CRT rebalances the loading conditions of
the heart, direct effects are sorted on regional
metabolic demand. Inhomogeneous distribution
Figure 2. Registration of electrocardiogram, left ventricular pressure, and rate of 
pressure rise (dP/dt). 
Immediately on initiation of biventricular pacing (RV-apex and posterolateral LV wall), there is an acute rise in 
LVP and dP/dt. Note that QRS width does not decrease. ECG: Electrocardiogram; LVP: Left ventricular pressure.
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of oxygen consumption [15,32], perfusion [15,27],
and glucose metabolism [26], induced by
mechanical dyssynchrony, are normalized by
CRT (Figure 5).
CRT not only affects resting perfusion, but
also perfusion reserve: it was recently
demonstrated that CRT augments perfusion
reserve in direct relation to the reduction in end-
diastolic wall stress [27]. This observation has
important consequences from a pathophysiolog-
ical point of view. Impairment of perfusion
reserve in congestive heart failure, independent
of its etiology, is believed to cause repetitive stun-
ning (intermittent periods of ischemia), leading
to chronic reversible LV dysfunction, which in
turn is associated with an adverse prognosis [36–
38]. Recovery of function observed during CRT
might, therefore, next to mechanical resynchro-
nization, be caused by improvement of perfusion
reserve and a reduction of ischemic episodes.
Randomized clinical trials
Several trials have been conducted to determine
whether the observed beneficial effects on
hemodynamics, chamber geometry, and energet-
ics translate into a more favorable clinical out-
come. This issue has been addressed by
McAlisters and colleagues, who have performed a
meta-analysis of nine randomized clinical trials
(3574 patients in total) [8]. In all trials patients
were enrolled with prolonged QRS width
(> 120 ms), depressed left ventricular function
(LVEF < 40%) and predominantly moderate-to-
severe symptomatic heart failure (85% NYHA III
or IV) despite optimized medical treatment.
These trials have shown improvement in
functional status, the distance patients can walk
in 6 min, and hospital admissions for heart fail-
ure, thereby increasing quality of life. None of the
individual trials have been able to demonstrate a
reduction in mortality, mainly due to relatively
small sample sizes. Combined results of the meta-
analysis, however, demonstrated a 21% reduction
in all-cause mortality (Figure 6). It should be noted
that this analysis has included results from the
Comparison of Medical Therapy, Pacing and
Defibrillation in Chronic Heart Failure
(COMPANION) trial, which also investigated the
value of a combination of CRT with an implanta-
ble cardioverter defibrillator (ICD) [10]. Therefore,
mortality reduction can in part be related to ICD
therapy and thus definitive proof of a mortality
reduction by CRT alone is still lacking.
Identifying responders to CRT
Although the benefits of CRT are becoming
increasingly apparent, there is a major pitfall in
treating patients with a BiV pacemaker.
Approximately 20–30% of selected patients do
Figure 3. 3D echocardiogram (end-diastolic frames) of a 
patient with nonischemic heart failure and left bundle branch 
block before (left) and 6 months after CRT (right). 
There is marked regression of left ventricular volume in addition to remodeling 
in shape from spherical to ellipsoid. (Courtesy of HJ Spruijt).
Figure 4. Comparison between responses of LV-pacing (solid 
squares) and dobutamine infusion (open squares) in patients 
with idiopathic dilated cardiomyopathy and left bundle 
branch block. 
Both LV-pacing and dobutamine cause an increase in cardiac performance 
(dP/dt). In contrast to dobutamine, however, pacing is not accompanied by an 
augmentation of oxygen consumption per heart beat, suggesting increased 
mechanoenergetic efficiency. Adapted from [12].
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not respond to CRT [6,39]. Determining markers
that can prospectively identify patients who are
most likely to respond is therefore of great
clinical importance. Although interventricular
dyssynchrony [40] and AV-dyssynchrony [13] are
of prognostic importance, intraventricular
dyssynchrony seems to be the most important
marker [7,41].
The most common marker of intraventricular
dyssynchrony is the presence and magnitude of
conduction delay on the surface electrocardio-
gram (ECG), which has been an inclusion crite-
rion in every major clinical trial. However, QRS-
width is, at best, a crude predictor of acute
hemodynamic response to BiV pacing [13,41].
Furthermore, there is no correlation between
change in QRS duration induced by CRT and
actual mechanical resynchronization [41,42].
These data emphasize that electrical asynchrony
may not accurately reflect mechanical dyssyn-
chrony. Imaging techniques are therefore
required to assess mechanical activation directly.
Echocardiography
In a short period of time, echocardiography has
evolved into a powerful technique for imaging
the mechanical activation sequence of the heart
[43]. Conventional echocardiography offers a
simple method for determining ventricular dys-
synchrony by M-mode imaging. In a short-axis
view the septal-to-posterior wall motion delay
(SPWMD) can be obtained. Pitzalis and co-
workers have demonstrated a reasonable relation
between baseline SPWMD and the degree of
reverse remodeling [44].
More advanced echocardiographic methods
for visualizing of mechanical dyssynchrony have
been proposed by Breithardt and colleagues [45]
and Kawaguchi and coworkers [46]. The first
group used a semiautomatic endomyocardial
contour detection on standard 2D echocardio-
graphic sequences from the apical four-chamber
view. Subsequently, based on Fourier transfor-
mation, septal and lateral wall motions were
quantified and related to each other. Kawaguchi
and coworkers used similar echocardiographic
sequences with the addition of a contrast agent
to optimize endocardial contour detection [46].
Regional fractional area changes were
determined and plotted versus time, yielding
displacement maps. These techniques result in a
quantitative description of mechanical
asynchrony.
An important limitation of both techniques is
the fact that only a single imaging plane is
analyzed and dyssynchrony of other walls is not
taken into account. 3D echocardiography may
overcome this limitation and the first results are
promising [47]. Figure 7 shows an example of a
polar map of mechanical activation derived by
3D echocardiography before and during CRT.
Before CRT, mechanical asynchrony is clearly
demonstrated with early activation of the septum
compared with the lateral wall. During CRT,
mechanical activation becomes more
homogeneous. Studies demonstrating the
clinical feasibility of this advanced technique,
however, are still needed.
Tissue Doppler imaging (TDI) is an
echocardiographic technique in which the
velocity of tissue can be quantified on a regional
level in time and space. TDI can therefore assess
the mechanical activation sequence of the sep-
tum and LV free wall and thus determine syn-
chrony. Using this technique, Bax and coworkers
could accurately identify responders with a most
sensitive threshold of 65 ms contraction delay
between septum and lateral wall [48].
Figure 5. Glucose metabolism (18F-fluorodeoxyglucose 
positron emission tomography) is reduced in the septum in a 
heart failure with mechanical dyssynchrony. 
Panel A: short axis, B: long axis. Two weeks after cardiac resynchronization 
therapy (panel C and D) glucose distribution is more evenly distributed 
throughout the left ventricle, indicating rebalancing of myocardial work. 
Adapted from [26].
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Magnetic resonance tissue tagging
Although echocardiography is an easy accessible
imaging tool and relatively low in cost, it suffers
from its dependency on an adequate acoustic
window, resulting in poor signal-to-noise ratios
in a substantial percentage of patients.
Cardiovascular magnetic resonance (CMR)
tissue tagging allows for accurate quantification
of deformation and motion of myocardial tissue
(strain) with high temporal and spatial
resolution (Figure 8) [19,20]. Therefore, strain can
be mapped for the entire left ventricle. Figure 9
displays strain curves of a healthy control subject
and a patient with idiopathic dilated cardiomy-
opathy and LBBB for anteroseptal and posterola-
teral myocardial segments. Contraction is
synchronous in the control subject, with nega-
tive strains (shortening) of almost similar ampli-
tude and phase. In contrast, the patient with
heart failure and LBBB displays marked hetero-
geneity in timing and shortening between the
two regions, clearly demonstrating dyssyn-
chrony. From these strain curves, a so-called dys-
synchrony index can be calculated, which
appears to be an excellent tool for identifying
responders to CRT [41].
Importantly, Figure 9 also shows strain curves
of a patient with heart failure without electrical
asynchrony. As can be observed, mechanical
asynchrony is not restricted to patients with
electrical asynchrony. In fact, using TDI, Yu and
colleagues have demonstrated that in a series of
67 heart failure patients with a narrow QRS
complex (< 120 ms), mechanical dyssynchrony
can be observed in over half of these patients
[49]. These results further indicate that QRS-
width does not accurately reflect mechanical
activation of the cardiac chamber. These new
insights may expand patient eligibility for CRT
to all refractory heart failure patients with
mechanical asynchrony, independent of
electrical asynchrony.
Furthermore, lead position optimization is an
important unresolved issue in CRT. To date,
pacemaker leads are usually implanted in the
right ventricular apex and in a posterolateral car-
diac vein in order to pace the interventricular
septum and left ventricular lateral free wall,
respectively. However, an individual tailored
approach based on selecting the pacing site to
the most delayed activated myocardial region
would be more logical in trying to optimally
resynchronize the heart. Using this approach,
Ansalone and colleagues [50] have demonstrated
that this mechanical activation sequence guided
approach by echocardiography is accompanied
by a better response to CRT, although more
studies are needed to confirm these results.
Finally, the underlying etiology of heart fail-
ure is of importance. It appears that patients
with ischemic heart failure and previous myo-
cardial infarction benefit to a lesser extent from
CRT in terms of clinical improvement and
reverse remodeling than nonischemic patients
[9,51]. Although the reason for the disparity
Figure 6. Pooled data from 9 randomized clinical trials with 
respect to all cause mortality of patients treated with CRT 
compared with controls.
CRT is associated with a 21% reduction in all cause mortality. Adapted from [8].
Figure 7. Polar map visualization of a 3D echocardiogram 
reflecting the mechanical activation sequence of the left 
ventricle in a heart failure patient with LBBB prior to (left) 
implantation of a biventricular pacemaker and immediately 
after (right). 
Note that before implantation, the septum is activated early relative to the 
lateral wall. After implantation, mechanical activation is resynchronized.  A: 
Anterior; I: Inferior; L: Lateral; LBBB: Left bundle branch block; S:Septal. 
(Courtesy of JA van der Heide).
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between these patient groups remains to be
elucidated, two potential mechanisms are likely
involved. First, pacing in scar tissue may not
adequately excite the myocardial tissue. This
should be considered in patients who do not
respond to CRT despite the presence of
favorable prognostic markers as mentioned
above. Second, tissue viability may be important
for the reverse remodeling process. CRT reduces
filling pressures and wall stress and consequently
creates the hemodynamic conditions that allows
for reverse remodeling. Clearly, scar tissue will not
benefit from these conditions, whereas viable tissue
may be able to facilitate reverse remodeling.
Preliminary data indeed suggest that the extent
of myocardial viability predict the response to
CRT [52–54].
Limitations
The complication rate of implantation of a BiV
pacemaker is far from negligible. Peri-procedural
mortality is estimated at 0.4%, vascular compli-
cations (e.g., coronary sinus dissection) at 6%,
and infection at 1% [8]. Failure to successfully
implant the device, even in the hands of an expe-
rienced physician, occurs in as many as 10% of
patients [8,39]. Moreover, after successful
implantation, lead dislodgment (9%) or device
malfunction (7%) is not uncommon [8].
Placebo response is another issue that should
not be taken lightly. In various clinical trials, an
improvement in functional class in the placebo
arm could be observed in up to 50% of
Figure 8. End-diastolic (A) and end-systolic (B) magnetic 
resonance tissue tagging images in a short axis view of a 
heart failure patient. 
Deformation of the myocardium results in deformation of the taglines. The 
extent and velocity of deformation can be plotted against time, resulting in a 
strain curve.
 A B 
Figure 9. Strain curves for anteroseptal and posterolateral segments in a control 
subject and in a heart failure patient with and without electrical asynchrony. 
Contraction is synchronous in the control subject with negative strains (contraction) of fairly similar amplitude 
and phase in both segments. Mechanical asynchrony is present in both patients, independent of the electrical 
asynchrony. The solid red line represents the closure of the aortic valve. (Courtesy of JJM Zwanenburg).
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patients [39]. Clearly, the implantation of the
device alone, together with the accompanying
increased medical care and follow-up frequency,
can result in enhanced well being. In addition,
in most clinical trials patients were randomized
after a successful device implant, limiting the
usefulness of the final results as compared with
a true intention-to-treat study design. Results
as observed in controlled trials may therefore be
difficult to replicate in general clinical practice.
Conclusion
Cardiac resynchronization therapy is a
relatively new therapy for a selected group of
patients with moderate-severe congestive heart
failure and mechanical asynchrony. By restoring
the mechanical activation sequence of the
heart, CRT exerts acute hemodynamic
improvement as well as more chronic effects
such as reverse remodeling. Furthermore, CRT
enhances mechano-energetic efficiency and
perfusion reserve. Clinical benefits include
increased quality of life, functional status, and
exercise capacity, whereas morbidity is reduced.
Pharmacotherapy, though limited, remains the
cornerstone of heart failure treatment.
Nevertheless, CRT has gained wide acceptance
as an additional treatment strategy for eligible
patients.
Future perspective
Current ACC/AHA/NASPE (American
College of Cardiology/American Heart
Association Task Force on Practice) guidelines
have classified biventricular pacing for dilated
cardiomyopathy as class IIA when the following
criteria are met: medically refractory, sympto-
matic NYHA class III or IV patients with idio-
pathic dilated or ischemic cardiomyopathy,
prolonged QRS width (> 130 ms), LV end-
diastolic diameter > 55 mm, and ejection frac-
tion < 35% [55]. Note that only 10% of the total
population of patients with moderate-to-severe
heart failure fulfill these criteria [55,56]. In addi-
tion, as mentioned above, 20–30% of this par-
ticular eligible patient population will not
respond to CRT. Finally, new insights have
already outdated some of these criteria.
First, due to the increasing awareness of
pursuing a mechanical rather than electrical
asynchrony-guided approach in selecting
patients for CRT, QRS width may soon be dis-
regarded. However, more studies are needed
that focus on the validation of various imaging
modalities to accurately identify patients with
mechanical asynchrony, and on the subsequent
demonstration of higher response rates.
Second, even though data are scarce, patients
with mild heart failure symptoms (NYHA II)
and intraventricular conduction delay may also
benefit from CRT. Abraham and coworkers
have shown that these patients do not benefit
from CRT in terms of exercise capacity, but they
do show a slight regression in LV volumes and
function, and improvement in clinical response,
suggesting that the remodeling process can be
arrested in these mildly symptomatic patients
[57]. Even more interesting, in the Dual
Chamber and VVI Implantable Defibrillator
(DAVID) trial [58], a patient group with
predominantly mild symptomatic ischemic LV
dysfunction and less than 30% incidence of
conduction delay, single site ventricular pacing
had detrimental effects on LV function
compared with non-pacing. These studies sug-
gest that CRT indications might be expanded
not only to patients with mild heart failure and
mechanical asynchrony; eventually, it may
replace single-site ventricular pacing when
indicated for brady-arrhythmias in combination
with LV dysfunction, independent of the
presence of mechanical asynchrony. Even when
indications are expanded, however, the vast
majority of heart failure patients will not be
eligible for CRT. Future treatment strategies will
therefore have to focus on this patient
population as a whole.
As pharmacological antagonists of the
neurohumoral pathway seem to have reached
its therapeutic limits [59], potential treatment
options with non-neurohumoral agents must
be explored further. Some of these include anti-
cytokine and immunomodulating agents,
matrix metalloproteinase inhibitors, metabolic
interventions, and antianemic agents [60]. Fur-
thermore, many ongoing investigations test the
potential of myocardial replacement therapy,
e.g., by injection of bone marrow cells and
autologous skeletal myoblast transplantation,
for restoring contractile function [61]. Finally,
mechanical support of the left ventricle prom-
ises to gain a role of importance in the treat-
ment of heart failure [62]. To date, because of
infective and hemorrhagic complications and
mechanical device failure, this treatment is used
primarily as a bridge to heart transplantation.
New (non-pulsatile) left ventricular assist
devices, however, appear to substantially reduce
these complications and clinical trials are now
being conducted [62,63].
4343
48
49
                                                                                                      Cardiac resynchronization therapy – REVIEW
Executive summary
Epidemiology
• Congestive heart failure affects about 1% of adults in USA, with a lifetime risk of 20%.
Prognosis
• Despite advances in medical treatment, prognosis remains poor. 1-year survival rate for symptomatic, end-stage heart failure 
patients is less than 50%.
Left bundle branch block
• Left bundle branch block (LBBB) occurs in a third of heart failure patients, and is accompanied by an adverse prognosis due to the 
detrimental effects of a dyssynchronous contraction pattern in the already failing heart.
Cardiac resynchronization therapy
• Simultaneously pacing the interventricular septum, i.e. right ventricular apex, and left ventricular free wall (biventricular pacing) 
can partially restore ventricular synchrony. The latter results in acute improvement of cardiac performance, induces reverse 
remodeling, and translates into improved quality of life and reduced morbidity. The effects on mortality remain to be elucidated.
Current selection criteria
• Refractory congestive heart failure NYHA III/IV.
• QRS width more than 130 ms.
• Left ventricular (LV) end-diastolic diameter more than 55 mm.
• LV ejection fraction less than 35%.
Response to therapy
• Disparity between electrical (prolonged QRS width) and mechanical asynchrony is primarily responsible for the fact that 20–30% 
of patients do not respond to cardiac resynchronization therapy (CRT). Imaging tools such as echocardiography and magnetic 
resonance imaging can accurately visualize the mechanical activation sequence of the heart. Therefore, these techniques are 
useful in identifying patients with mechanical asynchrony who are most likely to respond to CRT.
Limitations
• Only 10% of patients with moderate-to-severe heart failure meet the current criteria for CRT. Furthermore, failure to implant the 
device successfully occurs in as many as 10% of eligible patients.
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Perfusable Tissue Index as a Potential Marker of
Fibrosis in Patients with Idiopathic Dilated
Cardiomyopathy
Paul Knaapen, MD1; Ronald Boellaard, PhD2; Marco J.W. Go¨tte, MD, PhD1; Pieter A. Dijkmans, MD1;
Linda M.C. van Campen, MD1; Carel C. de Cock, MD, PhD1; Gert Luurtsema, BSc2; Cees A. Visser, MD, PhD1;
Adriaan A. Lammertsma, PhD2; and Frans C. Visser, MD, PhD1
1Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands; and 2PET Center, VU University Medical
Center, Amsterdam, The Netherlands
A varying degree of interstitial and perivascular fibrosis is a
common finding in idiopathic dilated cardiomyopathy (DCM).
The perfusable tissue index (PTI), obtained with PET, is a non-
invasive tool for assessing myocardial fibrosis on a regional
level. Measurements of the PTI in DCM, however, have not been
performed yet. This study was undertaken to test the hypothesis
that the PTI is reduced in patients with DCM. Methods: Fifteen
patients with an advanced stage of DCM (New York Heart
Association class III or IV and left ventricular ejection fraction
[LVEF]  35%) and 11 healthy control subjects were studied.
PET was performed using H215O and C15O to obtain the perfus-
able tissue fraction (PTF) and the anatomic tissue fraction (ATF),
respectively. Results: The PTI (PTF/ATF) was reduced in DCM
compared with control subjects (0.91  0.12 vs. 1.12  0.10;
P 0.01). Heterogeneity of the PTI, expressed as the coefficient
of variation, was increased in DCM versus that of healthy control
subjects (0.18  0.07 vs. 0.13  0.06; P  0.05). There was no
correlation between the PTI and echocardiographically derived
LVEF in both groups. Conclusion: The PTI was reduced in
patients with an advanced stage of DCM. Interstitial and
perivascular fibrosis may be responsible for this reduction. Fur-
thermore, the degree of the PTI reduction was variable in DCM
patients, both on a regional level and between patients. Nonin-
vasive assessment of fibrosis with the PTI offers the opportunity
to evaluate the effects of fibrosis on regional myocardial func-
tion, correlate fibrosis with prognosis, and monitor pharmaceu-
tical intervention.
Key Words: PET; perfusable tissue index; idiopathic dilated
cardiomyopathy
J Nucl Med 2004; 45:1299–1304
Idiopathic dilated cardiomyopathy (DCM) is a syndrome
characterized by cardiac enlargement and global systolic
dysfunction in the presence of normal coronary arteries (1).
Histologic examination often reveals a variable degree of
interstitial and perivascular fibrosis (2–8). Several studies
have made an attempt to link the severity of fibrosis to
myocardial (dys)function and prognosis (4,5,9–11). Results
have been conflicting, however, partly due to the difficulty
of quantifying myocardial fibrosis. Quantification of fibrosis
is only possible in explanted hearts or through endomyo-
cardial biopsies. A biopsy, however, is an invasive proce-
dure and it only yields information at a very limited regional
level.
The perfusable tissue index (PTI) could potentially be
used to noninvasively assess myocardial fibrosis. This index
is the ratio of the perfusable tissue fraction (PTF) and the
anatomic tissue fraction (ATF). It can be obtained with PET
using the tracers H215O and C15O (12). The PTI represents
the fraction of myocardium that is perfusable by water.
Myocardial fibrosis is not able to exchange water rapidly,
and a reduction of the PTI has been shown to correlate with
the extent of fibrosis after infarction (13). Therefore, the PTI
may be reduced in patients with DCM due to an increase in
myocardial fibrosis. In addition, because fibrosis is not
always distributed homogeneously in DCM (3,4,7), regional
differences in the PTI may be expected. To date, however,
no measurements of the PTI in patients with DCM have
been performed.
The purpose of this study was to evaluate whether (a) the
PTI is reduced in patients with DCM in comparison with
that of healthy volunteers, (b) the PTI is distributed heter-
ogeneously in DCM, and (c) the PTI is related to global
myocardial function.
MATERIALS AND METHODS
Patient Population
Fifteen patients with an advanced stage of DCM (New York
Heart Association class III or IV and left ventricular ejection
fraction [LVEF]  35%) and 11 healthy control subjects were
studied. The diagnosis of DCM was based on increased left ven-
tricular dimensions, a globally decreased contraction pattern as
determined by echocardiography, and the presence of normal
Received Nov 26, 2003; revision accepted Jan. 26, 2004.
For correspondence or reprints contact: Paul Knaapen, MD, Department of
Cardiology, 6D Room 120, VU University Medical Center, De Boelelaan 1117,
1081 HV Amsterdam The Netherlands.
E-mail: p.knaapen@vumc.nl
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coronary arteries as assessed by angiography. Patients were ex-
cluded if there was evidence of prior myocardial infarction, un-
derlying valvular pathology by echocardiography, uncontrolled
systemic hypertension, or any other systemic disease. Patients
were clinically stable on medication, including angiotensin-con-
verting enzyme inhibitors, diuretics, digoxin, and -blockers. All
healthy control subjects underwent a physical examination, elec-
trocardiography, laboratory analysis, and echocardiography. None
of the results from these examinations showed any abnormalities.
Characteristics of the study population are given in Table 1. All
subjects gave written, informed consent, and the protocol was
approved by the Medical Ethics Committee of the VU University
Medical Center.
Imaging Protocols
PET. All scans were performed in 2-dimensional mode, using an
ECAT EXACT HR scanner (Siemens/CTI). This scanner ac-
quires 63 planes of data over an axial field of view of 15 cm. A
10-min transmission scan, using 3 rotating 68Ge line sources to-
gether with sinogram windowing, was performed after a short
transmission scan for patient positioning. Subjects were constantly
monitored with single-lead electrocardiography, and blood pres-
sure was measured every 3 min.
After the transmission scan, 1,100 MBq H215O dissolved in 5
mL saline were injected intravenously by bolus injection, which
was followed by a 40-mL saline flush at a rate of 4 mL/s. A
dynamic scan was acquired consisting of 40 frames with variable
frame length for a total time of 10 min (12  5 s, 12  10 s, 6 
20 s, 10  30 s). Subsequently, blood-pool imaging was per-
formed. During a 2-min period subjects inhaled at least 2,000 MBq
C15O and a single frame was acquired for a 6-min duration, starting
1 min after the end of inhalation to allow for equilibration in the
blood pool. During the C15O scan, 3 venous blood samples were
drawn from the intravenous line and counted in a sodium iodide
well counter cross-calibrated against the scanner. Equilibrium of
C15O within blood was confirmed by comparison of the 3 decay-
corrected blood samples (data not shown). Emission data were
corrected for physical decay of 15O, dead time, scatter, randoms,
and photon attenuation. Reconstruction of the H215O emission
sinograms was performed using filtered backprojection (FBP) with
a Hanning filter at 0.5 of the Nyquist frequency. Transmission and
C15O sinograms were iteratively reconstructed using ordered-sub-
set expectation maximization ([OSEM] CTI version 7.1.1; 2 iter-
ations, 16 subsets). OSEM images underwent 5-mm full width at
half maximum gaussian postsmoothing to ensure resolution match-
ing (7 mm) between OSEM and FBP reconstructed images, as
shown by Boellaard et al. (14)
Echocardiography. All patients and control subjects underwent
complete 2-dimensional and Doppler echocardiography to deter-
mine left ventricular and valve function. Standard parasternal and
apical views were recorded on VHS videotape for subsequent
off-line analysis.
Data Analysis
PET. Data were transferred to a SUN workstation (SUN Micro-
systems Inc.) and analyzed using Siemens/CTI software. Anatomic
tissue images were generated according to the procedure describes
by Iida et al. (15) Briefly, blood volume images were normalized
to the radioactivity in blood as measured from the samples. The
reconstructed transmission data were normalized on a pixel-by-
pixel basis to the average pixel counts in a region of interest (ROI)
in the left ventricular chamber of the transmission image. Quan-
titative images of the ATF (mL/mL) were calculated taking into
account the differences between the densities of blood and tissue.
Transaxial ATF images of the left ventricle were reoriented
according to the anatomic axis of the heart and slices were dis-
played as short-axis slices. The same reslicing parameters were
applied to the dynamic H215O images. Figure 1A shows an ATF
image from a healthy control subject. ROIs were defined manually
at the basal and midventricular level of the left ventricle. Each
basal and midventricular slice was divided in 6 equidistant sectors
angulated 60° apart starting from the posterior insertion of the right
ventricular free wall into the left ventricular myocardium. Corre-
sponding ROIs from a variable number of slices were grouped in
each patient to generate 12 volumes of interest (6 basal and 6
midventricular). The inferior volumes of interest were excluded
from analysis because of anticipated PTF spillover effects from the
liver. Figure 1B displays a parametric PTF image in short-axis
view generated using a basis function method described by Lodge
et al. (16), clearly demonstrating the inability to delineate the
inferior wall from the liver. The apex was also excluded from
analysis due to difficulty in delineating apical myocardium from
adjacent structures on the ATF short-axis images in the patient
group.
Additional ROIs were defined in the left and right ventricular
chamber. This set of ROIs was projected on the dynamic H215O
images to generate image-derived input functions. Using the stan-
dard single-tissue compartment model together with these input
functions, myocardial blood flow (MBF) (mL/min/mL of perfus-
able tissue) and PTF (mL/mL) were determined for all myocardial
tissue time–activity curves (17,18). Corrections were made for
spillover from both the left and the right ventricle using the method
described by Hermansen et al. (19). As the resting MBF is related
to the rate–pressure product (RPP  heart rate  systolic blood
pressure), corrected resting MBF (MBF/RPP  10,000) was also
determined. Regional differences in the MBF and PTI were eval-
uated by grouping of volumes of interests such that the heart was
divided into 3 segments (anterior, lateral, and septal). For assess-
ment of heterogeneity, each of the 10 volumes of interest was used.
Echocardiography. Left ventricular end-diastolic and end-sys-
tolic volumes were determined from apical 2- and 4-chamber
views using the Simpson biplane formula according to the recom-
TABLE 1
Characteristics of Healthy Control Subjects
and DCM Patients
Parameter Control (n  11) DCM (n  15) P value
Age (y) 28  2 54  10 0.01
Sex (M/F) 8/3 7/8 NS
NYHA — 3.2  0.4 —
LVEF (%) 65  5 28  6 0.01
ESVI (mL/m2) 22  13 90  34 0.01
EDVI (mL/m2) 61  31 121  39 0.01
IVS (mm) 8.1  1.2 8.7  1.2 NS
LVPW (mm) 8.3  1.7 8.9  1.2 NS
RPP (bpm/mm Hg) 7,902  1,494 8,522  2,212 NS
NS  not significant; ESVI  end-systolic volume index; EDVI 
end-diastolic volume index; IVS  interventricular septum; LVPW 
left ventricular posterior wall; RPP  rate–pressure product.
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mendations of the American Society of Echocardiography (20).
The volumes were corrected for the body surface area. LVEF was
calculated as follows: 100  (end-diastolic volume  end-systolic
volume)/end-diastolic volume.
Statistical Analysis. Data are expressed as mean  SD. For
comparison of 2 datasets, the unpaired Student t test was per-
formed. Comparison of multiple datasets was performed using
ANOVA, and specific differences were identified by a Student t
test corrected for multiple comparisons with the Bonferroni in-
equality adjustment. The Pearson correlation coefficient was used
to investigate associations between study variables. Heterogeneity
was expressed as the coefficient of variation (COV) (SD/mean).
For graphical presentation of heterogeneity, both MBF and PTI
measurements were corrected for intersubject variation by dividing
the values of each volume of interest by the respective mean values
for that patient, yielding normalized MBF and PTI data (21).
Differences with a P value  0.05 were considered statistically
significant. All analyses were performed using SPSS version 9
(SPSS Inc.).
RESULTS
Healthy Control Group
PET data from the healthy control subjects and DCM
patients are summarized in Table 2. With the exception of
the PTF, all PET parameters were distributed homoge-
neously throughout the ventricular myocardium in the
healthy control group. PTF values in the lateral segments
were higher than those in the anterior segments (P  0.05).
The mean value for the PTI was 1.12  0.10.
DCM Group
MBF and ATF were distributed homogeneously in the
DCM group. The PTF and PTI, however, demonstrated
regional differences. The PTF was higher in the lateral
segment compared with that in the septal segment (P 
0.01) and the PTI was higher in the lateral segment than that
in the anterior and septal segments (P  0.05). The mean
value for the PTI was 0.91  0.12.
DCM Patients Versus Control Subjects
Comparison between DCM patients and the healthy con-
trol group demonstrated similar mean MBF values. Correc-
tions for the RPP did not alter the results. The mean PTI was
reduced in DCM patients (P  0.01; Fig. 2) due to an
increase in the mean ATF (P  0.01; Fig. 3A) and a
decrease in the mean PTF (P  0.05; Fig. 3B) compared
with that of healthy control subjects.
No correlation was found between the mean PTI and
LVEF for healthy control subjects (r  0.27; P  not
significant [NS]) or DCM patients (r  0.12; P  NS). The
end-systolic volume index (EDVI), a measure of disease
progression (1), did not correlate with the PTI either (r 
0.08; P  NS).
FIGURE 1. Short-axis ATF (A) and PTF (B) images of a healthy
volunteer. Arrow in PTF image indicates inferior wall. Spillover
effects from adjacent liver tissue are present.
TABLE 2
PET Data from Healthy Control Subjects and DCM Patients
Group MBF* (mL/min/mL) MBFcorr ATF (mL/mL) PTF (mL/mL) PTI
Control
Anterior 0.89  0.20 1.14  0.23 0.55  0.07 0.57  0.07 1.05  0.16
Lateral 0.91  0.18 1.16  0.16 0.55  0.06 0.63  0.04† 1.13  0.11
Septal 0.95  0.25 1.20  0.23 0.52  0.07 0.59  0.08 1.13  0.13
Mean  SD 0.92  0.20 1.17  0.19 0.54  0.06 0.61  0.05 1.12  0.10
P (ANOVA) NS NS NS 0.05 NS
DCM
Anterior 1.07  0.42 1.32  0.64 0.62  0.06 0.52  0.08 0.84  0.13
Lateral 1.14  0.36 1.39  0.40 0.62  0.06 0.60  0.06‡ 0.95  0.15§
Septal 0.85  0.33 1.03  0.40 0.58  0.08 0.49  0.12 0.84  0.19
Mean  SD 1.02  0.34 1.24  0.42 0.61  0.06 0.55  0.08 0.91  0.12
P (ANOVA) NS NS NS 0.01 0.05
*mL/min/mL of perfusable tissue.
†P  0.05 vs. anterior.
‡P  0.01 vs. septal.
§P  0.05 vs. anterior and septal.
MBFcorr  MBF corrected for rate–pressure product; NS  not significant.
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Heterogeneity
Table 3 shows COVs from PET data. Although segmen-
tal analysis of MBF by ANOVA did not reveal significant
differences between the anterior, lateral, and septal seg-
ments in DCM patients (Table 2), the COV for the MBF
determined from 10 myocardial segments in each subject
was higher in DCM patients (P  0.05; Fig. 4A). The PTF
and PTI (P  0.05; Fig. 4B) also demonstrated higher
COVs in DCM patients than those in healthy control sub-
jects. The COV for the ATF did not differ between groups.
DISCUSSION
The main finding of this study is that the PTI is reduced
in patients with DCM. Interstitial and perivascular fibrosis,
commonly found in this patient group (2–8), may be re-
sponsible for this reduction. This hypothesis is supported by
the data of Iida et al. (13), who found a positive correlation
between the reduction in the PTI and myocardial fibrosis
after infarction in canine hearts. The range of PTI values
observed in DCM overlapped with those observed in
healthy control subjects. These results are in agreement with
histopathologic findings in DCM, which show a varying
degree of fibrosis ranging from mild to as much as 50%
(3–5,7,8). Average values of fibrosis in DCM have been
reported to be approximately 10%–20% (3–5,7,8), which is
compatible with the reduction in the PTI seen in the present
DCM population.
Healthy Control Group
Values for the MBF and PTI from the healthy control
subjects are in line with previous studies (15,18,22). For
normal human myocardium, the PTF is approximately 10%
higher than the ATF because venous blood volume of the
heart is included in this parameter (0.10 mL/g of net
myocardium) (18,23). An expected value for the PTI is
therefore close to 1.1 in normal myocardium (15,18,22).
The only regional difference in PET data was a higher value
of the PTF in the lateral segment compared with that of the
anterior segment (P  0.05). This could be due to ROI
definition. The PTI, being the ratio of the PTF and ATF, is
unaffected by these observer-dependent effects.
DCM Group
The ATF and MBF were distributed homogeneously in
the DCM group, although the latter showed a trend toward
a lower MBF in the septal region. In addition, heterogeneity
expressed as COV was higher in DCM than that in control
subjects. This may be explained by the observation that in
advanced stages of DCM some form of intraventricular
conduction delay is often present, which in turn is associ-
ated with a reduced septal MBF (24). Furthermore, hetero-
geneity in regional myocardial function and oxygen con-
sumption has been noted in these patients (25). This also
might lead to heterogeneity in perfusion by means of auto-
regulatory mechanisms of the microvascular bed in re-
sponse to varying demand.
Regional differences were found for the PTF with the
lateral value being higher than the septal value (P  0.01)
and for the PTI with the lateral value being higher than the
anterior and septal value (P  0.05). Both of these param-
FIGURE 2. PTI for healthy control subjects and DCM patients.
FIGURE 3. ATF (A) and PTF (B) for
healthy control subjects and DCM patients.
TABLE 3
COVs from PET Data
Parameter Control DCM P value
MBF 0.17  0.05 0.25  0.10 0.05
ATF 0.09  0.04 0.10  0.03 NS
PTF 0.13  0.06 0.19  0.06 0.05
PTI 0.13  0.06 0.18  0.07 0.05
NS  not significant.
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eters also demonstrated increased COV compared with that
of control subjects (Table 3). Differences in regional distri-
bution of the PTI may reflect regional differences in myo-
cardial fibrosis. This is supported by previous studies dem-
onstrating heterogeneity in distribution of fibrosis in DCM
(3,4,7). The mean PTI was lower in DCM compared with
that of healthy control subjects due to both a higher ATF
and a lower PTF. Both PTF and ATF are dependent on the
physical dimensions of the heart wall (partial-volume ef-
fect), motion of the heart, and ROI size (15,18). The PTF is
also dependent on the physiologic properties of the myo-
cardial tissue contained within the ROI—that is, the ability
to exchange water. In line with necropsy findings (2), wall
thickness of the myocardium was similar for DCM patients
and healthy control subjects (Table 1) and therefore cannot
explain differences between groups with regard to the ATF
and PTF. Reduced contractility of the heart will result in
higher ATF and PTF values, because of less “smearing” of
the signal within the ROI during the cardiac cycle. This
would explain the higher ATF values. Fibrosis is probably
responsible for the lower value of the PTF, as fibrotic tissue
is not able to exchange water rapidly (13).
Because the PTI equals the ratio of the PTF and ATF, this
measurement is independent of partial-volume effects, mo-
tion of the heart, and ROI definition. The PTI reflects only
that portion of the myocardium able to exchange water
rapidly—that is, perfusable tissue.
Correlation Between PTI and LVEF
There was no correlation between the LVEF and PTI in
either the patient or the control group. Although myocardial
dysfunction in DCM is caused by myocyte pathology (e.g.,
energy compromise, mutation-induced alterations in myo-
fibrillar calcium sensitivity) (26), it can be hypothesized that
an increase in interstitial and perivascular fibrosis is accom-
panied by a decline in myocardial function. Previous studies
investigating this relationship showed conflicting results,
varying from no correlation (9,10,27) to a weak correlation
(4,5,11). Comparison between these studies is difficult be-
cause study populations were inhomogeneous and none of
the studies was able to accurately quantify myocardial fi-
brosis. Furthermore, no data are available on the relation
between function and fibrosis on a regional level. The latter
is especially interesting, as fibrosis and function are not
always distributed homogeneously (3,4,7,25).
The present study population was relatively small and only
patients with an advanced stage of DCM were included. A
wider range of disease stages might be necessary to establish a
relationship between the PTI and function. Further studies
must be conducted with special emphasis on the relation
between regional contractile function and fibrosis.
Recently, an alternative method for noninvasive assessment
of myocardial fibrotic tissue has emerged using gadolinium-
delayed-enhanced cardiovascular MRI (CMR-DE) (28). This
technique has proven to give accurate measurements of scar
tissue size after myocardial infarction (29). CMR-DE, how-
ever, is sensitive to regional differences in gadolinium accu-
mulation rather than an overall increase because it depends on
using remote normal myocardium as a reference (30). Diffuse
microscopic fibrosis seen in DCM patients, therefore, can
generally not be detected by CMR-DE (31).
Limitations
In this study no histologic samples by endomyocardial
biopsy were obtained; therefore, there is no evidence that
the reduction of the PTI in patients with DCM actually
represents myocardial fibrosis. As a biopsy is an invasive
procedure with associated complications (32), it was not
included in the present study protocol. In addition, biopsy
is subjected to sampling error and only provides endo-
myocardial information on a very limited regional level.
The first aim of the study was to verify whether the PTI
would be altered at all. Having demonstrated a reduction,
future studies need to compare the PTI and histologic
samples directly, especially because Herrero et al. (33)
have suggested that the PTI may be affected by perfusion
heterogeneity.
Furthermore, the healthy volunteers were not age matched.
Advanced age is accompanied by a slight increase in myo-
cardial fibrosis and, therefore, a possible reduction in the
PTI (34,35). Previous studies, comparing the PTI between
healthy volunteers and patients with myocardial infarction
(12,15) had a similar age difference between groups. In
those studies, the PTI did not differ between healthy vol-
unteers and the normal contractile remote myocardium of
FIGURE 4. Frequency distributions (per-
centage of left ventricle) of normalized
MBF (A) and PTI (B) for both healthy control
subjects (solid lines) and DCM patients
(dashed lines). COVs were increased for
MBF and PTI in DCM patients compared
with COVs for control subjects, indicating
increased heterogeneity (P  0.05).
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patients. Therefore, the influence of aging on the PTI may
be limited.
CONCLUSION
The PTI offers the possibility of noninvasively quantify-
ing myocardial fibrosis at a regional level. In patients with
an advanced stage of DCM, the PTI is significantly reduced
compared with that of healthy control subjects. In these
patients the degree of fibrosis as determined by the reduc-
tion of the PTI was highly variable, both on a regional level
and between patients. The exact relationship between re-
gional fibrosis and function as well as the effects of fibrosis
on prognosis need to be elucidated.
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Purpose: To prospectively evaluate, by using positron emission to-
mography (PET) and magnetic resonance (MR) imaging,
the interrelationships between regional myocardial fibro-
sis, perfusion, and contractile function in patients with
idiopathic dilated cardiomyopathy (DCM).
Materials and
Methods:
The study protocol was approved by the hospital ethics
committee, and all subjects gave written informed con-
sent. Sixteen patients with idiopathic DCM (mean age, 54
years 11 [standard deviation]; nine men) and six healthy
control subjects (mean age, 28 years  2; five men) were
examined with PET and MR tissue tagging. Oxygen 15–
labeled water and carbon monoxide were used as tracers
at PET to assess myocardial blood flow (MBF) and the
perfusable tissue index (PTI), which is inversely related to
fibrosis. MBF was determined at rest and during pharma-
cologically induced hyperemia. Maximum circumferential
shortening (Ecc) was determined with MR tissue tagging.
Student t tests were performed for comparison of data
sets, and linear regression was used to investigate the
association between parameters.
Results: Mean global hyperemic MBF (2.23 mL/min/mL  0.73),
Ecc (10.5%  2.9), and PTI (0.95  0.10) were lower in
the patients with DCM than in the control subjects (4.33
mL/min/mL  0.85, 17.4%  0.6, and 1.09  0.12,
respectively; P  .05 for all). In the patients with DCM,
regional PTI was related to Ecc (r  0.21, P  .009) but
not to resting or hyperemic MBF. Furthermore, regional
Ecc was correlated to both resting (r  0.28, P  .004)
and hyperemic MBF (r  0.29, P  .001). In addition,
the ratio of left ventricular end-diastolic volume to mass,
as a reflection of wall stress, was related to global hyper-
emic MBF (r  0.52, P  .047) and to global Ecc (r 
0.69, P  .003).
Conclusion: In idiopathic DCM, the extent of myocardial fibrosis is
related to the impairment in contractile function, whereas
fibrosis and perfusion do not seem to be interrelated. The
degree of impairment of hyperemic myocardial perfusion
is related to contractility and end-diastolic wall stress.
 RSNA, 2006
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Idiopathic dilated cardiomyopathy(DCM) is a primary cardiac diseasecharacterized by depressed contrac-
tility and dilatation of the left and/or
right ventricle in the presence of normal
coronary arteries (1). In DCM, the in-
terstitium is altered and collagen con-
tent is increased (1–9), leading to dia-
stolic dysfunction (10). The effects of a
stiff cardiac interstitium on systolic per-
formance in this patient group, how-
ever, remain unclear because reported
studies have yielded conflicting results
(3,4,6–9). In particular, the difficulty of
performing accurate quantification of fi-
brosis and contractile function has been
a major limitation in these studies.
Moreover, myocardial fibrosis and
function are not always homogene-
ously distributed in patients with DCM
(2,3,5,11,12). Assessment of these pa-
rameters on a regional level is, there-
fore, necessary for the exploration of a
potential correlation.
Another hallmark of DCM is impair-
ment of perfusion reserve, the severity
of which is related to systolic dysfunc-
tion (13) and contractile reserve (14).
In addition, impairment of perfusion re-
serve is an independent prognostic fac-
tor for adverse events (15). It has been
hypothesized that, in addition to endo-
thelial dysfunction (16) and high wall
stress (13,14,17), increased collagen
content may in part be responsible for
these perfusion abnormalities (18–20).
Data supporting this hypothesis, how-
ever, are missing.
Nowadays, improved imaging tech-
niques offer the possibility of overcom-
ing some of the aforementioned limita-
tions. Positron emission tomography
(PET) performed by using oxygen 15–
labeled water (H2
15O) and carbon mon-
oxide (C15O), enables noninvasive
quantification of both myocardial perfu-
sion (21,22) and fibrosis (23). The latter
can be quantified through calculation of
the perfusable tissue index (PTI), which
enables differentiation between perfus-
able and nonperfusable tissue (22,23).
Studies have demonstrated that a re-
duction in PTI can be used as an esti-
mate of fibrosis in a chronic myocardial
infarction model (24) and in patients
with idiopathic DCM (25). The amount
and timing of regional myocardial con-
traction can be measured accurately—
thereby enabling quantification of con-
tractile function—by using cardiovascu-
lar magnetic resonance (MR) tissue
tagging (26,27).
Thus, the purpose of our study was
to prospectively evaluate, by using PET
and MR imaging, the interrelationships
between regional myocardial fibrosis,
perfusion, and contractile function in
patients with idiopathic DCM.
Materials and Methods
Patient and Control Populations
Sixteen consecutive patients with idio-
pathic DCM (New York Heart Associa-
tion functional class, III or IV; left ven-
tricular [LV] ejection fraction, 45%)
and six healthy control subjects were
examined at our institution with PET
and MR imaging between September
2003 and November 2004. The patients
with DCM ranged in age from 32 to 69
years (mean, 54 years  11), and the
control subjects ranged in age from 25
to 30 years (mean, 28 years  2). The
diagnosis of DCM was based on in-
creased LV dimensions, a globally de-
creased contraction pattern as deter-
mined with echocardiography, and nor-
mal coronary arteries at angiography.
None of the patients with DCM under-
went myocardial biopsy. Patients were
excluded when there was an absolute or
relative contraindication to PET or MR
imaging (eg, a pacemaker, claustropho-
bia, atrial fibrillation) or if there was
evidence of uncontrolled systemic hy-
pertension or any other systemic dis-
ease. Patients were clinically stable on
medications that included angiotensin-
converting enzyme inhibitors, diuretics,
digoxin, and -blockers. All healthy
control subjects underwent a physical
examination, electrocardiography, lab-
oratory testing, and echocardiography.
None of the results from these examina-
tions revealed any abnormalities. Char-
acteristics of the study population and
results of statistical comparisons are
given in Table 1. All subjects gave writ-
ten informed consent, and the protocol
was approved by the medical ethics
committee. The investigation con-
formed to the principles outlined in the
Declaration of Helsinki.
Imaging Protocols
PET scanning.—All examinations were
performed in two-dimensional mode by
using an ECAT EXACT HR scanner
(Siemens/CTI, Knoxville, Tenn). Pa-
tients and subjects were constantly
monitored with single-lead electrocardi-
ography, and blood pressure was mea-
sured every 3 minutes. After a transmis-
sion scan, 1100 MBq of H2
15O dissolved
in 5 mL of saline was injected intrave-
nously in 2 seconds by using a pump;
this was followed by a 40-mL saline flush
at a rate of 4 mL/sec (bolus injection). A
dynamic scan (ie, a scan with multiple
frames) was performed that consisted
Published online
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Radiology 2006; 240:380–388
Abbreviations:
ATF  anatomic tissue fraction
DCM  dilated cardiomyopathy
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LV  left ventricular
LVEDV  LV end-diastolic volume
LVM  LV mass
MBF  myocardial blood flow
PTI  perfusable tissue index
ROI  region of interest
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Advances in Knowledge
 Interstitial fibrosis does not im-
pair perfusion in idiopathic di-
lated cardiomyopathy.
 The extent of interstitial fibrosis is
related to systolic dysfunction in
idiopathic dilated cardiomyopathy.
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of the acquisition of 40 frames with vari-
able frame length for a total of 10 min-
utes (ie, 12 frames were acquired for 5
seconds each; 12 frames, for 10 seconds
each; six frames, for 20 seconds each;
and 10 frames, for 30 seconds each).
After the rest study, myocardial
blood flow (MBF) was determined dur-
ing hyperemia by infusing adenosine at
a rate of 140 g per kilogram of body
weight per minute. In one patient with
DCM, adenosine infusion during PET
was terminated because of anxiety
caused by palpitations. Data on hyper-
emic MBF in patients with DCM there-
fore consist of findings in 15 patients.
Blood pool imaging was then per-
formed. During a 2-minute period, the
patient or subject inhaled at least 2000
MBq of C15O and a single frame (static
scan) was acquired for 6 minutes, start-
ing 1 minute after the end of inhalation
to allow for equilibration in the blood
pool. During the C15O scan, three ve-
nous blood samples were drawn intra-
venously and were counted in a sodium
iodide well counter that was cross cali-
brated against the scanner.
Emission data were corrected for
the physical decay of 15O, dead time,
scatter, randoms, and photon attenua-
tion. Reconstruction of the H2
15O emis-
sion scans was performed by using fil-
tered back projection with a Hanning
filter at 0.5 of the Nyquist frequency.
Transmission and C15O scans were iter-
atively reconstructed by using ordered-
subset expectation maximization, or
OSEM (version 7.1.1; CTI, Knoxville,
Tenn), with two iterations and 16 sub-
sets. OSEM images underwent 5-mm
full width at half maximum Gaussian
postsmoothing to ensure resolution
matching between images recon-
structed with OSEM and those recon-
structed with filtered back projection
(resolution, approximately 7 mm).
MR imaging.—Electrocardiographi-
cally triggered MR imaging was per-
formed with a 1.5-T system (Sonata;
Siemens Medical Systems, Erlangen,
Germany) and a phased-array body coil.
Patients and subjects were imaged in
the supine position. Conventional cine
imaging was performed to enable as-
sessment of LV volumes and ejection
Figure 1
Figure 1: ExampleMRtagging images forpatientwith idiopathicDCM(toprow)andhealthysubject (bottomrow).
Tag linesbecomean intrinsic property of the myocardium for a brief period, and maximum circumferential shortening
(Ecc) can be calculated from the extent of deformation of tag lines from the resting state to end systole (ES). Note that
deformation of tag lines at end systole occurs more homogeneously and to a greater extent in the healthy subject.
Table 1
Characteristics of Control Subjects and Patients with Idiopathic DCM
Characteristic*
Control Subjects
(n  6)†
Patients with
DCM (n  16)† P Value
Age (y) 28 2 54 11 .001
Male-to-female ratio 5:1 9:7 .35
NYHA functional class NA 2.8 0.7 . . .
LVEF (%) 61 5 22 11 .001
LVESV (mL) 66 23 242 107 .001
LVEDV (mL) 166 41 303 101 .005
Heart rate (beats/min) 64 12 72 17 .31
Systolic blood pressure (mm Hg) 123 10 112 12 .08
Diastolic blood pressure (mm Hg) 75 9 67 11 .15
Rate-pressure product ([beats/min]  mm Hg) 8020 1955 8001 2007 .98
* LVEDV  LV end-diastolic volume, LVEF  LV ejection fraction, LVESV  LV end-systolic volume, NA  not applicable,
NYHA  New York Heart Association.
† Unless otherwise specified, data are mean values  standard deviations.
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fraction (26,27). Steady-state free pre-
cession cine imaging with myocardial
tagging, in conjunction with linearly in-
creasing start-up angles, was applied to
acquire tagged images with a high tem-
poral resolution (14 msec) (Fig 1) (28).
Five short-axis tagged images (tag-to-
tag distance, 7 mm) with complemen-
tary spatial modulation of magnetization
tagging for improved strain calculations
were acquired from base to apex (yield-
ing two basal and two midventricular
sections and one apical section) by using
the multiple expiration breath-hold
technique to suppress the blurring ef-
fect of respiratory motion (29). In addi-
tion, delayed contrast material–en-
hanced images were acquired in the
same view as that used at cine MR imag-
ing by using a two-dimensional seg-
mented inversion-recovery prepared
gradient-echo sequence (repetition
time msec/echo time msec/inversion
time msec, 9.8/4.4/250–300; typical
voxel size, 1.3  1.6  5 mm3) 15–20
minutes after intravenous administra-
tion of 0.2 mmol/kg gadopentetate
dimeglumine.
Data Analysis
PET.—Anatomic tissue images were
generated as described previously (25).
Transaxial anatomic tissue fraction
(ATF) images of the left ventricle were
reoriented according to the anatomic
axis of the heart, and sections were dis-
played as five short-axis sections (two
basal and two midventricular sections
and one apical section) that were identi-
cal to the anatomic images derived at
MR imaging (Fig 2). The same resec-
tioning parameters were applied to the
dynamic H2
15O images. ROIs (size
range, 3–20 mm3, depending on heart
size) were defined manually at the basal
and midventricular levels such that each
section was divided into six equidistant
sectors angled 60° apart starting from
the posterior insertion of the right ven-
tricular free wall into the LV myocar-
dium. All regions were defined indepen-
dently of the MR imaging data by a sin-
gle observer (P.K., with 6 years of
experience in cardiac PET). Corre-
sponding ROIs from two sections (ei-
ther basal or midventricular) were
grouped in each patient to generate 12
(six basal and six midventricular) vol-
umes of interest. The inferior volumes
of interest were excluded from analy-
sis because of anticipated perfusable
tissue spillover effects from the liver
(25); this resulted in a 10 segments
per patient model. The apex was also
excluded from analysis because of the
difficulty of delineating apical myocar-
Figure 2
Figure 2: PET-derived short-axis ATF images in (a) healthy volunteer and (b) patient with idiopathic DCM.
Note marked dilatation of left ventricle in patient with DCM. ATF images were used to define regions of interest
(ROIs) that were subsequently projected onto dynamic myocardial perfusion images obtained with H2
15O. The
inferior wall was excluded from analysis because of spillover artifacts from the liver.
Figure 3
Figure 3: Circumferential strain
curve from myocardial segment in
healthy volunteer. Circumferential
shortening is observed for approx-
imately 600 msec after the R wave
with a temporal resolution of 14
msec. After 400 msec, circumfer-
ential shortening has reached its
maximum negative value (ie, max-
imum contraction).
Table 2
PET and MR Imaging Data for Control Subjects and Patients with DCM
Parameter*
Control Subjects
(n  6)†
Patients with DCM
(n  16)† P Value
MBF 0.99 0.22 0.90 0.28 .47
MBFcorr 1.25 0.18 1.14 0.35 .48
Hyperemic MBF 4.33 0.85 2.23 0.73 .001
PTI 1.09 0.12 0.95 0.10 .014
ECC (%) 17.4 0.6 10.5 2.9 .001
LVEDV/LVM ratio 1.45 0.18 2.26 0.59 .004
* All MBF values are presented as milliliters per minute per milliliter of perfusable tissue.
† Data are mean values  standard deviations.
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dium from adjacent structures on the
short-axis ATF images in the patient
group.
Additional ROIs were defined in the
left and right ventricular chambers.
This set of ROIs was projected on the
dynamic H2
15O images to generate im-
age-derived input functions. Using the
standard single tissue compartment
model together with these input func-
tions, we determined MBF (in milliliters
per minute per milliliter of perfusable
tissue) and perfusable tissue fraction (in
milliliters per milliliter) for all myocar-
dial tissue time-activity curves. Intrinsic
corrections for spillover from both left
and right ventricles were performed by
using the method described by Her-
mansen et al (30). PTI was then ob-
tained as the ratio of perfusable tissue
fraction to ATF. Because resting MBF is
related to the rate-pressure product, or
RPP (ie, heart rate in beats per minute
multiplied by systolic blood pressure in
millimeters of mercury), corrected rest-
ing MBF, or MBFcorr, which was calcu-
lated as (MBF/RPP)  10.000, was also
determined. Regional differences in
MR imaging and PET parameters were
evaluated by grouping volumes of inter-
est so that the heart was divided into
three segments (anterior, lateral, and
septal).
MR imaging.—All MR imaging post-
processing was performed by a single
observer (M.J.W.G., with 10 years of
experience in cardiac MR imaging).
Global LV function parameters, includ-
ing LVEDV, LV end-systolic volume, LV
ejection fraction, and myocardial mass
were derived from the cine images by
using the MASS software package
(MEDIS, Leiden, the Netherlands) The
ratio of LVEDV to LV mass (LVM) was
calculated and used as a measure of the
extent of adaptive LV hypertrophy and
thus a reflection of global end-diastolic
wall stress (31).
The images acquired with comple-
mentary spatial modulation of magnetiza-
tion were used to calculate circumferen-
tial strain curves by using the harmonic
phase strain analysis method. Ecc, which
indicates maximum regional myocardial
contraction, was derived for each re-
gion from the strain curves (Fig 3).
Each myocardial segment was eval-
uated for the presence of hyperen-
hancement, which was defined as an
area of signal enhancement greater than
5 standard deviations of the signal of
nonenhanced myocardium.
Statistical Analysis
Data are expressed as means  stan-
dard deviations. For comparison of two
data sets, paired or unpaired Student t
tests were performed where appropri-
ate. Comparison of multiple data sets
was performed by using analysis of vari-
ance, and specific differences were
identified with a Student t test whose
results were corrected for multiple
comparisons with the Bonferroni in-
equality adjustment. Correlation coeffi-
cients were calculated to describe the
associations between study variables.
When correlation coefficients were esti-
mated on a segmental level, all 10 seg-
ments per patient were used, with ap-
plication of a correction for the interde-
pendency of the segmental data within
one patient. To this end, a linear mixed-
effects model was used. Regional differ-
ences in MR imaging and PET parame-
ters were evaluated by grouping vol-
umes of interest so that the heart was
divided into three segments (anterior,
lateral, and septal). For graphic presen-
tation, regional measurements were
corrected for intersubject variation by
dividing the values of each volume of
interest by the respective mean value
for that patient; this yielded normalized
parameters. Differences with a P value
of less than .05 were considered statis-
tically significant. All analyses were per-
formed by using SPSS, version 12
(SPSS, Chicago, Ill).
Figure 4
Figure 4: Bar graph shows normalized values for MBF, hyperemic MBF, PTI, and Ecc in septum (SEP) and anterior (ANT) and lateral (LAT)walls in control subjects
and patients with idiopathic DCM. (a) In control subjects, only Ecc demonstrated a small but significant regional difference ( P .05 [analysis of variance]). (b) In
patients with DCM, all parameters are distributed heterogeneously ( P .05 [analysis of variance]).
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Results
PET and MR Imaging Data
Rate-pressure product increased during
the hyperemic PET studies for both con-
trol subjects (from 8020 beats per
minute  mm Hg  1955 to 11 443 beats
per minute  mm Hg  1308, P  .001)
and patients with idiopathic DCM (from
8001 beats per minute  mm Hg  2007
to 9822 beats per minute  mm Hg 
2163, P  .001). Neither control sub-
jects nor patients with DCM demon-
strated any delayed contrast enhance-
ment.
Resting MBF did not differ between
groups. Correcting MBF for the rate-
pressure product (MBFcorr) did not al-
ter the results (Table 2). Hyperemic
MBF was significantly blunted in the pa-
tients with DCM (P  .001). Average
PTI was decreased in patients with
DCM (P  .014). Ecc was less negative
in patients with DCM (P  .001), indi-
cating reduced contractile function.
The LVEDV/LVM ratio was signifi-
cantly higher in patients with DCM
(P  .004).
Regarding the regional distribu-
tion of the PET and MR imaging pa-
rameters in the patients with DCM,
there was a gradual increase in all pa-
rameters from the interventricular
septum to the lateral wall (P  .05
[analysis of variance]); this was most
significant for Ecc (Fig 4). In healthy
volunteers, similar observations of Ecc
were made, although regional differ-
ences were small. In healthy volun-
teers, resting and hyperemic perfu-
sion and PTI were distributed homo-
geneously.
Correlations between Segmental PET and
MR Imaging Parameters
In patients with DCM, Ecc correlated
with MBFcorr, hyperemic MBF, and
PTI (Table 3). When segments were
divided into three subgroups, the
mean Ecc decreased progressively in
direct relation to MBFcorr, hyperemic
MBF, and PTI (Fig 5) (P  .01 [analysis
of variance]). PTI was not related to
either resting or hyperemic MBF. None
of these correlations were present for
control subjects.
Correlations between Extent of Adaptive
LV Hypertrophy and Global PET and MR
Imaging Parameters
The LVEDV/LVM ratio was positively
related to global Ecc (r  0.69, P 
.003), and inversely related to hyper-
emic MBF (r  0.52, P  .047) in
patients with DCM, whereas no correla-
tion was present for control subjects
(Fig 6). There was no correlation be-
tween LVEDV/LVM ratio and global
resting MBFcorr (r0.33, P .80), or
PTI (r  0.16, P  .55) in patients with
DCM or control subjects.
Discussion
To the best of our knowledge, this is the
first study to explore the interrelation-
ships between myocardial fibrosis, con-
tractile function, perfusion at rest, and
hyperemic perfusion in patients with id-
iopathic DCM. The results indicate that
myocardial fibrosis is related to contrac-
tile function, whereas fibrosis and rest-
ing or hyperemic perfusion do not seem
to be interrelated. Furthermore, the de-
gree of impairment of hyperemic myo-
cardial perfusion and of systolic func-
tion were both related to end-diastolic
wall stress.
Delayed Contrast-enhanced MR Imaging
in Patients with DCM
None of the patients with idiopathic
DCM demonstrated any delayed con-
trast enhancement, which excludes the
Figure 5
Figure 5: Bar graphs show relationships between Ecc and (a)MBFcorr, (b) hyperemic MBF, and (c) PTI for patients with DCM. Results are based on all analyzed seg-
ments. (Ten segments were analyzed per patient; they were subsequently divided into subgroups for trend analysis.) For each PET parameter, Ecc decreased progressively
for the three subgroups.P values were calculated with analysis of variance. Error bars standard error of the mean.
Table 3
Correlations between Segmental PET and MR Imaging Data in Patients with DCM
Parameter
MBFcorr Hyperemic MBF PTI
r Value P Value r Value P Value r Value P Value
ECC 0.28 .004 0.29 .001 0.21 .009
PTI 0.09 .36 0.07 .45 . . . . . .
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possibility of a previous myocardial in-
farction (32). Apparently, the intersti-
tial fibrosis that is irrefutably present in
these patients (33) is not detected with
delayed contrast-enhanced MR imag-
ing. These results are in line with data
from McCrohon et al (32), who demon-
strated that in the majority of patients
with DCM, delayed contrast enhance-
ment is absent. The lack of a normal
reference area, which is necessary to
null the delayed contrast-enhanced sig-
nal, is responsible for the inability of
late contrast-enhanced MR imaging to
depict diffusely spread interstitial fibro-
sis in patients with DCM (32). There-
fore, late contrast-enhanced MR imag-
ing cannot be relied on to reveal the
true presence or extent of interstitial
fibrosis in such patients.
Fibrosis versus Contractile Function
Use of the PTI, because it enables differ-
entiation between perfusable and non-
perfusable tissue, can permit quantifica-
tion of myocardial fibrosis after chronic
myocardial infarction. This has been
validated in both experimental (24) and
clinical settings (34). More recently, it
has been demonstrated that PTI could
be used as a potential noninvasive
marker of fibrosis in idiopathic DCM.
However, no correlation could be estab-
lished between LV ejection fraction and
PTI (25). In fact, previous studies of the
relation between fibrosis and systolic
performance in DCM have yielded con-
flicting results (3,4,6–9). The lack of
consistent results suggests that a one-
to-one relationship between the extent
of fibrosis and systolic function in DCM
is unlikely. Moreover, the distribution
pattern of collagen is not always homo-
geneous, necessitating a regional ap-
proach to investigate potential relation-
ships (2,3,5). Myocardial dysfunction in
DCM is generally considered to be
caused by myocyte abnormality (eg, en-
ergy compromise, calcium handling dys-
function, alterations of sarcomeric pro-
tein) (35).
The relationship observed in the
present study between PTI and Ecc in
patients with idiopathic DCM could be
consistent with the presence of a higher
degree of interstitial fibrosis accompa-
nying more severe myocyte dysfunction.
Interstitial stiffening could, however,
also exert a direct detrimental effect on
myocyte contractile performance, be-
cause recent studies (36,37) on per-
fused rat papillary muscles have shown
that reversible stiffening of the myocar-
dial interstitial matrix appears to be ac-
companied by transient reductions in
tension development. More studies are
needed to explore a potential causal re-
lation between fibrosis and function in
this patient group.
Fibrosis versus Perfusion
It has been hypothesized that fibrosis
might lead to perfusion abnormalities
(18–20). Parodi and colleagues (20) ex-
amined the effects of fibrosis on resting
perfusion in patients with ischemic or
nonischemic heart failure undergoing
heart transplantation. Neglia et al (19)
investigated the relationship between fi-
brosis and perfusion reserve in patients
with DCM. Neither group could demon-
strate a clear link between the extent of
fibrosis and perfusion abnormalities.
The present study did not reveal such a
correlation either.
Hyperemic Perfusion versus Contractile
Function versus Wall Stress
Impairment of myocardial perfusion re-
serve is one of the hallmarks of DCM.
Endothelial dysfunction (16) and high
wall stress (13,14,17) are thought to be
the main mechanisms for this phenome-
non. Impairment in perfusion reserve is
believed to induce intermittent periods
of ischemia (repetitive stunning), which
subsequently affect myocardial func-
tion. Signs of ischemia have been ob-
served in patients with idiopathic DCM
at PET (13) and dobutamine stress
echocardiography (38). As heart failure
progresses, remodeling occurs and dia-
stolic wall stress increases (1), causing
extravascular compression of the mi-
crovascular bed. In baseline conditions,
myocardial perfusion is unaffected by
these forces because the microvascular
bed has the capability of compensating
through vasodilation (20). During phar-
macologically induced vasodilation,
however, this mechanism is exhausted
and compression of the microvascular
bed occurs, leading to a reduction in
hyperemic perfusion that is propor-
tional to the level of wall stress
(13,14,17).
The results of the present study sup-
port the presence of this mechanism in
that a direct relationship between
LVEDV/LVM ratio and hyperemic per-
fusion was found. Consequently, a vi-
cious circle, in which the increased wall
stress limits hyperemic perfusion and
induces demand ischemia, may be cre-
Figure 6
Figure 6: Scatterplots show correlations between LVEDV/LVM ratio and (a) Ecc and (b) hyperemic MBF for
patients with DCM (F) and control subjects (E). Linear regression was applied to the patient data only. No
correlations were present for the control subjects.
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ated. These ischemic episodes can exac-
erbate systolic dysfunction and lead to a
further increase in wall stress (13,38).
Moreover, increased mechanical stress
itself may lead to activation of intracel-
lular signaling pathways that have direct
detrimental effects on cardiomyocytes
(eg, hampering hypertrophy, favoring
apoptosis, and impairing calcium han-
dling) (39); these effects further com-
promise contractile function.
Contractile Function versus Resting
Perfusion
In general, DCM is not considered to be
a regional myocardial disorder because
the entire myocardium is affected. Nev-
ertheless, heterogeneity in contractile
function (11,12), oxygen consumption
(11), wall stress (40), and perfusion
(25) have been noted, although the
mechanisms of the heterogeneity of
these factors warrant further investiga-
tion. In the present study a correlation
between regional resting myocardial
perfusion and contractile function was
found. This might be expected, because
resting myocardial perfusion is closely
coupled to oxygen consumption and
thus to myocardial function through au-
toregulation of the microvascular bed in
response to varying demand (41).
Clinical Implications
From a clinical point of view, the results
of this study suggest that reduction of
wall stress and regression of interstitial
fibrosis are potential therapeutic goals
in patients with idiopathic DCM. Some
of the beneficial effects of pharmaco-
logic agents that antagonize the neuro-
humoral pathway (eg, angiotensin-con-
verting enzyme inhibitors, -blockers)
are related to the reduction in loading
conditions they exert. The reduction in
wall stress may subsequently enhance
hyperemic MBF and decrease episodes
of ischemia. A similar mechanism has
recently been observed during wall
stress reduction by cardiac resynchroni-
zation therapy in patients with heart
failure (42). Furthermore, angiotensin-
converting enzyme inhibitors are known
to induce regression of interstitial fibro-
sis in patients with hypertensive LV hy-
pertrophy and are associated with re-
covery of systolic function (43). Regres-
sion of fibrosis in patients with
idiopathic DCM that is mediated
through angiotensin-converting enzyme
inhibitors could result in similar recov-
ery of myocardial function, although
more studies are needed to test this hy-
pothesis.
Study Limitations
We used PTI to assess interstitial fibro-
sis. Although it has been shown that PTI
enables accurate identification of myo-
cardial fibrosis after infarction (24,34),
histologic comparisons in patients with
DCM are currently lacking. Therefore,
further studies on the use of PTI as a
marker of fibrosis are needed. In addi-
tion, in the control subjects, due to the
high spatial and temporal resolution of
MR imaging, minute physiologic re-
gional differences in contractile function
were observed, as recently described
(26,27). These differences could not be
observed in the PET parameters, most
likely due to the relatively limited reso-
lution of PET. Finally, control subjects
were not matched to the patients with
respect to age or population size. The
role of the control population in this
study, however, was limited because
the main goal was to establish relation-
ships within the DCM population.
Conclusions
The results of our study indicate that in
idiopathic DCM, the extent of myocar-
dial fibrosis is related to contractile dys-
function, whereas fibrosis and perfusion
do not seem to be interrelated. Further-
more, the degree of impairment of hy-
peremic myocardial perfusion is related
to contractile function and end-diastolic
wall stress. These results indicate that
wall stress and not fibrosis limits hyper-
emic perfusion.
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Delayed Contrast Enhancement and Perfusable
Tissue Index in Hypertrophic Cardiomyopathy:
Comparison Between Cardiac MRI and PET
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Marco J.W. Go¨tte, MD, PhD1; Ronald Boellaard, PhD2; Aernout M. Beek, MD1; Cees A. Visser, MD, PhD1;
Albert C. van Rossum, MD, PhD1; Adriaan A. Lammertsma, PhD2; and Frans C. Visser, MD, PhD1
1Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands; and 2Department of Nuclear Medicine
and PET Research, VU University Medical Center, Amsterdam, The Netherlands
Delayed contrast enhancement (DCE) visualized by cardiac MRI
(CMR) is a common feature in patients with hypertrophic car-
diomyopathy (HCM), presumed to be related to myocardial
fibrosis. The pathophysiologic basis of hyperenhancement in
this patient group, however, remains unclear as limited histo-
logic comparisons are available. The present study compares
the perfusable tissue index (PTI), an alternative marker of myo-
cardial fibrosis obtained by PET, with DCE-CMR in HCM.Meth-
ods: Twenty-one patients with asymmetric septal HCM, 12
chronic myocardial infarction (MI) patients, and 6 age-matched
healthy control subjects were studied with DCE-CMR and PET.
PET was performed using 15O-labeled water and carbon mon-
oxide to obtain the PTI. Results: No hyperenhancement was
observed in control subjects and the PTI was within normal
limits (1.10  0.07 [mean  SD]). In MI patients, the extent of
hyperenhancement (25%  16% [mean  SD]) was inversely
related to the decrease in the PTI (0.94  0.12; r  0.65, P 
0.05). Average hyperenhancement in HCM was 14%  12%,
predominantly located in the interventricular septum. The PTI in
the hypertrophied interventricular septum, however, was not
reduced (1.12  0.13). Furthermore, in contrast to MI patients,
there was a modest positive correlation between the extent of
DCE and the PTI in HCM (r 0.45, P 0.05). Conclusion: DCE
in the hypertrophied septum of HCM patients is not accompa-
nied by a decline in the PTI, and there is a positive correlation
between the extent of DCE and the PTI. These results suggest
that hyperenhancement may not be caused solely by fibrotic
replacement scarring in this patient group. Other pathologic
changes associated with HCM may also cause gadolinium-
diethylenetriaminepentaacetic acid hyperenhancement.
Key Words: hypertrophic cardiomyopathy; MRI; delayed con-
trast enhancement; PET; perfusable tissue index
J Nucl Med 2005; 46:923–929
Hypertrophic cardiomyopathy (HCM) is a relatively
common primary cardiac disease with great diversity of
morphologic, functional, and clinical features (1). Although
HCM is associated with a variety of mutations in genes
encoding proteins of the sarcomere, connective tissue ele-
ments are also involved in the disease process (2). Several
types of myocardial fibrosis (interstitial, perivascular, re-
placement, and plexiform) can be found in patients with
HCM (2–13).
Among several factors, the severity of myocardial fibro-
sis is of prognostic significance in HCM (2,5,9,11). For the
purpose of risk stratification, noninvasive assessment of
fibrosis is desirable. Gadolinium delayed contrast-enhanced
(DCE) cardiac MRI (CMR) allows visualization of fibrotic
tissue in patients with coronary artery disease (CAD)
(14,15). Furthermore, hyperenhancement visualized by
DCE-CMR is a common feature of HCM, the extent of
which is related to left ventricular function parameters,
progressive disease, and markers of clinical risk for sudden
death (16,17). Although the histologic basis of hyperen-
hancement in HCM remains unclear as histopathologic
comparison is limited to a single case report (18), it has been
suggested that it most likely represents scar tissue (16–18).
The perfusable tissue index (PTI), obtained with PET
using 15O-labeled water (H215O) and carbon monoxide
(C15O), reflects the fraction of the myocardium that is able
to exchange water rapidly—that is, is perfusable by water
(19–21). Differentiation between fibrosis and myocardium
can be made on the basis of this principle, and it has been
shown that a reduction of the PTI correlates with the extent
of fibrosis after infarction (19). Furthermore, the PTI is
reduced in patients with an advanced stage of idiopathic
dilated cardiomyopathy, possibly due to increased intersti-
tial and perivascular fibrosis (22). Matched measurements
of DCE and PTI can therefore provide more insight into the
pathophysiologic nature of DCE in HCM.
The present study was conducted to test whether (a) the
PTI is reduced in patients with HCM as compared with
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healthy control subjects and (b) the extent to which DCE-
CMR and the PTI are related in HCM. As changes in both
DCE-CMR and the PTI are well documented in patients
with chronic myocardial infarction (MI) (14,15,19–21), this
patient group served as a reference.
MATERIALS AND METHODS
Patient Population
Twenty-one HCM patients, 12 chronic MI patients, and 6 age-
matched healthy volunteers were studied with CMR and PET.
HCM was diagnosed by the presence of a nondilated and hyper-
trophied left ventricle (LV) on 2-dimensional (2D) echocardiog-
raphy (maximal wall thickness 15 mm in adult index patients or
13 mm in adult relatives of an HCM patient) in the absence of
any other systemic or cardiac disease. Exclusion criteria were any
absolute or relative contraindication to CMR or PET (e.g., pace-
maker, claustrophobia), atrial fibrillation, and history of CAD. All
HCM patients had asymmetric septal hypertrophy. CAD was ex-
cluded by angiography in 8 patients. Of the remaining 13 patients,
1 had anginal symptoms. CAD was excluded in this particular
patient by a negative nuclear imaging stress test. MI was defined
by a previously documented typical MI. MI patients with a recent
(1 mo) acute coronary syndrome were excluded. All healthy
control subjects underwent physical examination, electrocardiog-
raphy, and echocardiography. None of the results from these
examinations showed any abnormalities. All subjects gave written
informed consent, and the protocol was approved by the Medical
Ethics Committee of the VU University Medical Center.
Imaging Protocols
PET. All scans were performed in 2D mode, using an ECAT
EXACT HR scanner (Siemens/CTI). The scanning protocol was
identical to that described previously (22). Briefly, after a trans-
mission scan, 1,100 MBq of H215O dissolved in 5 mL saline were
injected intravenously, followed by a 40-mL saline flush at a rate
of 4 mL/s (bolus injection). A dynamic scan was acquired for a
duration of 10 min. Subsequently, blood-pool imaging was per-
formed. During a 2-min period, subjects inhaled at least 2,000
MBq of C15O and a single frame was acquired for a duration of 6
min, starting 1 min after the end of inhalation to allow for equil-
ibration in the blood pool. During the C15O scan, 3 venous blood
samples were drawn from the intravenous line and radioactivity
was counted in a sodium iodide well counter cross-calibrated
against the scanner. Emission data were corrected for the physical
decay of 15O, dead time, scatter, randoms, and photon attenuation.
Reconstruction of the H215O emission sinograms was performed
using filtered backprojection (FBP) with a Hanning filter at 0.5 of
the Nyquist frequency. Transmission and C15O sinograms were
iteratively reconstructed using ordered-subset expectation maximi-
zation ([OSEM], CTI version 7.1.1; 2 iterations, 16 subsets).
OSEM images underwent 5-mm full width at half maximum
(FWHM) gaussian postsmoothing to obtain a transaxial spatial
resolution of 7-mm FWHM, equal to that of FBP images (23).
MRI. MRI was performed on a 1.5-T scanner (Sonata; Siemens),
using a 4-element phased-array body radiofrequency receiver coil.
All images were acquired with electrocardiogram gating and dur-
ing repeated breath-holds of 10–15 s, depending on the heart rate.
After localizing scouts, cine images were acquired using a seg-
mented steady-state-free precession sequence in 3 long-axis views
(2-, 3-, and 4-chamber view) and in multiple short-axis views with
a slice distance of 10 mm, covering the whole LV from base to
apex. Scan parameters were as follows: temporal resolution, 34
ms; repetition time (TR), 3.0 ms; echo time (TE), 1.5 ms; typical
voxel size, 1.4  1.8  5 mm3.
Contrast-enhanced images were acquired 15–20 min after intra-
venous administration of 0.2 mmol/kg gadolinium-diethylenetri-
aminepentaacetic acid (Fig. 1A) in the same view used as cine
CMR, using a 2D segmented inversion-recovery prepared gradi-
ent-echo sequence (TE, 4.4 ms; TR, 9.8 ms; inversion time, 250–
300 ms; typical voxel size, 1.3  1.6  5 mm3).
Data Analysis
PET. Anatomic tissue fraction (ATF) images were generated
according to the procedure described by Iida et al. (20) Briefly,
blood-volume images were normalized to the radioactivity in
blood as measured from the samples. The reconstructed transmis-
sion data were normalized on a pixel-by-pixel basis to the average
pixel counts in a region of interest (ROI) in the left ventricular
chamber of the transmission image. Quantitative images of the
ATF (mL/mL) were calculated taking into account the differences
between the densities of blood and tissue.
Transaxial ATF images of the LV were reoriented according to
the anatomic axis of the heart and slices were displayed as short-
axis slices (Fig. 1B). The same reslicing parameters were applied
to the dynamic H215O images. ROIs were defined manually at the
basal and midventricular level of the LV as previously described
(22). Corresponding ROIs from a variable number of slices were
grouped in each patient to generate 12 volumes of interest (6 basal
and 6 midventricular). The inferior volumes of interest were ex-
cluded from analysis because of anticipated perfusable tissue frac-
tion (PTF) spillover effects from the liver (22).
Additional ROIs were defined in the left atrium and right ven-
tricular chamber. This set of ROIs was projected on the dynamic
H215O images to generate image-derived input functions. Using the
standard single-tissue compartment model together with these in-
put functions, myocardial blood flow (MBF) (mL/min/mL of per-
fusable tissue) and PTF (mL/mL) were determined for all myo-
cardial tissue time–activity curves. Corrections were made for
spillover from both the LV and right ventricle (RV) using the
method described by Hermansen et al. (24) Global PET parameters
were calculated by grouping all volumes of interest. In addition,
septal and lateral parameters were determined by grouping of the
FIGURE 1. Midventricular short-axis view of a gadolinium
delayed enhanced CMR image (A) of HCM patient. Note patchy
hyperenhancement located at hypertrophied interventricular
septum at junctions of septum and right ventricular free walls
(arrows). (B) Anatomic tissue fraction image of same patient
derived by PET.
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corresponding septal and lateral volumes of interest. As resting
MBF is related to the rate–pressure product (RPP  heart rate 
systolic blood pressure), corrected MBF (MBF/RPP  10,000)
was also determined. Finally, the PTI was obtained by dividing the
PTF by the ATF.
MRI. The same regions on the short-axis slices were defined as
described. Each myocardial segment was evaluated for the pres-
ence of hyperenhancement, defined as an area of signal enhance-
ment  2 SD of the signal of nonenhanced myocardium. The total
myocardial area and the contrast-enhanced area per sector were
traced manually. The extent of contrast enhancement was ex-
pressed as a percentage of the total myocardial area studied.
Statistical Analysis
Data are expressed as mean  SD. For comparison of 2 data-
sets, paired or unpaired Student t tests were performed where
appropriate. Comparison of multiple datasets was performed using
ANOVA, and specific differences were identified by a Student t
test corrected for multiple comparisons with the Bonferroni in-
equality adjustment. Correlations were analyzed using linear re-
gression. A P value  0.05 was considered significant.
RESULTS
Patient Population
Baseline characteristics are given in Table 1. The mean
interventricular wall thickness was 21  6 mm (range,
13–33 mm) in HCM patients.
DCE
CMR and PET data from healthy control subjects, HCM
patients, and MI patients are summarized in Table 2. None
of the control subjects demonstrated hyperenhancement. In
4 HCM patients (19%), virtually no hyperenhancement was
present (3% of myocardium). The mean DCE in HCM
was 14%  12% (Fig. 2), predominantly localized at the
junctions of the interventricular septum and the right ven-
TABLE 1
Characteristics of Control Subjects, HCM Patients, and MI Patients
Characteristic Control (n  6) HCM (n  21) MI (n  12) P
Age (y) 50  6 56  12 58  12 NS
Sex (M/F) 5/1 18/3 9/3 NS
NYHA functional class (I/II/III) — 13/6/2 6/4/2 —
LVEF (%) 58  4 65  6 30  11* 0.01
IVS thickness (mm) 8  1 21  6† 7  2 0.01
LVPW thickness (mm) 6  1 8  2 6  1 NS
Medication
	-Blocker — 8 11 —
Calcium antagonist — 3 4 —
*P  0.01 vs. control and HCM.
†P  0.01 vs. control and MI.
NS  not significant; NYHA  New York Heart Association; LVEF  left ventricular ejection fraction; IVS  interventricular septum;
LVPW  left ventricular posterior wall.
TABLE 2
CMR and PET Data from Control Subjects, HCM Patients, and MI Patients
CMR and PET parameters Control (n  6) HCM (n  21) MI (n  12) P
DCE (%)
Average — 14  12 25  16 0.01
Septal — 17  15 29  24 0.05
Lateral — 3  2 22  17 0.05
MBF (mL/min/mL)
Average 0.94  0.22 0.88  0.23 0.92  0.27 NS
Septal 0.89  0.27 0.82  0.20 0.92  0.32 NS
Lateral 0.99  0.24 0.94  0.31 0.91  0.27 NS
PTI
Average 1.10  0.07 1.05  0.12 0.94  0.12* 0.05
Septal 1.14  0.05 1.12  0.13 0.96  0.21* 0.05
Lateral 1.12  0.12 1.03  0.13† 0.93  0.17* 0.05
*P  0.05 vs. control and HCM.
†P  0.05 vs. control and MI.
NS  not significant.
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tricular free wall (17%  15%), whereas virtually no DCE
was observed in the lateral wall (3% 2%). All MI patients
showed hyperenhancement with a mean value of 25% 
16%, significantly higher compared with HCM patients.
MBF
In contrast to the control subjects, MBF was not homo-
geneously distributed in the HCM patients. Septal MBF was
lower compared with the lateral wall (0.82  0.20 vs.
0.94  0.31 mL/min/mL; P  0.05).
PTI
The PTI was reduced in the MI group compared with
control subjects and HCM patients (Table 2; P 0.05). The
PTI did not differ between control subjects and HCM pa-
tients on a global level (Fig. 2), although the range was
larger in HCM patients (0.79–1.25) than in control subjects
(0.97–1.17). The PTI in the septum was comparable be-
tween control subjects and HCM patients. In HCM patients,
however, the PTI in the lateral wall was reduced compared
with that of the septum (1.03  0.13 vs. 1.12  0.13; P 
0.01). Furthermore, the PTI in the lateral wall was reduced
compared with that of the control subjects (1.03  0.13 vs.
1.12  0.12; P  0.05). As shown in Figure 3, segments
without hyperenhancement had a lower PTI compared with
hyperenhanced segments in HCM patients (1.02  0.18 vs.
1.09  0.19, respectively; P  0.05).
Correlations Between CMR and PET Parameters
Global PTI correlated modestly with the extent of global
DCE in HCM patients (r  0.45, P  0.05; Fig. 4). In MI
patients, there was an inverse correlation between PTI and
DCE (r0.65, P 0.05). In addition, the left ventricular
ejection fraction (LVEF) was inversely related to the extent
of hyperenhancement (r  0.51, P  0.05) and the PTI
(r  0.52, P  0.05; Fig. 5) in HCM patients. There was
no correlation between maximum wall thickness and either
DCE or PTI.
DISCUSSION
The similarity in distribution pattern between hyperen-
hanced areas visualized by DCE-CMR and scarring found
in necropsy studies has led to the assumption that hyperen-
hancement in HCM represents fibrotic tissue (16–18). The
present study was conducted to validate this hypothesis by
comparing DCE-CMR with the PTI, an alternative validated
marker of myocardial fibrosis (19,21).
Control Subjects
No hyperenhancement was observed in control subjects,
and the PTI was in line with previous studies (20,21). For
normal human myocardium, the PTF is approximately 10%
higher than the ATF because venous blood volume of the
heart is included in this parameter (0.10 mL/g of net
myocardium) (25). The expected value for the PTI in nor-
mal myocardium is therefore close to 1.1 (20,21).
Chronic MI
As might be expected, hyperenhancement was present
in all patients with documented MI. In addition, the
extent of hyperenhancement was directly related to the
reduction in the PTI (Fig. 5), confirming the validity of
both DCE-CMR and the PTI as noninvasive markers of
scar tissue in chronic MI.
HCM
Hyperenhancement was observed in 81% of HCM pa-
tients, predominantly localized in the interventricular sep-
tum at the junctions of the septum and right ventricular free
FIGURE 2. DCE (A) and PTI (B) for
healthy control subjects, HCM patients,
and MI patients. *P  0.05 vs. control sub-
jects and HCM patients.
FIGURE 3. PTI for segments with (DCE) and without (DCE)
hyperenhancement in HCMpatients. PTI was significantly higher in
areas with hyperenhancement. *P  0.05 for DCE vs. DCE.
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wall. Furthermore, in line with Choudhury et al. (17), the
extent of DCE was related to the LVEF (Fig. 5).
The PTI was reduced in the nonhypertrophied lateral free
wall of HCM patients compared with that of control sub-
jects. This can be explained by the presence of interstitial
fibrosis, which is commonly found not only in the septum
but also in the lateral wall, albeit to a lesser extent
(4,7,8,10). Recently, a similar PTI reduction was found in
patients with idiopathic dilated cardiomyopathy (22), a dis-
ease process also characterized by interstitial fibrosis. In
addition, the observed absence of hyperenhancement in the
lateral wall does not rule out the absence of fibrosis. As
DCE depends on regional differences in gadolinium accu-
mulation, it requires a reference area without hyperenhance-
ment. In HCM, fibrosis is diffusely spread throughout the
LV, lacking a normal reference area.
However, unlike our hypothesis, hyperenhancement in
the hypertrophied interventricular septum of HCM patients
was not accompanied by a decline in the PTI. Segments
without hyperenhancement demonstrated lower PTI values
than those with hyperenhancement (Fig. 3). Moreover, the
extent of global hyperenhancement and the PTI were posi-
tively related, whereas, in the presence of myocardium and
scar tissue alone, an inverse relation would be expected as
found in patients with MI (Fig. 4).
Pathophysiologic Conditions in HCM and Its Relation
to Hyperenhancement and PTI
The disease process of HCM is dynamic. Transgenic
rodent models have demonstrated that histology is virtually
normal in the early stages of the disorder, whereas, later in
the disease process, myocardial disarray, hypertrophy, in-
flammation, myolysis, necrosis, and interstitial and replace-
ment fibrosis can be observed (26–28). More advanced
stages reveal increasing quantities of fibrotic tissue, whereas
disarray and inflammation decrease. Furthermore, several
types of fibrosis can be found in HCM patients (6), such as
plexiform fibrosis. Formation of fibrosis in HCM may—
next to primary connective tissue abnormalities—occur as a
result of myocardial ischemia and infarction (1,3,29), caus-
ing the loss of cellular membrane integrity and interstitial
edema. Human histopathology reports have shown similar
results (3,9,12,13).
Gadolinium is an inert extracellular contrast agent, un-
able to cross the intact sarcolemmal membrane. Hyperen-
hancement of gadolinium is dependent on the volume of
FIGURE 4. Scatter plots show relation
between DCE and PTI in HCM patients (A)
and MI patients (B).
FIGURE 5. Scatter plots show relation
between LVEF and DCE (A) and PTI (B) in
HCM patients.
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distribution (Vd) of the contrast agent and washin/washout
kinetics (30,31). Hyperenhancement occurs not only in col-
lagenous scar tissue but also in any condition accompanied
by a larger Vd of gadolinium, such as disruption of cellular
membrane, edema, and increased blood volume (30,32,33).
Therefore, hyperenhancement in HCM may be related
not only to fibrosis but also to other conditions resulting in
a larger Vd of gadolinium, such as disarray, inflammation,
myolysis, and necrosis (26–28). This hypothesis is sup-
ported by an experimental study of Aso et al. (28), who
found varying concentrations of gadolinium in transgenic
HCM hamsters depending on the different stages of the
disease process—that is, increased during the early stage of
inflammation and lymphocytic infiltration as compared with
less accumulation of gadolinium in the later stage charac-
terized by more densely packed collagen fibers.
In the present study, hyperenhancement in the hypertro-
phied septum of HCM patients was characterized by a larger
Vd of both gadolinium and water (Fig. 6), as PTI values
were (near) normal in the septum of HCM patients. This is
a distinctly different pattern than that observed in scar tissue
of MI patients (i.e., increased Vd of gadolinium and de-
creased Vd of water-exchangeable tissue), suggesting a dif-
ferent histologic basis of hyperenhancement in HCM pa-
tients.
The PTI is the ratio of the PTF and the ATF. As the PTF
is dependent on the Vd of water—that is, water-exchange-
able tissue—the PTI is also dependent on the extent of
water-exchangeable tissue. Because myocardial fibrosis is
irrefutably present in the hypertrophied enhanced segments,
a potential reduction of the PTI caused by fibrotic tissue, as
observed in the lateral wall, could be compensated by an
expansion of the water-diffusable volume surrounding the
fibrotic tissue in the septum—the net result being a near-
normal value for the PTI.
As stated earlier, ischemia/necrosis and inflammation can
be observed in HCM (3,12,13,26–28). Both conditions are
accompanied by extravasation of fluid (edema), which is
characterized by an increased water content of tissue. Inter-
estingly, Inoue et al. observed a positive relation between
water content and gadolinium accumulation in ischemic
myocardium (34). Furthermore, during inflammation caused
by myocarditis, transient hyperenhancement can be de-
tected, which is related to the acute phase of lymphocytic
infiltration and edema (35,36). Similar conditions in HCM
could therefore be responsible for the presence of hyperen-
hancement in combination with water-diffusable tissue, ex-
plaining the preserved values of the PTI in the hyperen-
hanced myocardium.
Limitations
Corrections were made for both LV and RV spillover
effects using a previously validated method (24). By defi-
nition, wall thickness of the interventricular septum is in-
creased in patients with HCM, resulting in decreased spill-
over fractions from the LV and the RV and concomitant
increased PTF and ATF values due to a reduction in the
partial-volume effect. However, the PTI, being the ratio of
the PTF and the ATF, will be virtually unaffected by these
fluctuations in spillover and partial-volume effects as they
affect the PTF and the ATF to a similar degree. Moreover,
increasing wall thickness should result in more reliable data,
as fewer corrections for spillover and partial-volume effects
are made.
In addition, the spatial resolution of PET is considerably
lower than that of CMR; therefore, it was not possible to
accurately delineate regions that demonstrated DCE-CMR
on the PET images. Instead, relative large, fixed anatomic
sectors were used, which reflect a mixture of enhanced and
nonenhanced tissue. One might argue that the PTI is not
sensitive enough to detect the islands of fibrosis, explaining
the similarity of the PTI values found in control subjects and
HCM patients. This is, however, unlikely as the PTI was
significantly reduced in the nonenhanced segments, sugges-
tive of interstitial fibrosis. In the presence of scar tissue, the
PTI in the enhanced segments would be expected to be even
more reduced, whereas in those particular segments the PTI
in HCM did not differ compared with that of control sub-
jects. Nevertheless, histologic comparisons in patients with
HCM are currently lacking and further studies on the use of
the PTI as a marker of fibrosis are needed.
Furthermore, the extent and range of DCE was larger in
MI patients than that in HCM patients, which might have
resulted in a bias in the interpretation of the data. The latter
limitation, however, cannot account for the observed oppo-
FIGURE 6. Short-axis view of DCE image (A) and parametric
PTF image (B) in patient with anterior MI. Area of DCE matches
absence of water-perfusable tissue in PTF image, indicating
scar tissue. (C and D) Same images, as in A and B in HCM
patient, demonstrate presence of water-perfusable tissue in
hyperenhanced septal area.
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site correlation patterns between DCE and PTI in MI and
HCM patients.
Finally, as the disease process of HCM is dynamic, it
would be of special interest to perform serial matched DCE
and PTI studies with relatively large time lags. Any alter-
ations would provide more insight into the pathophysiologic
basis of both DCE and PTI in HCM.
CONCLUSION
In asymmetric HCM patients, the PTI in the nonhyper-
trophied lateral wall is reduced, suggestive of the presence
of interstitial fibrosis. However, in the hypertrophied inter-
ventricular septum, the PTI is not reduced and hyperen-
hancement by DCE-CMR can be observed. These results
suggest that hyperenhancement in the hypertrophied septum
is not solely caused by fibrotic replacement scarring. Other
pathologic changes associated with HCM may also account
for the hyperenhancement. Further studies are warranted
with respect to the histologic basis of both DCE and PTI
in HCM.
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Regional heterogeneity of resting perfusion in
hypertrophic cardiomyopathy is related to delayed
contrast enhancement but not to systolic function:
A PET and MRI study
Paul Knaapen, MD,a Willem G. van Dockum, MD,a Marco J. W. Götte, MD, PhD,a
Kimiko A. Broeze, MSc,a Joost P. A. Kuijer, PhD,b Jaco J. M. Zwanenburg, PhD,b
J. Tim Marcus, PhD,b Wouter E. M. Kok, MD, PhD,c Albert C. van Rossum, MD, PhD,a
Adriaan A. Lammertsma, PhD,d and Frans C. Visser, MD, PhDa
Background. Regional differences in resting myocardial blood flow (MBF) have been
observed in patients with hypertrophic cardiomyopathy (HCM), but their determinants are
currently unknown. This study verifies whether MBF at rest in HCM is related to delayed
contrast enhancement (DCE) or regional systolic function (or both) as determined by magnetic
resonance imaging.
Methods and Results. Fourteen patients with HCM were studied. MBF was measured with
positron emission tomography by use of oxygen 15–labeled water. DCE and tissue tagging, to
calculate end-systolic circumferential shortening (Ecc), were obtained with magnetic resonance
imaging. The mean resting MBF was 0.78  0.19 mL · min1 · mL1, and there was a trend
toward reduced MBF in the septum (0.72  0.11 mL · min1 · mL1) compared with that in the
lateral wall (0.84  0.29 mL · min1 · mL1) (P  .092). The distribution patterns of DCE and
Ecc were both heterogeneous, displaying significantly increased enhancement and impaired
regional systolic function in the hypertrophic septum compared with the lateral wall (both P <
.001). Resting MBF was inversely related to the extent of DCE (r  0.30, P < .001), whereas
MBF was not significantly related to Ecc (r  0.15, P  .072).
Conclusions. Regional heterogeneity of resting perfusion in HCM is related to the extent of
DCE but not to regional systolic function. (J Nucl Cardiol 2006;13:660-7.)
Key Words: Hypertrophic cardiomyopathy • myocardial blood flood • positron emission
tomography • magnetic resonance imaging
Hypertrophic cardiomyopathy (HCM) is a primary
cardiac disease characterized by hypertrophy of the
myocardium in the absence of any systemic or other
cardiac disease, which predominantly affects the inter-
ventricular septum.1 Impairment of hyperemic myocar-
dial blood flow (MBF) is a hallmark of HCM, not only in
the hypertrophied septum but also in the nonhypertro-
phied lateral wall, the extent of which is of prognostic
significance.2,3 Although global MBF at rest usually is
within normal limits, conflicting results have been re-
ported on its regional distribution. In the hypertrophied
septum MBF may be either decreased,4-6 similar,7-9 or
increased2,3 compared with the lateral wall. Some of
these inconsistencies could be related to regional
differences in systolic function, which have been
documented in HCM.10-12 Perfusion may subsequently
adapt to varying oxygen demand through autoregula-
tion at the microvascular level, explaining the perfu-
sion heterogeneity.
More recently, it has become apparent that gado-
linium delayed contrast enhancement (DCE) visual-
ized by magnetic resonance imaging (MRI) is also a
common feature in patients with HCM. Although the
histologic basis of this observation remains uncertain,
it most likely reflects different phases of myocardial
injury—among others, myocardial scarring.4,12-14 The
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distribution pattern of DCE is very heterogeneous and
shows a predilection of hyperenhancement at the
junctions of the septum and the right ventricular free
wall.12-14 Whether either the heterogeneous distribu-
tion of regional systolic function or the underlying
pathology that causes DCE is responsible for the
regional distribution of resting perfusion in HCM is
currently unknown.
This study was therefore conducted to evaluate the
relationships of regional resting MBF determined by
positron emission tomography (PET) by use of oxygen
15–labeled water with regional DCE and systolic func-
tion assessed by MRI.
METHODS
Patient Population
A subset of 14 patients with HCM from a study
population described previously was studied with PET and
MRI.4 HCM was diagnosed by the presence of a nondilated
and hypertrophied left ventricle on 2-dimensional echocar-
diography (maximal wall thickness 15 mm in adult index
patients or 13 mm in adult relatives of an HCM patient) in
the absence of any other systemic or cardiac disease.
Exclusion criteria were any absolute or relative contraindi-
cation to MRI or PET (eg, pacemaker and claustrophobia),
atrial fibrillation, and a history of coronary artery disease
(CAD). CAD was excluded by angiography in 6 patients. Of
the remaining 8 patients, only 1 had anginal symptoms. CAD
was excluded in that particular patient by a negative nuclear
imaging stress test. All subjects gave written informed
consent, and the protocol was approved by the Medical
Ethics Committee of the VU University Medical Center,
Amsterdam, The Netherlands.
Imaging Protocols
PET. All PET scans were obtained in 2-dimensional
mode, by use of an ECAT EXACT HR scanner (Siemens/
CTI, Knoxville, Tenn). The scanning protocol was identical to
that described previously.15 In brief, after a transmission scan,
1100 MBq O-15–labeled water dissolved in 5 mL saline
solution was injected intravenously, followed by a 40-mL
saline solution flush at a rate of 4 mL/s (bolus injection). A
dynamic scan was acquired for a duration of 10 minutes.
Subsequently, blood pool imaging was performed. During a
2-minute period, subjects inhaled at least 2000 MBq O-15–
labeled carbon monoxide, and a single frame was acquired for
a duration of 6 minutes, starting 1 minute after the end of
inhalation to allow for equilibration in the blood pool. Emission
data were corrected for physical decay of O-15, dead time,
scatter, randoms, and photon attenuation. Reconstruction of the
O-15–labeled water emission sinograms was performed via
filtered backprojection with a Hanning filter at 0.5 of the
Nyquist frequency. Transmission and O-15–labeled carbon
monoxide sinograms were iteratively reconstructed by use of
ordered-subsets expectation maximization (CTI version 7.1.1, 2
iterations and 16 subsets).
MRI. MRI was performed on a 1.5-T clinical scanner
(Sonata; Siemens AG, Erlangen, Germany) by use of a 4-element
phased-array receiver coil. All images were acquired with electro-
cardiographic gating and during repeated single breath-holds of 10
to 15 seconds depending on heart rate. Cine images were acquired
by use of a segmented steady-state free precession gradient-echo
sequence in 3 long-axis views (2-, 3-, and 4-chamber views) and
in short-axis views acquired every 10 mm, covering the whole
left ventricle from base to apex, to calculate the global
ventricular function (Figure 1A and 1B). Scan parameters were
as follows: temporal resolution, 34 milliseconds; repetition
time, 3.0 milliseconds; echo time, 1.5 milliseconds; and typical
voxel size, 1.4  1.8 · 5 mm3. Contrast-enhanced images
were acquired 15 to 20 minutes after intravenous adminis-
tration of 0.2-mmol/kg gadolinium– diethylenetriamine pen-
taacetic acid in the same view used for cine MRI, by use of
a 2-dimensional segmented inversion-recovery–prepared
gradient-echo sequence (Figure 1E). MRI tissue tagging via
spatial modulation of magnetization was applied to create
noninvasive markers (tags) within the myocardium for calcu-
lation of strain.16 Tagged images were acquired in short-axis
views only (Figure 1C and 1D).
Data Analysis
PET. Anatomic tissue images were generated by subtrac-
tion of the blood pool image from the transmission image.
Transaxial anatomic images of the left ventricle were reori-
ented according to the anatomic axis of the heart, and slices
were displayed as short-axis slices (Figure 1F). The same
reslicing parameters were applied to the dynamic O-15–labeled
water images. Regions of interest (ROIs) were defined manu-
ally at the basal and midventricular level of the left ventricle as
previously described.15 In short, each basal and midventricular
slice was divided into 6 equidistant sectors angulated 60° apart,
starting from the posterior insertion of the right ventricular free
wall into the left ventricular myocardium (1, inferoseptal; 2,
anteroseptal; 3, anterior; 4, anterolateral; 5, posterolateral; and
6, inferior). Corresponding ROIs from a variable number of
slices were grouped in each patient to generate 12 volumes of
interest (6 basal and 6 midventricular; mean size per volume,
11.2  1.5 mL). Additional ROIs were defined in the left atrial
and right ventricular chamber. This latter set of ROIs was
projected onto the dynamic O-15–labeled water images to
generate image-derived input functions. By use of the standard
single–tissue compartment model together with these input
functions, MBF (in milliliters per minute per milliliter) was
determined for all myocardial tissue time-activity curves.17
It should be noted that this method provides MBF estimates
of perfusable tissue only (ie, flow to the mass of tissue that
is capable of rapidly exchanging water). Fibrotic tissue lacks
this ability and is therefore excluded from analysis. Correc-
tions were made for spillover from both the left and right
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ventricle by use of the method described by Hermansen
et al.18
Regional analysis of MBF, DCE, and end-systolic circum-
ferential shortening (Ecc) was evaluated by considering each of
the 12 segments (ie, volume of interests) separately. For the
sake of clarity and brevity, in Table 1 each of the regions was
assigned to the anterior, lateral, inferior, or septal wall. For
global analysis, measurements for all 12 regions were aver-
aged. As resting MBF is related to the rate-pressure product
(RPP) (RPP  Heart rate  Systolic blood pressure), corrected
MBF (MBF/RPP  10,000) was also determined. The repro-
ducibility of these PET and MRI measurements has previously
been reported.19,20
MRI. Global left ventricular function parameters, includ-
ing end-diastolic volume, end-systolic volume, ejection frac-
tion, and myocardial mass, were derived from the cine images
by use of the MASS software package (Medis, Leiden, The
Netherlands). The same regions on the short-axis slices were
defined as described previously. Each myocardial segment was
evaluated for the presence of hyperenhancement, defined as an
area of signal enhancement greater than 2 SDs of the signal of
nonenhanced myocardium. The extent of contrast enhancement
was expressed as a percentage of the total myocardial area
studied. Tagged images were processed by use of a dedicated
software package (SPAMMVU; University of Pennsylvania,
Philadelphia, Pa),21 and circumferential strain curves were
generated for each myocardial segment. Ecc for each segment,
indicating maximum regional myocardial contraction, was derived
from the strain curves. It is important to emphasize that Ecc
represents shortening and is therefore expressed as a negative
value, where negative values of larger magnitude indicate better
systolic function than negative values of smaller magnitude.
Statistics
Data are expressed as mean  SD. For comparison of 2
data sets, paired or unpaired Student t tests were used where
appropriate. Comparison of multiple data sets was performed
by use of analysis of variance, and specific differences were
identified by use of a Student t test corrected for multiple
comparisons with the Bonferroni inequality adjustment. Corre-
lation coefficients were calculated to describe the associations
between study variables. When correlation coefficients were
estimated on a segmental level, a correction for the interdepen-
dency of the segmental data within 1 patient was applied. To
this end, a linear mixed-effects model was used. P  .05 was
considered statistically significant.
Figure 1. End-diastolic (A) and end-systolic (B) MRI cine images and end-diastolic (C) and
end-systolic (D) line-tagging images at the midventricular level in a short-axis view of a patient with
concentric HCM. The obliteration of the left ventricular cavity at end systole on the cine image
should be noted. Furthermore, tagging images show that deformation of the tag lines at end systole
is impaired in the anteroseptal regions compared with the inferolateral regions, despite a similar
degree of hypertrophy. E, Delayed contrast-enhanced image with enhancement at the junctions
of the interventricular septum and right ventricular free wall. F, Anatomic tissue image obtained
with PET.
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RESULTS
Study Population
We studied 14 patients (mean age, 55 12 years; 13
men and 1 woman). Patients were predominantly asymp-
tomatic (New York Heart Association class I in 10 and
class II in 4). The mean left ventricular ejection fraction
was 65%  5%. The pattern of hypertrophy was asym-
metric (septal hypertrophy) in all patients, even though in
2 patients the lateral wall thickness was also more than
15 mm (imposing as concentric hypertrophy). The mean
septal wall thickness (22 4 mm; range, 16-29 mm) was
significantly increased compared with the mean lateral
wall thickness (8  1 mm) (P  .01). The RPP did not
significantly differ between the PET and MRI studies
(7567  1470 beats/min · mm Hg vs 7780  1502
beats/min · mm Hg, respectively; P  not significant).
Regional Distribution Patterns of PET
and MRI Data
Table 1 lists the data obtained from PET and MRI.
A total of 168 segments were analyzed (12 segments in
each patient). The mean resting MBF was 0.78  0.19
mL · min1 · mL1, and there was a trend toward reduced
MBF in the septum (0.72  0.11 mL · min1 · mL1)
compared with that in the lateral wall (0.84  0.29
mL · min1 · mL1), although this difference was not sta-
tistically significant (P  .092). On average, 16% of the
analyzed myocardium demonstrated DCE, predominantly
localized in the anteroseptal region at the junction with the
right ventricular free wall (Table 1, Figure 1E), and DCE
was virtually absent in the lateral wall. Ecc in the hyper-
trophied septum was significantly impaired compared
with the anterior and lateral regions (P  .01) (Table 1).
Interrelationships Between MBF, DCE, and Ecc
As depicted in Figure 2, MBF and Ecc were reduced
in segments that displayed DCE (n  82) compared with
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Figure 2. Bar charts demonstrating that MBF (A) and Ecc (B)
are significantly impaired in regions that display DCE (black
bars) compared with nonenhanced segments (white bars).
Asterisk, P  .01 versus nonenhanced segments.
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Figure 3. Bar chart demonstrating MBF values for segments
with (black bars) and without (white bars) enhancement for
varying degrees of systolic function expressed as end-systolic
Ecc categorized as normal (22%-40%) or mildly (17%-22%),
moderately (10%-17%), or severely (2%-10%) impaired.
MBF is consistently reduced in segments with enhancement,
regardless of function. Asterisk, P  .05 versus nonen-
hanced segments.
Table 1. PET and MRI data from HCM patients (n  14)
Region
MBF (mL · min1 · mL1
of perfusable tissue) DCE (%) Ecc (%)
Anterior 0.80 0.20 24 22* 17.5 7.2
Lateral 0.84  0.29 3 2† 22.4 4.0‡
Inferior 0.72 0.21 12 12 15.5 5.0
Septal 0.72  0.11 21 15 10.3 3.7‡
All 0.78 0.19 16 11 16.5 3.8
Data are given as mean  SD. The P values (as determined by analysis of variance) for MBF, DCE, and Ecc were as follows: P  .053, P 
.001, and P  .001, respectively.
*P  .05 versus lateral and inferior.
†P  .01 versus anterior and septal.
‡P  .01 versus all regions.
Journal of Nuclear Cardiology Knaapen et al
Volume 13, Number 5;660-7 Hypertrophic cardiomyopathy
92
93
nonenhanced segments (n  86) (both P  .01). Figure 3
demonstrates that MBF was consistently reduced in
hyperenhanced segments, regardless of systolic function
expressed in quartiles of Ecc (ranging from normal to
severely impaired), whereas MBF was not significantly
affected by the extent of systolic dysfunction (P  not
significant, analysis of variance). Univariate linear re-
gression analysis confirmed these findings, as MBF was
inversely related to the extent of DCE (r  0.30, P 
.001) but not Ecc (r  0.15, P  .072). In addition, a
significant correlation between the extent of DCE and
regional Ecc was found (r  0.42, P  .001). Figure 4
displays these correlations. Multivariate linear regression
analysis demonstrated that only DCE (P  .001) was
independently related to RPP-corrected MBF when Ecc
(P  .71) was added to the model.
DISCUSSION
Regional differences in resting perfusion are well
documented in patients with HCM, although conflicting
results regarding its distribution pattern have been re-
ported.2-6 In this study perfusion in the hypertrophied
septum tended to be lower than that in the lateral wall,
although statistical significance could not be reached,
which may be related to the relatively small sample size
of the study population. Systolic function, however,
expressed by Ecc via MRI tissue tagging, demonstrated
marked heterogeneity and was mainly impaired in the
hypertrophied interventricular septum. These results are
in line with previous tagging studies in HCM pa-
tients.10,11 In addition, DCE was present in all patients
and was predominantly located in the anteroseptal region
at the junction with the right ventricular free wall, the
extent of which was closely correlated to systolic func-
tion, as previously described.4,12-14
The main finding of this study was that regional
heterogeneity in resting perfusion was independently
related to the extent of enhancement, whereas perfusion
and regional systolic function correlated poorly.
Resting Perfusion Versus Systolic Function
The poor and nonsignificant correlation between
perfusion and systolic function is remarkable. Under
normal conditions at a basal state, perfusion is autoregu-
lated at the microvascular level in response to varying
oxygen demand.22 The latter is mainly dependent on
systolic function, heart rate, and systolic blood pres-
sure.23 Therefore a relationship between systolic func-
tion and (RPP-corrected) perfusion is to be expected. The
lack of agreement in our study population suggests that
there is uncoupling of oxidative metabolism and func-
tion. This has already been demonstrated by Ishiwata
et al,24 who demonstrated reduced mechanical efficiency
(mechanical cardiac work in relation to myocardial
oxygen consumption) in patients with HCM in both the
hypertrophied septum and the nonhypertrophied lateral
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Figure 4. Scatter plots demonstrating correlations between MBF and DCE, MBF and Ecc, and Ecc
and DCE. SEE, Standard error of the estimate; NS, not significant.
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wall. At least 2 mechanisms may contribute to this
observation. First, impairment of perfusion reserve is a
hallmark in patients with HCM and likely induces
episodes of ischemia (repetitive stunning).2,3 Studies in
patients with CAD have revealed that resting perfusion
often is within normal limits in repetitively stunned
dysfunctional myocardium.25 Therefore uncoupling of
perfusion and function occurs, and mechanical efficiency
is reduced. This ischemic etiology may also apply in
patients with HCM, as the same pattern is observed (ie,
impaired hyperemic perfusion and systolic dysfunction
in combination with relatively preserved resting perfu-
sion). Second, histopathologic examination of hypertro-
phied myocardium in patients with HCM reveals myo-
cyte disarray in virtually all cases.26 The disorganized
structure of the myocytes prohibits an effective contrac-
tion of the myocardial wall, resulting in reduced systolic
function. Nevertheless, oxidative metabolism in each
individual contracting myocyte may be normal. Conse-
quently, mechanical efficiency will be reduced.
Resting Perfusion Versus DCE
Our data suggest that, in contrast to systolic func-
tion, the underlying pathologic process that causes DCE
in HCM is, at least in part, responsible for the variation
in regional distribution of perfusion at rest. Regardless of
the degree of systolic function, perfusion was consis-
tently reduced in segments that displayed hyperenhance-
ment (Figure 3). In addition, the extent of DCE was
independently and inversely related to absolute resting
perfusion. Although the histologic basis of DCE in HCM
remains uncertain, as histologic comparison in human
beings is limited to 2 case reports of patients with HCM
in the end stage of dilated congestive heart failure,27,28
indirect evidence from animal and clinical imaging
studies suggests that it may be caused by plexiform
fibrosis, acute cell death, inflammation, macroscopic
scarring, fiber disarray, and edema.4,12,29-33 All of these
features, which are known to occur in HCM,31,32 are
associated with increased interstitial spaces and altered
wash-in/washout kinetics that cause DCE.34 Because the
disease process of HCM is dynamic with distinct differ-
ent histopathologic phases,26,29,30,32 it probably reflects
an admixture of one or more of these features to a
varying degree. More studies are warranted to elucidate
the histologic basis of DCE in HCM. Whatever the
underlying histologic pathology of DCE may be, reduced
resting perfusion is conceivable in any of the aforemen-
tioned conditions, and therefore the results from our
study seem valid. Furthermore, preliminary data from
Melacini et al33 point toward similar conclusions, as
these authors have also described reduced basal perfu-
sion, measured with first-pass contrast MRI, in areas
demonstrating DCE in HCM patients.
Comparison with previous studies shows some dis-
crepancies in the observed regional distribution of abso-
lute resting perfusion. Such a comparison, however, is
difficult because of differences in patient characteristics,
as well as characteristics related to the imaging tech-
nique. HCM demonstrates great diversity in morpho-
logic, functional, and clinical features.1 Our patient
population had either mild or asymptomatic HCM, and
more advanced disease states might yield different re-
sults. Nevertheless, all patients showed contrast enhance-
ment, the extent of which is related to progressive
disease and serves as a marker of clinical risk for
sudden death.13 Furthermore, PET studies are sub-
jected to partial-volume effects, which are directly
related to wall thickness and motion. Therefore some
of the conflicting data from previous studies may be
related to differences in correction of these partial-
volume effects. In our study, however, O-15–labeled
water was used as a perfusion tracer, which allows for a
kinetic modeling procedure that provides data that are
independent of partial-volume effects and, thus, wall
thickness and motion.17
Limitations
Only a limited number of patients were studied,
which may have obscured the extent of heterogeneity in
resting perfusion, as well as a significant relationship
between regional systolic function and perfusion. Nev-
ertheless, in this small study population a strong associ-
ation between the presence of DCE and reduced resting
perfusion in HCM patients was clear. Furthermore, in 7
patients CAD was not excluded by angiography or stress
testing. It is, however, unlikely that the results were
significantly influenced by the potential presence of
asymptomatic CAD in these patients, as previous studies
have demonstrated that resting MBF is only affected by
critical coronary artery stenoses.35,36 The severity of this
type of stenosis would probably have resulted in anginal
complaints.
Conclusions
Regional heterogeneity of resting perfusion in HCM
is related to the extent of DCE and not to systolic
function.
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Abstract
Background: The water-perfusable tissue index (PTI) is assumed to differentiate viable
myocardium from scar tissue, but histological comparisons in humans are lacking. The present
study compares PTI with delayed contrast-enhanced magnetic resonance imaging (DCE-MRI),
a validated marker of fibrotic tissue, in patients with ischemic left ventricular (LV) dysfunction. In
addition, the optimal PTI threshold for detection of myocardial viability was defined when DCE-
MRI was taken as a reference.
Materials: Twenty patients with ischemic LV dysfunction were studied with positron emission
tomography, using oxygen-15-labeled water and carbon monoxide as tracers, and DCE-MRI.
Results: Of the 200 analyzed segments, 112 demonstrated DCE and were subsequently divided
in three subgroups according to the severity of enhancement. PTI was 1.04 T 0.21 in control
segments and gradually decreased with increasing extent of DCE to 0.77 T 0.31 for segments
with transmural enhancement ( p G 0.001). However, PTI progressively underestimated infarct
size with increasing quantities of scar tissue (r = 0.61, p G 0.01). A PTI cutoff value of 0.89
yielded the best diagnostic accuracy for detection of myocardial viability with sensitivity and
specificity values of 75 and 77%, respectively.
Conclusions: PTI is inversely related to the extent of scar tissue estimated by DCE-MRI in
patients with chronic ischemic heart disease and LV dysfunction. However, with increasing
quantities of scar tissue, PTI overestimates the extent of residual viable tissue. A PTI threshold
of 0.89 yields the best diagnostic accuracy for viability detection.
Key words: Perfusable tissue index, Positron emission tomography, Delayed contrast-
enhanced MRI, Ischemic heart disease, Viability
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Introduction
It has long been recognized that the perfusable tissueindex (PTI) serves as a marker of viability in patients
with ischemic left ventricular (LV) dysfunction [1Y4]. PTI
reflects the fraction of myocardium that is able to rapidly
exchange water, i.e., is perfusable by water, and can be
obtained with positron emission tomography (PET) using
oxygen-15-labeled water (H2
15O) and carbon monoxide
(C15O) [5]. It has been hypothesized that based on this
principle, a distinction can be made between scar (non-
perfusable) and viable (perfusable) tissue. In line with this
hypothesis, Iida et al. [6] have demonstrated, in a study
performed in open chest dogs, that the mass and proportion
of histochemically defined necrotic tissue correlated with
the reduction of PTI. Histological comparisons in humans,
however, are currently lacking.
More recently, an alternative method for noninvasive
assessment of myocardial fibrotic tissue has emerged using
delayed contrast-enhanced magnetic resonance imaging
(DCE-MRI) with the extracellular contrast agent gadolini-
um. In several experimental studies, DCE-MRI has shown
to accurately identify necrotic tissue after myocardial
infarction [7Y9]. Using high spatial resolution techniques,
the size and shape of hyperenhanced areas at DCE-MRI
were identical to areas of histologic defined irreversible
injury. This technique therefore allows for accurate delin-
eation between scar and viable tissue in patients with
ischemic heart disease. Similar to PTI, DCE-MRI can also
predict recovery of function prior to revascularization in
chronic ischemic myocardial dysfunction [10, 11].
The aim of the present study was to test PTI as a marker
of scar tissue in patients with chronic ischemic heart disease
by direct comparison with DCE-MRI. In addition, the
optimal PTI threshold for detection of myocardial viability
was defined when taking DCE-MRI as a reference.
Methods
Patient Population
Twenty patients with LV dysfunction and coronary artery disease
were studied with PET and MRI within two weeks of each other.
All patients were in a stable clinical condition for at least one
month, and there were no ischemic events or revascularization
procedures in the period between the different examinations.
Exclusion criteria were any absolute or relative contraindication to
PET or MRI (e.g., pacemaker, claustrophobia, atrial fibrillation).
Baseline characteristics of the patient population are given in
Table 1. The protocol was approved by the Medical Ethics
Committee of the VU University Medical Center, and all patients
gave written informed consent.
Imaging Protocols
Positron Emission TomographyR All scans were performed in
2-D mode using an ECAT EXACT HR+ (Siemens/CTI, Knoxville,
TN, USA). The scanning protocol was identical to that described
previously [12]. Briefly, after a transmission scan, 1100 MBq of
H2
15O was injected intravenously as a bolus injection. A dynamic
scan was acquired for a duration of 10 minutes. During a two-
minute period, subjects inhaled at least 2000 MBq of C15O, and a
single frame was acquired for a duration of six minutes, starting
one minute after the end of inhalation to allow for equilibration in
the blood pool. During the C15O scan, three venous blood samples
were drawn from the intravenous line and counted in a sodium
iodide well counter cross-calibrated against the scanner.
Magnetic Resonance ImagingR Magnetic resonance imaging
was performed on a 1.5-T scanner (Sonata, Siemens, Erlangen,
Germany), using a four-element phased-array body radio-frequen-
cy receiver coil. All images were acquired with electrocardiogram
gating and during repeated expiration breath holds of 10Y15 sec-
onds, depending on heart rate. After localizing scouts, cine images
were acquired using a segmented steady-state-free precession se-
quence in three long axis views (two-, three, and four-chamber
view) and in multiple short-axis views with a slice distance of
10 mm, covering the whole LV from base to apex. Scan pa-
rameters were as follows: temporal resolution 34 milliseconds, TR
3.0 milliseconds, TE 1.5 milliseconds, typical voxel size 1.4 
1.8  5 mm3. Contrast-enhanced images were acquired 15Y20
minutes after intravenous administration of 0.2 mmol kgj1
gadoliniumYDTPA in the same view used as cine MRI, using a
two-dimensional segmented inversion-recovery prepared gradient-
echo sequence (TE 4.4 milliseconds, TR 9.8 milliseconds,
inversion time 250Y300 milliseconds, typical voxel size 1.3 
1.6  5 mm3).
Data Analysis
Positron Emission TomographyR Anatomical tissue fraction
(ATF, mL mLj1) images were generated according to the
procedure described by Iida et al. [13]. Transaxial ATF images
of the left ventricle were reoriented according to the anatomic axis
of the heart, and slices were displayed as short-axis slices. The
same reslicing parameters were applied to the dynamic H2
15O
images. Regions of interest (ROI) were defined manually by a
single observer (P.K.) at the basal and midventricular level of the
left ventricle as previously described [12, 14]. Corresponding ROIs
from a variable number of slices were grouped in each patient to
generate 12 volumes of interest (six basal and six midventricular).
Table 1. Patient characteristics (n = 20)
Age (years) 61 T 12
Sex (M/F) 14/6
Previous myocardial infarction 16
Single-vessel disease 4
Two-vessel disease 6
Three-vessel disease 10
LVEF (%) 34 T 16
LVEDV (mL) 242 T 91
LVESV (mL) 170 T 96
Systolic blood pressure (mm Hg) 122 T 16
Diastolic blood pressure (mm Hg) 74 T 10
Heart rate (beats minj1) 66 T 11
Rate pressure product (mm Hg minj1) 7999 T 1746
LVEF = left ventricular ejection fraction; LVEDV = left ventricular end-
diastolic volume; LVESV = left ventricular end-systolic volume.
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The inferior volumes of interest were excluded from analysis
because of anticipated perfusable tissue fraction (PTF) spillover
effects from the liver [12]. Additional ROIs were defined in the
left and right ventricular chambers. This set of ROIs was projected
on the dynamic H2
15O images to generate tissue time activity
curves and image-derived input functions. Using the standard
single tissue compartment model together with these input
functions, myocardial blood flow in perfusable tissue (MBFp;
mL minj1 mLj1) and PTF (mL I mLj1) were determined from all
myocardial tissue time activity curves [15]. Corrections were made
for spillover from both left and right ventricle using the method
described by Hermansen et al. [15]. PTI was obtained by dividing
PTF by ATF. In addition, transmural MBF (MBFt), i.e., MBF for
perfusable and nonperfusable tissue together, was calculated by
multiplying MBFp with PTI (Fig. 1). Global PET parameters were
calculated by grouping all volumes of interest. As resting MBF is
related to the rate pressure product (RPP = heart rate  systolic
blood pressure), corrected MBF (MBF  RPPj1  10,000) was
also determined for both MBFp and MBFt.
Magnetic Resonance ImagingR The same regions on the short
axis DCE-MRI slices were defined as described above. Each
myocardial segment was evaluated for the presence of hyper-
enhancement, defined as an area of signal enhancement 95 SD of
the signal of nonenhanced myocardium [16]. The extent of con-
trast enhancement was expressed as a percentage of the total myo-
cardial area studied and subsequently divided in three groups of
hyperenhancement: subendocardial (e33%), intermediate
(34Y66%), and transmural (Q67%; Fig. 2). Per heart, the fraction
of nonhyperenhanced tissue was calculated by dividing the non-
hyperenhanced tissue by total mass of the analyzed segments.
Wall motion was assessed by visual interpretation independent
from the DCE data by a single observer (O.B.) using a five point
scale: 1 = normal contractile function; 2 = mild hypokinesia; 3 =
moderate to severe hypokinesia; 4 = akinesia; 5 = dyskinesia.
Additionally, segmental end-diastolic wall thickness and wall
thickening were determined by manual tracing of endocardial
Fig. 2. Delayed contrast-enhanced images visualized by MRI in a short axis view at a midventricular level. Myocardium in
panel A displays no hyperenhancement. Panels B, C, and D demonstrate regional subendocardial, intermediate, and
transmural enhancement, respectively.
Fig. 1. Schematic diagram of a myocardial segment com-
prising both viable (striped area) and scar tissue (black area).
Only viable tissue is assumed to exchange oxygen-15-
labeled water rapidly, and PTI reflects the fraction of the
total anatomical tissue that is perfusable by water. Myocar-
dial blood flow in perfusable tissue (MBFp) represents
perfusion in viable tissue only, whereas MBFt represents
transmural perfusion equivalent to the microsphere tech-
nique (MBFt = MBFp  PTI), i.e., average perfusion in both
viable and fibrotic tissue.
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and epicardial borders in end-diastolic and end-systolic images,
excluding trabeculations and papillary muscles. Finally, dysfunc-
tional segments (WMS Q 3) were graded viable or nonviable using
a recently validated cutoff value of 37% hyperenhancement per
segment [14].
Statistics
Data are expressed as mean T SD. For comparison of two data sets,
paired or unpaired Student’s t tests were performed where ap-
propriate. Comparison of multiple data sets was performed using
analysis of variance (ANOVA), and specific differences were
identified by a Student’s t test corrected for multiple comparisons
with the Bonferroni inequality adjustment. Correlations were an-
alyzed using linear regression. The area under the receiver op-
erator characteristic curve (AUC) was considered a measure of
accuracy of PTI and MBF to discriminate between viable and
nonviable myocardium, as defined by DCE-MRI. A p value G 0.05
was considered statistically significant.
Results
Positron emission tomography and MRI data are summa-
rized in Table 2. Of the 200 segments in 20 patients that
were analyzed, 88 did not show any hyperenhancement. Of
these segments, 61 demonstrated no wall motion abnormal-
ities either and were considered control segments. Of the
112 segments that demonstrated hyperenhancement, more
than half was limited to the subendocardium (53%).
Perfusable Tissue Index vs. Delayed
Contrast Enhancement
Perfusable tissue index in control segments was 1.04 T 0.21.
There was a gradual decrease in PTI with increasing extent
of DCE from a subendocardial to transmural level ( p G
0.001 by ANOVA, Fig. 3A). As demonstrated in Fig. 4,
global PTI per patient correlated with the DCE-MRI
determined fraction of nonhyperenhanced tissue per patient
Table 2. Segmental PET and MRI data
Extent of DCE
Control (n = 61) Subendocardial (n = 59) Intermediate (n = 33) Transmural (n = 20) p Value (ANOVA)
PTI 1.04 T 0.21 0.97 T 0.21 0.85 T 0.25* 0.77 T 0.31. G0.001
MBFp 1.06 T 0.30 0.94 T 0.36 0.84 T 0.33* 0.59 T 0.23
- G0.001
Corrected 1.22 T 0.38 1.23 T 0.43 1.10 T 0.41 0.92 T 0.42. 0.018
MBFt 1.07 T 0.29 0.91 T 0.39* 0.69 T 0.28
. 0.44 T 0.21- G0.001
Corrected 1.23 T 0.36 1.17 T 0.43 0.91 T 0.34. 0.69 T 0.37. G0.001
WMS 1.0 T 0.0 2.4 T 1.1* 3.4 T 0.9. 3.4 T 0.9. G0.001
EDWT 7.5 T 2.2 6.5 T 1.7* 5.1 T 1.3. 4.3 T 1.8. G0.001
Wth 4.6 T 1.5 2.0 T 1.6* 0.5 T 1.1. 0.7 T 1.2. G0.001
*p G 0.05 vs. control; .p G 0.05 vs. control and subendocardial; -p G 0.05 vs. control, subendocardial, and intermediate.
DCE = delayed contrast enhancement; PTI = perfusable tissue index; MBFp = myocardial blood flow in perfusable tissue (mL min
j1 mLj1); MBFt = MBFp 
PTI = transmural myocardial blood flow (mL minj1 mLj1); corrected = corrected for the rate pressure product; WMS = wall motion score; EDWT = end-
diastolic wall thickness (mm); Wth = wall thickening (mm).
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Fig. 3. Bar charts showing PTI and MBF values (corrected for the rate pressure product) for myocardial segments with
varying degree of MRI delayed contrast enhancement. Error bars represent standard error of the mean. *p G 0.01 vs. control;
.p G 0.05 vs. control and subendocardium; -p G 0.01 vs. MBFp.
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( y = 0.47x + 0.59, r = 0.58, p G 0.01). The slope (0.47) and
y intercept (0.59) of the regression analysis, however, re-
vealed a systematic discrepancy between PTI and DCE.
Myocardial Blood Flow vs. Delayed
Contrast Enhancement
Segmental MBF, both in perfusable (MBFp) and transmural
tissue (MBFt), progressively decreased with increasing ex-
tent of hyperenhancement, although the differences between
groups were more apparent for MBFt (both p G 0.05 by
ANOVA, Table 2). The extent of nonhyperenhanced tissue
in individual patients was directly related to the RPP (r =
0.6, p G 0.01). When MBFp and MBFt values were sub-
sequently corrected for RPP, differences between hyper-
enhancement groups were attenuated (Table 2). Compared
with control segments, MBFt was significantly reduced
from the level of intermediate hyperenhancement (p G
0.05), whereas MBFp was reduced in segments with trans-
mural hyperenhancement only (p G 0.05, Fig. 3B).
Accuracy of PTI and MBF as Markers of Viability
Ninety-nine of 200 (50%) analyzed segments demonstrated
wall motion abnormalities of which 56 (57%) and 43 (43%)
were graded as viable (DCE e 37%) and nonviable (DCE 9
37%), respectively, based on the extent of hyperenhance-
ment. The AUC of PTI, MBFp, and MBFt to predict myo-
cardial viability defined by DCE-MRI were 0.80, 0.64, and
0.80, respectively (Fig. 5). The AUC of MBFp was sig-
nificantly lower compared with PTI and MBFt (both p G
0.01), whereas AUCs between the latter two did not sig-
nificantly differ ( p = NS). Correction of MBF values for
RPP did not significantly alter these results ( p = NS). A
threshold of 0.89 for PTI yielded optimal sensitivity and
specificity values of 75 and 77%, respectively. Optimal
thresholds for MBFp and MBFt were 0.81 and 0.70 mL
minj1 mLj1, with sensitivity values of 50 and 68% and
specificity values of 74 and 84%, respectively.
Discussion
The present study demonstrates that the reduction of PTI in
patients with chronic ischemic LV dysfunction is related to
the extent of myocardial hyperenhancement visualized by
MRI. Furthermore, a PTI cutoff value of 0.89 yielded the
best diagnostic accuracy to discriminate between viable and
nonviable myocardium as defined by DCE-MRI.
Perfusable Tissue Index vs. Delayed Contrast
Enhancement
Increased interstitial space, which results in an increase in
volume of distribution of the extracellular contrast agent
gadolinium, and altered wash-in/wash-out kinetics are re-
sponsible for the regional hyperenhancement in chronic in-
farct tissue [8, 9]. In contrast to DCE-MRI, PTI identifies
the extent of residual viable tissue and is dependent on the
physiological property of the myocardium to exchange
water rapidly [5, 6, 13]. Scar tissue is assumed to lack this
property, and a reduction of PTI is associated with the
presence of fibrotic tissue [6].
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Fig. 4. Scatter plot giving the relation between PTI and
fraction of nonhyperenhanced tissue. Dotted lines represent
95% confidence intervals.
Fig. 5. Receiver operator characteristics analysis of the
differentiation between viable and nonviable segments by
PTI, MBFp, and MBFt using delayed contrast-enhanced MRI
as a reference standard. Optimal cutoff values were 0.89 for
PTI and 0.81 and 0.70 mL minj1 mLj1 -for MBFp and MBFt,
respectively.
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The current data support this hypothesis as PTI in control
segments was close to the expected value of unity, and in-
creasing scarring identified by DCE-MRI was accompanied
by a gradual decrease in PTI. However, with increasing
infarct size, a systematic discrepancy between the extent of
hyperenhancement and PTI was observed. The latter could
be caused by either an overestimation by hyperenhancement
or an underestimation by PTI compared with true infarct
size. As extensive ex vivo analyses of histochemically de-
fined infarction in experimental animal models using DCE-
MRI have shown an accurate estimate of scar size [7Y9],
and given the fact that even in segments with (near) trans-
mural hyperenhancement, the average PTI value did not
nearly approach zero (0.77 T 0.31), an underestimation of
infarct size by PTI seems more likely. This phenomenon has
already been observed by Iida et al. [6], who also observed
an overestimation of PTI in the center of transmural scar
tissue after chronic myocardial infarction in open chest dogs.
The following mechanisms may be involved. First,
Herrero et al. [17] have demonstrated that H2
15O can dif-
fuse into necrotic infarcted tissue within the timeframe of
the PET study. Scar tissue may therefore, to some extent, be
included in the PTF and hence influence PTI. This effect
would further be augmented with increasing quantities of
scar tissue per segment, as observed in the present study.
Second, the currently used modeling procedure assumes that
the bloodYmyocardium partition coefficient is constant and
similar for viable myocardium and scar tissue [15, 18]. The
latter assumption may not hold true and, in the event of an
increased partition coefficient in scar tissue, may result in
an overestimation of PTF. Consequently, PTI would under-
estimate infarct size. Third, wall thickness and thickening
are inversely related to the extent of scarring. For large
myocardial infarctions, more spillover corrections from the
left and right ventricular cavity will therefore be necessary
with decreasing dimensions of the LV wall. A nonlinear re-
lationship in spillover correction and wall thickness may re-
sult in bias regarding PTF values, affecting PTI.
On the other hand, the possibility of overestimation of
infarct size with DCE-MRI must not be disregarded, as the
only reported case to date of human histologic comparison
showed a slight overestimation of hyperenhancement com-
pared with fibrotic tissue [19]. Furthermore, quantitative
analysis of hyperenhancement is observer-dependent through
threshold definition [16]. In addition, even in so-called
transmural myocardial infarction, viable islets of myocytes
can frequently be detected within the scar region on his-
tologic examination. DCE-MRI may not be sensitive enough
to detect this residual viable tissue [20]. Finally, overesti-
mation of hyperenhancement is known to occur in the acute
phase of a coronary syndrome because of increased in-
terstitial spaces caused by acute cell death and edema [21].
Although care was taken to exclude patients who suffered
from a coronary syndrome within the preceding month, the
possible inclusion of these patients (i.e., with silent is-
chemia) cannot be excluded.
Perfusable Tissue Index and Myocardial Blood
Flow as Markers of Viability
Recently, a cutoff value of 37% hyperenhancement per
myocardial segment was identified as an accurate threshold
to determine viability in patients with chronic ischemic LV
dysfunction [14]. The present data indicate that a PTI cutoff
value of 0.89 yields the best diagnostic accuracy for iden-
tification of myocardial viability when taking DCE-MRI as
a reference. To date, four studies have been published that
have assessed the value of PTI as a marker of viability
[1Y4]. In three of these studies, a cutoff value of 0.7 gave
the best diagnostic accuracy [1, 2, 4], which is distinctly
lower than the optimal threshold found in the present study.
However, a more recent study by Gerber et al. [3] in 30
patients suggested that 0.9 may be the best PTI cutoff value
to predict recovery of function after revascularization in this
patient group. The latter value is similar to the one found in
the present study. It should be noted, however, that blood
pool imaging in that particular study was performed with
early phase 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) im-
aging, which may have contributed to a lower ATF value
resulting in a higher PTI cutoff value. Pooled data of these
four studies yielded sensitivity and specificity values of 94
and 84% [5], respectively, which is higher than the values
of 75 and 77% observed in the present study. Although
there are some differences in methodology and patient
characteristics between these studies, bias was introduced in
the present study by the fact that not recovery of function
but DCE-MRI served as reference of myocardial viability. It
has recently been demonstrated, however, that DCE-MRI is
not perfect as a viability marker [22], and additional
information on the viability status of the remaining non-
enhanced myocardium is needed to improve diagnostic
accuracy [11].
In line with previous studies [3, 23, 24], MBFp was a
relatively poor marker of myocardial viability with sensi-
tivity and specificity values of 50 and 74%, respectively.
Moreover, when perfusion values were corrected for the
hemodynamic conditions, MBFp was only reduced in seg-
ments with (near) transmural scarring. The latter indicates
that perfusion in residual viable tissue in dysfunctional
myocardium remains relatively preserved. This phenome-
non has already been observed by Marinho et al. [24] and
further supports the notion that chronic hypoperfusion is
not likely to be the leading cause of contractile dysfunc-
tion in viable but dysfunctional myocardium [25]. Trans-
mural MBF (MBFt = MBFp  PTI) showed a diagnostic
accuracy for detection of viability comparable to that of PTI
(Fig. 5). Therefore, there seems to be no incremental benefit
in determining MBFp with H2
15O PET over the assessment
of myocardial scarring alone. These results suggest that
the diagnostic accuracy of microsphere equivalent trans-
mural MBF tracers (e.g., nitrogen-13-ammonia) for detec-
tion of viability, which represents an average flow per unit
mass of tissue including both viable myocardium and scar,
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is based predominantly on their ability to detect irrevers-
ible myocardial injury rather than perfusion in residual
viable tissue.
Limitations
A limitation of the present study is that recovery of myo-
cardial function after revascularization was not assessed.
Thus, conclusions on the functional recovery of dysfunc-
tional segments deemed viable by PET or DCE-MRI cannot
be drawn. Furthermore, results from different imaging mo-
dalities were combined. Although care was taken in match-
ing myocardial territories, some misalignment might have
occurred.
Conclusions
Perfusable tissue index is inversely related to the extent of
scar tissue estimated by DCE-MRI in patients with chronic
ischemic heart disease and LV dysfunction, although PTI
underestimates DCE-MRI-determined infarct size with in-
creasing quantities of scar tissue. A PTI cutoff value of 0.89
yields the best diagnostic accuracy for detection of myo-
cardial viability when taking DCE-MRI as a reference.
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SUMMARY 
Myocardial perfusion abnormalities occur in a variety of cardiac disease states, including 
coronary artery disease, and both primary and secondary cardiomyopathies. The assessment of 
perfusion in these pathological conditions yields important diagnostic and prognostic information 
and allows for monitoring the effect of therapeutic interventions. Positron emission tomography 
(PET) using a flow tracer, such as oxygen-15-labeled water (H215O), can noninvasively measure 
myocardial blood flow (MBF) in absolute terms. Furthermore, this particular tracer provides the 
possibility of estimating the volume of distribution of water in myocardial tissue, which 
correlates with the extent of fibrosis. In this thesis, clinical studies in patients with heart failure 
are described in order to extend the knowledge of the interactions between perfusion, fibrosis, 
and function and to assess the effects of therapy. 
In chapter 1, the validation process of H215O as a PET perfusion tracer is described. In addition, 
outcome of clinical studies in cardiac (patho)physiology are discussed. Furthermore, the clinical 
value of the perfusable tissue index (PTI) as an index of myocardial fibrosis and a marker of 
myocardial viability was evaluated. Pooling of viability studies revealed that dysfunctional, but 
viable, myocardium was characterized by a significantly higher PTI value than non-viable tissue. 
This finding supports the hypothesis that scar tissue in not able to rapidly exchange water and a 
reduction in PTI reflects the extent of myocardial scarring. A cut-off value of 0.7 yielded the best 
diagnostic accuracy in the distinction between viable and non-viable tissue in three out of four 
examined studies. It should be mentioned, however, that these results were based on studies from 
a limited number of centers in a small number patients. More studies are warranted to gain 
further insight into the clinical value of PTI. 
In chapter 2.1, the effects of cardiac resynchronization (CRT) therapy on MBF in fourteen 
patients with either ischemic or idiopathic dilated cardiomyopathy and intraventricular 
conduction delay are reported. Hyperemic perfusion was impaired in these heart failure patients, 
regardless of aetiology, although in ischemic cardiomyopathy the extent of impairment was more 
pronounced. In addition, MBF at rest displayed marked heterogeneity with a reduction in 
perfusion in the interventricular septum compared with the lateral free wall. During cardiac 
resynchronization by means of biventricular pacing, these regional differences were completely 
abolished. Moreover, in a subset of patients, predominantly affected by idiopathic dilated 
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cardiomyopathy, global hyperemic MBF increased significantly. This phenomenon was related 
to a reduction in estimated wall stress induced by CRT. 
Subsequently, in chapter 2.2, an overview is given of the currently available literature regarding 
the metabolic effects of CRT and the assessment of cardiac mechanical dyssynchrony. As also 
described chapter 2.1, regional differences in perfusion, glucose metabolism, and oxygen 
consumption between interventricular and lateral free walls are normalized by CRT. These 
observations are compatible with the hypothesis that CRT rebalances the loading conditions of 
the dyssynchronous failing heart. In contrast to positive inotropic agents, improved cardiac 
function is not achieved at the expense of increased oxygen consumption. Indeed, myocardial 
efficiency is increased. Furthermore, studies have demonstrated that electrical intraventricular 
conduction delay is at best a moderate marker of actual mechanical dyssynchrony. The latter 
observation is a possible explanation for the fact that approximately 20-30% of eligible patients 
do not respond to this form of therapy. Identifying patients who are most likely to respond by 
assessing mechanical dyssynchrony rather than electrical conduction delay is therefore important. 
Various echocardiographic markers have been validated to determine mechanical dyssynchrony, 
including M-mode, two and three dimensional echocardiography, and tissue Doppler imaging. 
The most accurate manner to assess the pattern of mechanical activation of the heart can be 
derived with high temporal and spatial resolution MRI tissue tagging. This method, however, is 
limited by its limited availability, elaborate postprocessing, and relatively high costs. 
In chapter 3.1, the potential of noninvasive quantification of myocardial fibrosis using the water 
perfusable tissue index (PTI) was explored in patients with idiopathic dilated cardiomyopathy. 
This primary cardiomyopathy is characterized by the presence of interstitial fibrosis and a 
reduction in PTI in this patient group was hypothesized. Fifteen symptomatic idiopathic dilated 
cardiomyopathy patients were compared with 11 healthy volunteers and PTI was indeed reduced 
in the patient group. In addition, the reduction in PTI was highly variable, both at a regional level 
and between patients. There was, however, no correlation between the reduction in PTI and left 
ventricular ejection fraction measured with echocardiography. This study suggests that PTI can 
be used to non-invasively assess interstitial fibrosis, which may be useful for investigating the 
relation between the extent of fibrosis and prognosis, and for monitoring therapeutic 
interventions in future studies. It must be noted, however, that histological validation studies 
remain imperative to fully elucidate the value of PTI in this patient group. 
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In chapter 3.2, the interrelationships between myocardial perfusion, fibrosis (PTI), and 
contractile function were investigated on a regional level in patients with idiopathic dilated 
cardiomyopathy through the combination of PET and MRI tissue tagging. Sixteen patients and 6 
healthy controls were studied. In line with previous studies, hyperemic MBF, PTI, and contractile 
function were all impaired in patients with cardiomyopathy and MBF at baseline was comparable 
between patients and controls. In patients, both resting and hyperemic MBF as well as PTI were 
related to systolic function, whereas PTI and MBF did not show agreement. The reduction in 
hyperemic perfusion was directly related to the estimate in left ventricular end-diastolic wall 
stress. These data suggest that, next to endothelial dysfunction, hyperemic perfusion is impaired 
due to extravascular compression of the microvascular vessels. The latter may in turn induce 
periods of myocardial ischemia and exacerbate systolic dysfunction. 
In chapter 4.1, PTI measurements were performed in patients with hypertrophic 
cardiomyopathy. In these patients delayed contrast enhancement (DCE) visualized with MRI is a 
common finding in the hypertrophied interventricular septum. The pathophysiologic basis of this 
observation remains unclear as currently histologic comparison is lacking. Nevertheless, it is 
generally assumed that DCE-MRI represents myocardial fibrosis. Therefore the study described 
in chapter 6 was conducted to compare PTI and DCE-MRI in 21 patients with hypertrophic 
cardiomyopathy. Twelve patients with chronic myocardial infarction and 6 healthy volunteers 
served as control groups. In healthy volunteers no DCE was present and PTI was within the 
normal range. In patients with a previous myocardial infarction, PTI was reduced in proportion to 
the extent of DCE, indicating scar tissue. In patients with hypertrophic cardiomyopathy, 
however, an opposite pattern was observed, i.e. an increase in DCE was accompanied by an 
increase in PTI. These observations indicated that DCE in hypertrophic cardiomyopathy may not 
solely represent myocardial fibrosis and other pathological changes are, at least in part, 
responsible for DCE in these patients. 
In chapter 4.2, additional MRI tissue tagging was performed in a subset of 14 of the patients 
with hypertrophic cardiomyopathy described in the previous chapter. It is well established that 
regional MBF at baseline is not homogeneous in hypertrophic cardiomyopathy. The determinants 
of resting perfusion, however, are not well defined. The results indicated that not regional 
heterogeneity in systolic function determined by MRI tissue tagging, but the extent of DCE-MRI 
correlated with resting MBF. 
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Finally in chapter 5, in 20 patients with chronic ischaemic left ventricular dysfunction, PTI and 
DCE-MRI were compared. As hypothesized and already observed in chapter 6, a reduction in 
PTI was correlated with the extent of DCE. PTI, however, underestimated infarct size relative to 
DCE-MRI estimated infarct size. The mechanisms responsible for this discrepancy warrants 
further investigations. Furthermore, a cut-off value of 0.89 for PTI yielded the highest diagnostic 
accuracy when DCE-MRI was taken as a reference for detection of myocardial viability. This 
value is distinctly higher than the value found in previous studies as mentioned in chapter 1. 
Again, follow-up studies after revascularization procedures are needed to define the optimum 
cut-off value. MBF in perfusable tissue was shown to be a poor marker of viability and confirms 
the hypothesis that chronic hypoperfusion is not likely the leading cause of contractile 
dysfunction in chronic ischaemic heart disease. 
FUTURE PERSPECTIVES 
Quantification of myocardial perfusion using PET has proven to provide valuable insight into the 
(patho)physiology of the human heart. Nevertheless there are some important issues that warrant 
further investigation and development. First, almost without exception, perfusion deficits first 
occur in the subendocardium. Current PET scanners are generally not equipped to distinguish 
between subendocardial and subepicardial MBF, except for some limited experience in extreme 
left ventricular hypertrophy. Corrections for cardiac and respiratory motion and improvement in 
spatial resolution with 3D PET scanners in the near future will hopefully facilitate transmural 
quantification of metabolism and perfusion. Initial experiences in this field are in fact promising. 
Second, given the fact that there is close coupling between metabolism and function, it is of 
paramount importance to combine metabolic with functional imaging techniques. In the present 
thesis, for this purpose, studies were performed that combined MRI or echocardiography with 
PET. Alignment between imaging techniques was performed by consensus in region of interest 
definition using anatomical landmarks. Although this generally yields reliable results in matching 
between myocardial territories, image fusion in the postprocessing phase may give more accurate 
results and should be further explored. Moreover, new developments in dual-imaging-techniques, 
such as PET/CT, allow for almost perfect alignment and, in contrast to separate imaging 
techniques, metabolic and anatomical imaging can be performed within a timeframe of a few 
minutes assuring almost identical hemodynamic conditions. The first reports on cardiac 
applications of PET/CT indeed look promising. Even more exciting are the first prototypes of 
combined PET/MRI scanners, which allow for simultaneous imaging acquisition without the 
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additional radiation burden that accompanies a CT-acquisition. This latter technique, however, is 
only just glooming at the horizon and still far removed from clinical applications. Finally, at 
present, perfusion PET is predominantly used as a research tool. The increasing number of PET 
scanners and on-site cyclotrons worldwide in addition to a reduction in postprocessing time will 
increase the availability of perfusion imaging with PET, which may result in better access for 
diagnostic purposes. This could be especially beneficiary for patients with e.g. obesity, where 
conventional imaging techniques such as SPECT and echocardiography are limited with respect 
to their capacity of detecting ischemic heart disease due to lack of attenuation correction and 
poor ultrasound window, respectively. Larger prospective trials are needed to assess diagnostic 
accuracy of perfusion PET for detecting ischemic heart disease. 
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SAMENVATTING 
Hartspier doorbloedingsstoornissen (myocardiale perfusiestoornis) komen voor in een scala aan 
verschillende hartziekten, waaronder veroorzaakt door kransslagaderverkalking (atherosclerose) 
of door primaire danwel secundaire aandoeningen van de hartspier zelf (cardiomyopathie). Het 
meten van de myocardiale perfusie bij deze ziektebeelden levert belangrijke diagnostische en 
prognostische informatie op en maakt het mogelijk het effect van behandelingen te toetsen. 
Positron emissie tomografie (PET) met het gebruik van een radioactieve tracer zoals oxygen-15-
gelabeld water (H215O), maakt het mogelijk om de myocardiale perfusie te meten in absolute 
eenheden. Additioneel kan worden berekent welk percentage van de hartspier daadwerkelijk 
wordt doorbloed, hetgeen het mogelijk maakt om een inschatting te maken van de hoeveelheid 
littekenweefsel er in het hart aanwezig is. In dit proefschrift worden klinische studies in patiënten 
met verschillende vormen van hartfalen beschreven ten einde de interacties tussen myocardiale 
perfusie, littekenweefsel en hartfunctie te onderzoeken en het effect van behandelingen hierop te 
toetsen.  
In hoofdstuk 1 wordt het validatie proces beschreven van H215O om als PET tracer voor 
myocardiale perfusie te fungeren. Tevens worden de uitkomsten van klinische studies met deze 
tracer besproken in een aantal pathophysiologische condities. Verder wordt de klinische waarde 
van de zogenoemde ‘perfusable tissue index’ (PTI) besproken als voorspellende maat voor de 
aanwezigheid van hartspierlittekenweefsel en potentieel herstel van hartfunctie na een dotter 
behandeling of bypass operatie. Uit analyse van de literatuur blijkt dat een afkapwaarde van de 
PTI van 0.7 een goed voorspellend vermogen heeft voor hartfunctie herstel na dergelijke 
procedures. De hoeveelheid literatuur is echter beperkt en is verkregen in een klein aantal 
patiënten vanuit slechts enkele PET centra wereldwijd hetgeen voorzichtigheid noodzakelijk 
maakt in het interpreteren van deze gegevens. 
In hoofdstuk 2.1 worden de effecten van cardiale resynchronisatie therapie (CRT) op de 
myocardiale perfusie bestudeerd in veertien patiënten met hartfalen en niet-synchroon contractie 
patroon van het hart. Bij deze patiënten was, zoals al uit eerdere onderzoeken is gebleken, de 
stress perfusie gestoord en bestonden er grote regionale verschillen in rust perfusie, gekenmerkt 
door hypoperfusie in het septum van het hart. Gedurende CRT, door implantatie van een 
biventriculaire pacemaker, bleken deze regionale verschillen volledig reversibel. Tevens was er 
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toename van de stress perfusie in een selectie van patiënten met idiopathisch hartfalen, hetgeen 
gerelateerd bleek te zijn aan de afname van de wandspanning door CRT. 
Vervolgens geeft hoofdstuk 2.2 een overzicht van de beschikbare literatuur met betrekking tot de 
effecten van CRT op het metabolisme van het hart. Uit de literatuur blijkt dat, zoals ook al 
beschreven in hoofdstuk 2.1, de regionale verschillen in myocardiale perfusie, glucose 
metabolisme en zuurstof consumptie opgeheven worden door middel van een biventriculaire 
pacemaker. Deze observaties bevestigen de hypothese dat CRT de arbeidsverdeling weer 
homogeen verdeelt over de verschillende delen van het falende hart. In tegenstelling tot positief 
inotrope middelen gaat de verbeterde hartfunctie niet gepaard met een toename van de 
zuurstofconsumptie van het hart. Derhalve wordt de efficiëntie door CRT verbeterd. Tevens 
blijkt uit de literatuur dat het ECG een matig diagnosticum is om een inschatting te maken van de 
asynchronie van de contractie van het hart. Indien louter de ECG gegevens worden gebruikt om 
patiënten te selecteren die in aanmerking komen voor een biventriculaire pacemaker dan blijkt 
dat 20-30% van de patiënten geen baat heeft bij deze therapie. Additionele beeldvormende 
technieken die direct de contractie asynchronie kunnen meten, zoals echocardiografie en MRI, 
zijn dan ook nodig om een betere selectie te maken in patiënten die met CRT kunnen worden 
behandeld. 
Na validatie van de PTI als marker voor littekenweefsel in patiënten met een eerder doorgemaakt 
hartinfarct zoals beschreven in hoofdstuk 1, wordt in hoofdstuk 3.1 de mogelijkheid bestudeerd 
om de PTI te gebruiken om fibrose in het hart te meten bij patiënten met idiopathisch hartfalen. 
Vijftien patiënten werden vergelijken met elf gezonde vrijwilligers en het bleek inderdaad dat de 
PTI verlaagd was in de patiënten groep. Deze bevinding is meest waarschijnlijk gerelateerd aan 
de mate van fibrose. Het ontbreken van histologisch vergelijkingsmateriaal echter maakt een 
definitieve uitspraak hieromtrent onmogelijk. Toekomstige studies zullen nodig zijn om deze 
hypothese te toetsen.  
Vervolgens wordt in hoofdstuk 3.2 de relatie onderzocht tussen de mate van fibrose (gemeten 
middels PTI), myocardiale perfusie en regionale contractie. Dit laatste werd gemeten met gebruik 
van MRI tagging. Zestien patiënten met idiopathisch hartfalen en zes gezonde vrijwilligers 
werden onderzocht. Zoals gebleken uit eerdere studies is de stress perfusie, PTI en 
contractiekracht van het hart sterk verminderd bij de patiënten met hartfalen. Zowel rust en stress 
perfusie als PTI bleken gerelateerd aan regionale contractie, terwijl perfusie en PTI geen relatie 
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vertoonden. De mate van perfusie beperking was direct gerelateerd aan de geschatte 
wandspanning van het hart. Dit onderzoek toont aan dat stress perfusie onder andere onderhevig 
is aan compressie factoren van de microvasculatuur hetgeen waarschijnlijk zuurstofgebrek van de 
hartspier uitlokt en contractiekracht verder verslechtert. Potentiële behandelingen kunnen zich 
dan ook richten op drukverlagende therapieën om de stress perfusie te verbeteren, zoals ook 
besproken in hoofdstuk 2.1.  
Na een PTI vermindering te hebben aangetoond in patiënten met idiopathisch hartfalen werden 
patiënten onderzocht met hypertrofische cardiomyopathie (hoofdstuk 4.1), een hartspierziekte die 
wordt gekarakteriseerd door een onbegrepen hartspierverdikking en tevens fibrose. Bij deze 
patiënten werd een vergelijking gemaakt met contrast MRI. Aankleuring bij contrast MRI is zeer 
gebruikelijk bij hypertrofische cardiomyopathie waarvan algemeen wordt aangenomen dat dit, 
net als na een hartinfarct, littekenweefsel of fibrose weergeeft. Het bleek echter dat contrast MRI 
bij patiënten met een eerder doorgemaakt hartinfarct een essentieel andere grondslag had in 
vergelijking met hypertrofische cardiomyopathie aangezien de contrast MRI aankleuring bij deze 
laatste groep gepaard ging met een verhoogd water gehalte (PTI). Deze observaties geven aan dat 
er waarschijnlijk oedeem voorkomt in het hart van patiënten met een hypertrofische 
cardiomyopathie.  
In het hierop volgende hoofdstuk 4.2 wordt een subanalyse verricht in 14 van de 21 patiënten uit 
het voorgaande hoofdstuk waarbij additioneel MRI tagging was verricht. Doel van de analyse 
was om de heterogeniteit die in rust perfusie bestaat in hypertrofische cardiomyopathie te 
verklaren. In de bestudeerde patiënten bleek niet de regionale contractie maar de aanwezig van 
contrast MRI aankleuring gecorreleerd aan de rust perfusie.  
Ten slotte wordt in hoofdstuk 5 onderzocht wat de beste afkapwaarde is voor de PTI in patiënten 
met hartfalen veroorzaakt door kransslagaderverkalking met betrekking tot vitaliteit detectie. 
Contrast MRI werd in deze studie als gouden standaard gebruikt. In tegenstelling tot de literatuur 
zoals genoemd in hoofdstuk 1, bleek niet een afkapwaarde van 0.7 maar 0.9 het beste te fungeren 
als vitaliteit marker. Rust perfusie van het hart bleek een slechte voorspeller van vitaliteit.  
Samenvattend kan worden gesteld dat PET met gebruik van H215O belangrijke informatie geeft 
over de doorbloeding van de hartspier alsmede de mate van aanwezigheid van littekenweefsel. 
Beide parameters zijn van diagnostisch en prognostisch belang in tal van hartziekten.  
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ondersteuning die gepaard gaat met PET-research. Slechts het aanleveren van een obscuur artikel 
uit een oud tijdschrift die methodes beschreef met rare tekens als ⊗, waren vaak genoeg voor jou 
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om in korte tijd in-house software te ontwikkelen zodat ik aan de slag kon. Ook het dummy-
proof maken van de software werd door mij, alsmede door vele andere dokters, gewaardeerd. 
 
Prof.dr. C.A. Visser, beste Cees, als hoofd van de afdeling en opleider tijdens mijn klinische 
periodes heb je mij geïnspireerd voor de cardiologie. De basis voor het vak van cardioloog is 
gelegd, waarvoor mijn dank. 
 
De leden van de beoordelingscommissie, bestaande uit prof.dr. P.G. Camici, dr. F.J. ten Cate, 
prof.dr. A.C. van Rossum, dr. K.P. Schäfers, dr. J.F. Verzijlbergen en prof.dr. N. Westerhof, wil 
ik bedanken voor hun tijd, aandacht en kritische beoordeling van het uitgevoerde werk. 
 
Medeonderzoekers weten als geen ander hoe het leven er in de kelders van het VUmc aan toe kan 
gaan. Successen met elkaar delen is van groot belang, frustraties nog veel belangrijker. In beide 
gevallen kwam de beertender goed van pas. Het is daarom niet verbazingwekkend dat ik de 
volgende ‘meanderthalers’ een warm hart toe draag (alfabetische volgorde): Ivo van der Bilt, 
Olga Bondarenko, Jeroen van Dijk, Pieter Dijkmans, Willem van Dockum, Tjeerd Germans, 
Ramon van Loon en Robin Nijveldt. 
 
Van de afdeling cardiologie wil ik de cardiologen Cor Allaart, Aernout Beek, Jean Bronzwaer, 
Otto Kamp, Koen Marques en Gerrit Veen bedanken voor hun medewerking vanuit hun 
subspecialisaties. Carel de Cock (“Dat kan wel zo zijn Knaapen… maar heb jij eigenlijk wel eens 
een derde harttoon gehoord?”) wil ik speciaal bedanken voor zijn niet aflatende steun bij het 
project met biventriculair pacen. Uiteraard wil ik ook alle collega arts-assistenten bedanken voor 
het aanhoren van weer een zoveelste verhaal over myocardiale perfusie stoornissen. Speciale 
vermelding krijgen Lucas Klein en Arno van der Weerdt die mij de fijne kneepjes van de PET-
analyse hebben bijgebracht. Verder iedereen van de verpleging voor hun belangstelling en 
interesse. Ankie Müller, Sandra van der Horst, Els Groot, Annelies Folkers en Mary Belderok 
ben ik zeer erkentelijk voor alle ondersteuning op logistiek vlak, inclusief het organiseren van de 
loterij. Helaas is de jackpot nooit gevallen. Johan Karreman is reeds voor vele promovendi 
onmisbaar gebleken op het technische vlak m.b.t. data verzamelen en beheren, powerpointjes in 
elkaar draaien, tiff naar gif converteren en vice versa en het installeren van semi-legale software. 
Zo ook gold dat voor mij, dank hiervoor Johan. 
 
118 
119
                     
 
Van de afdeling nucleaire geneeskunde & PET research wil ik als eerste de MNW-ers Rob 
Koopmans, Suzette van Balen, Reina Kloet, Annemarie Greve-de Wildt en Femke Jongsma mijn 
erkenning geven. Zonder jullie inzet, flexibiliteit en vaardigheid zouden slechts weinig studies 
een goede afloop kennen. Vaak wordt er gezeurd, met name door mij, bij een studie die is 
mislukt. Bij deze mijn bewondering en dank voor het overgrote deel van studies die perfect zijn 
verlopen. Dezelfde argumenten gelden voor de chemici die, onder de bezielende leiding van Gert 
Luurtsema, het cyclotron aan de praat hebben weten te houden; Kevin Takkenkamp, Patricia van 
Ophemert, Henri Greuter, Robert Schuit en Richard Versteegh. Ook Amanda Kroonenberg-
Kalwij en Jaap van der Kuij wil ik bedanken voor alle bewezen diensten. Met name het 
tussendoor inplannen van een afspraak bij ‘Big L.’, wiens agenda gebruikelijk t/m 2011 is 
volgeboekt, wordt altijd gewaardeerd. Voor Remi Schmeitz, de nucleaire equivalent van Johan 
Karreman (vide supra), gaan dezelfde argumenten op als bij Johan zelf. In tegenstelling tot 
bovengenoemde personen heeft fysicus Mark Lubberink geen enkele bijdrage aan de inhoud van 
dit proefschrift geleverd, maar des te meer aan het werk dat sindsdien wordt verricht. Derhalve 
wil ik toch deze gelegenheid aangrijpen om hem te bedanken voor onze samenwerking.   
 
Mijn ouders ben ik de meeste dank verschuldigd. Pa, helaas heb je alleen de aanvangsperiode van 
mijn wetenschappelijke carrière mogen mee maken. Het doorzettingsvermogen om dit 
proefschrift te voltooien had je echter al lang daarvoor aan mij gegeven. Moeke, het is niet 
gemakkelijk geweest en dat is het soms nog niet. Daarom ben ik des te meer gezegend met een 
moeder die altijd haar liefde, steun en interesse is blijven tonen ondanks mijn saaie hartspier-
doorbloedingsverhalen. Ook mijn broer, schoonzus en schoonvader passen in dit rijtje thuis. 
 
Lieve Arieke, je steun en vertrouwen zijn fantastisch. Iedere publicatie werd op jouw initiatief 
gevierd met champagne. Ik stel voor dat we die traditie voortzetten.  
 
Als laatste gaat mijn dank uit naar de patiënten die onbaatzuchtig hun medewerking hebben 
verleend aan de (belastende) onderzoeken. Zonder hen zou dit proefschrift in zijn geheel niet 
mogelijk zijn geweest.  
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Curriculum Vitae 
 
De auteur van dit proefschrift werd geboren op 3 maart 1975 te Heemskerk. Na behalen van het 
Gymnasium B studeerde hij Geneeskunde aan de Vrije Universiteit te Amsterdam (1994-2001). 
In de periode 2001-2002 werd klinische ervaring opgedaan in de cardiologie in het Medisch 
Centrum Alkmaar (opleider prof.dr. A.E.R. Arnold) en in het VU medisch centrum (opleider 
prof.dr. C.A. Visser). Aansluitend werd in 2002 aangevangen met klinisch wetenschappelijk 
onderzoek aan de vakgroepen cardiologie (promotor prof.dr. F.C. Visser) en nucleaire 
geneeskunde & PET research (promotor prof.dr. A.A. Lammertsma) van het VU medisch 
centrum, hetgeen heeft geresulteerd in dit proefschrift. Op 1 juni 2005 werd gestart met de 
opleiding cardiologie aan het VU medisch centrum (opleider dr. G. Veen). In het kader van die 
opleiding, is hij momenteel werkzaam op de afdeling inwendige geneeskunde (opleider dr. F. 
Stam) van het Medisch Centrum Alkmaar. 
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